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Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), 
which is one of the leading infectious diseases worldwide. The current therapy for drug-
sensitive TB is complex and lasts for at least six months. Improper use of antibiotics 
during this regimen has led to the emergence of drug resistance, which represents a 
grave threat to human health. This problem is further exacerbated by the ability of the 
bacterium to persist in the host in a non-replicating state despite the use of antibiotics. 
The majority of antibiotics currently used to treat tuberculosis only affect replicating 
bacteria. Therefore, it is critical to develop new antitubercular drugs that can shorten the 
current therapy while maintaining activity against persistent bacteria as well as the drug-
resistant strains. In this dissertation, structural and drug discovery studies on Mtb 
proteins related to drug resistance and persistence are presented.  
InhA, the enoyl-ACP-reductase enzyme of the mycolic acid biosynthesis 
pathway, is the molecular target of the antitubercular prodrugs isoniazid and 
ethionamide, and it is one of the best validated targets for Mtb drug discovery. A target-
based high throughput screening and a structure-based drug design were performed to 
identify potent activation-free InhA inhibitors that were effective against drug-resistant 
Mtb strains. The molecular basis of InhA inhibition by these inhibitors was revealed by 
X-ray crystallography. In addition, the mode of action for ethionamide was revealed by 
using a cell-based activation system and X-ray crystallography. Furthermore, it was 




regulation of InhA function was also studied, which revealed that phosphorylation of 
InhA occurs at its C-terminal. Phosphomimetic mutants showed that phosphorylation 
decreases InhA activity by decreasing the affinity toward cofactor NADH. The results of 
these studies are presented in Chapters II, III, IV, and V. 
It is essential to understand the physiology of the bacterium to target the 
persistent state of Mtb infection. In Chapter VI, I report our studies on CarD, an essential 
Mtb transcription regulator that is required for persistent infection. The structure of the 
CarD/RNAP complex was determined by X-ray crystallography and the CarD-DNA 
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CHAPTER I  
INTRODUCTION: FURTHERING OUR UNDERSTANDING OF DRUG 
SUSCEPTIBILITY, DRUG RESISTANCE AND PERSISTENCE OF Mycobacterium 
tuberculosis 
 
Background: Mycobacterium tuberculosis and TB 
 
Tuberculosis and Mtb pathogenesis 
Tuberculosis (TB) is an infectious disease that is as old as the history of 
humanity (Wirth et al., 2008). In humans, TB is caused mainly by the airborne pathogen 
Mycobacterium tuberculosis (Mtb). The presence of the Mtb DNA in Egyptian mummies 
dating back to 2000 B.C. indicates that humankind has been in constant battle with this 
pathogen since ancient times (Zink et al., 2003).  
TB is transmitted by inhalation of aerosol droplets containing the active Mtb that 
are directly expectorated from an individual with the acute disease. The pulmonary TB 
infection develops in lungs, where the bacteria are recognized and phagocytosed by the 
alveolar macrophages. These macrophages produce pro-inflammatory cytokines and 
chemokines, such as tumor necrosis factor (TNF)-α and interleukin-1 beta (IL-1β), to 
recruit more leukocytes to the infection site (Sakamoto, 2012). Neutrophils and 
monocytes phagocytose more bacteria together with the dendritic cells, which migrate to 
the lymph nodes to present mycobacterial antigens to lymphocytes and to activate the 




is achieved by activation of macrophages with interferon-gamma (INF-γ) that is released 
by the T cells (Fenton et al., 1997). This results in the production of reactive-nitrogen 
(RNI) and reactive-oxygen (ROI) intermediates, acidification of the phagosome, and 
fusion of the phagosome with the lysosome (Schluger and Rom, 1998). However, Mtb 
can arrest the phagosome at an early stage of maturation and prevent acidification and 
the phagolysosome formation through various mechanisms such as blocking the proton 
ATPase pumps on the phagosomal membrane (Kaufmann, 2001; Stokes and Waddell, 
2009). The pH of the unmatured mycobacterial phagosomes remains around 6.2, 
whereas the pH of the phagolysosomes remains around 5.5 or lower (Russell, 2011). The 
ability of Mtb to regulate the fusion of the phagosome with the lysosome is also seen in 
other pathogenic mycobacterium species such as M. bovis, M. leprae and M. avium 
(Russell, 2005).  
Macrophages and the other immune cells gathered together through cytokine and 
chemokine signaling form the granuloma, which is the characteristic pathological 
signature of the tuberculosis disease. Inside the granuloma, macrophages that 
differentiate to epithelioid or foamy macrophages fuse to form giant, multinucleated 
cells. They are also surrounded by lymphocytes and fibroblasts (Silva Miranda et al., 
2012). The mature granuloma represents an equilibrium between the virulent 
mycobacteria and the host immune response (Bold and Ernst, 2009). Previously, it was 
thought that granuloma formation was only beneficial to the host by containing and 
restricting the mycobacteria at the site of infection; however, studies performed with a 




formation of granuloma during the early stages in order to spread the infection by 
recruiting and infecting the newly arriving macrophages (Davis and Ramakrishnan, 
2009). The granuloma also protects Mtb from cytokine producing lymphocytes and 
provides a lipid rich medium for mycobacterial survival (Silva Miranda et al., 2012).  
Over time, the center of the granuloma undergoes necrosis (cell death), resulting in a 
caseous appearance. The bacteria in the caseous center of the granuloma are thought to 
be in a non-replicating persistent state, but are not completely killed (Trucksis, 2000). 
The caseating granuloma releases the bacteria into the extracellular environment where 
they can multiply again. Partially activated macrophages at the periphery of the 
granuloma and the non-activated macrophages throughout the body can phagocytose the 
released bacilli; however, Mtb can still proliferate in these cells (Trucksis, 2000). If the 
immune system fails to keep the infection under control with activated macrophages, 
then the tissue damaging immune response will dominate and the disease progresses to 
liquefaction and cavity formation (Rodriguez-Herrera and Jordan-Salivia, 1999; 
Trucksis, 2000). When this happens, the active Mtb multiplies extensively, spreading 
within the lung and through the respiratory tract allowing it to spread to new individuals 
(Lyadova, 2012).   
One factor that makes Mtb such a successful pathogen is the fact that even the 
fully activated mature macrophages cannot eradicate 100% of the resident Mtb. 
Persistent bacteria proceed to a dormant state with reduced metabolic activity and adapt 
to the nutrient and oxygen poor environment inside macrophages. Mtb can live in the 




(called latent-infection), which is held in control by the immune response. Latent disease 
is characterized by a positive tuberculin skin test, but displays no radiological, clinical, 
or microbiological evidence for the active disease (Trucksis, 2000). In fact, only around 
10% of the Mtb infected individuals develop an active disease, and approximately 90% 
of the immunocompetent individuals infected with Mtb develop the latent disease. In 
general, immunocompromised individuals such as newborns and people with human-
immunodeficiency-virus (HIV) develop the active disease upon primary infection. This 
is thought to correlate with a high bacterial load, increased virulence, or one’s 
immunodeficiency (Hopewell and Jasmer, 2005). However, any deficiency in the 
immunity can cause reactivation of the latent disease (Trucksis, 2000). In many cases, 
the initial infection is controlled by the host immune response and the active disease 
develops later as a result of reactivation (Kaufmann, 2001). Aside from the lungs, other 
areas such as the central nervous system, internal organs, and the genitourinary tract can 
also be infected by Mtb that is known as extra-pulmonary TB. Indeed, around 15% of 
reactivated latent TB cases occur at extra-pulmonary sites (Sakamoto, 2012). 
 
TB treatment 
The tubercle bacillus was discovered in 1882 by Robert Koch (Koch, 1982). 
Before the introduction of anti-tubercular drugs in the 1940’s, the main treatment of 
tuberculosis involved isolating patients into sanatoriums where they could receive plenty 
of fresh air, sleep, wholesome food, and exercise. The Bacille Calmette Guerin (BCG) 




exhibited a protective effect against TB in young children, but failed to prevent primary 
infection with adult pulmonary TB and reactivation of the latent disease. Also, the 
efficacy of the vaccine varies from strain to strain and the culture medium, making it an 
ineffective TB vaccine (McShane et al., 2012; Venkataswamy et al., 2012). However, 
the BCG vaccine is still administered to infants at birth in regions where TB is endemic 
(Zumla et al., 2013b). Despite constant efforts and research, to date, there is still no 
approved vaccine that exhibits a preventive effect against adult pulmonary TB (Koff et 
al., 2013).   
Many anti-tubercular drugs have been developed to help mitigate TB. The first 
anti-tubercular drug was streptomycin (STM). It was isolated from the bacterium 
Streptomyces griseus in 1944 and then immediately used in clinical trials. In 1946, para-
aminosalicylic acid (PAS) was found to be effective against TB. The frequent emergence 
of STM resistance led to the development of multi-drug therapies. PAS and STM 
combination therapy demonstrated better potency and less drug resistance (Mitchison 
and Davies, 2012). In the field of tuberculosis research, the landmark discovery was that 
of the anti-tubercular drug isoniazid (INH), which has been in use as a first-line drug 
since 1952. The discovery of INH was based on the observation that nicotinamide 
exhibited activity against tubercle bacillus (Chorine, 1945). Soon after, other 
nicotinamide based drugs such as pyrazinamide (PZA), ethionamide (ETH), and 
prothionamide (PTH) were synthesized. In the following years, ethambutol (EMB) was 
discovered. Screening for antibiotics from soil bacteria led to the discovery of many 




capreomycin, and finally, rifampicin (RIF), which were included in multi-drug regimens 
and are still in use today (Zhang, 2005) (Table 1-1 and Figure 1-1). 
Since the 1950s, a tremendous amount of research has been done on TB to 
understand, diagnose, and eliminate this ancient disease. Specifically, in the last 10-15 
years a number of promising compounds exhibited potency against Mtb in both in-vitro 
and in-vivo models (Mitchison and Davies, 2012). However, the current TB treatment 
against the acute infection still depends on the antibacterials discovered 50 years ago. 
The current TB regimen against drug-sensitive Mtb consists of two-phases and includes 
the use of four first-line anti-TB drugs (INH, EMB, PZA, and RIF) for a period of two 
months, followed by a combination of INH and RIF for an additional four months. This 
regimen is administered for pulmonary and most extra-pulmonary TB regardless of the 
HIV coinfection, and can achieve cure rates of >95% if implemented under the DOTS 
(directly observed treatment, short-course) strategy (Zumla et al., 2013a). INH has a 
high early bactericidal activity, which causes a significant decrease in the colony-
forming units in the first few weeks of the therapy. While the actively replicating 
bacteria can be efficiently killed during the initial phase of the treatment, the therapy is 
followed for six months in order to eradicate the persistent Mtb (Zumla et al., 2013a). 
However, the long-duration of treatment brings issues such as patient adherence, drug 
toxicity, intolerance, and pharmacokinetic drug-drug interactions, especially with the 










Molecular Target / Effect 
STM 1944 No S12 and 16S rRNA of 30S ribosomal subunit / 
Inhibits protein synthesis  
PAS 1946 Limited 
use for 
XDR-TB 




 line Enoyl-acyl-carrier-protein reductase  





 line S1 component of 30S ribosomal subunit / Inhibits 













 line 30S ribosomal subunit / Inhibits protein synthesis  
KAN 1957 2
nd




 line Ribosome / Inhibits protein synthesis  
CIP 1981 2
nd





 line DNA gyrase / Inhibits DNA supercoiling  
ETH 1961 2
nd
 line Enoyl-acyl-carrier-protein reductase  
(InhA) / Inhibits mycolic acid synthesis  
Cycloserine 1955 2
nd
 line D-alanine racemase and ligase / Inhibits 
peptidoglycan synthesis  
CFZ 1950s 3
rd
 line genomic DNA, potassium transporters / Proposed 
to intercalate to DNA 
 LZD 1990s 3
rd








2000s Phase II 
trials 
ND /Inhibition of cell wall, mycolic acid 
synthesis, NO poisoning of cytochrome c oxidase 
SQ109 2003 Phase II 
trials 
MmpL3 / Inhibits mycolic acid biogenesis 
Bedaquiline 
 
























This results in interruptions in the treatment and presents challenges to the current 
therapy for the drug-susceptible TB (Zumla et al., 2013a). Therefore, investment has 
been made in significant drug-discovery and development efforts that can shorten the 
therapy, with fewer drug-drug interactions that are more tolerable.  
 
Problem of drug resistance and persistence  
The improper use of antibiotics, together, with the incompletion of the therapy 
for drug-susceptible TB leads to the emergence of drug resistant (Multi-drug resistant 
(MDR) and extensively drug resistant (XDR)) tuberculosis. Furthermore, an individual 
who develops MDR-TB can transmit this form of the disease to others (Zumla et al., 
2013b). MDR-TB strains are resistant to two or more drugs, usually to INH and RIF, and 
treatment of MDR-TB is administered for at least two years with second-line antibiotics 
such as amikacin (AMK), kanamycin (KAN), capreomycin, ciprofloxacin (CIP), 
moxifloxacin (MFX), ethionamide (ETH), and  cycloserine (Table 1-1). MDR-TB 
regimens include at least four second-line drugs administered under the DOTS strategy, 
which are determined based on factors such as previous treatment of the patient for 
MDR-TB, the presence of any underlying medical condition, drugs that were 
administered earlier to the patient, the adverse effects of the drugs, and the local 
resistance pattern of the disease (Zumla et al., 2013a; Zumla et al., 2013b).  
 XDR-TB are resistant to fluoroquinolones and at least one of the injectible 
second-line drugs: AMK, KAN, and capreomycin as well as INH and RIF (Campbell et 




the use of third-line antibiotics such as clofazimine (CFZ), linezolid (LZD), and 
amoxicillin plus clavulanate (AMX/CLV), which lack accessibility and are usually more 
toxic (Zumla et al., 2013a). While the MDR-TB cure rate is approximately 50% (Zhang, 
2005), the mortality rate for XDR-TB is close to 100% for patients co-infected with HIV 
(Zumla et al., 2013b). About half a million new MDR-TB cases were detected in 2011, 
and about one-tenth of those cases exhibited XDR-TB (Abubakar et al., 2013). Most of 
the second- and third-line drugs are toxic, they have severe side effects and treatment of 
MDR- and XDR-TB is very costly compared to the standard regimen (Campbell et al., 
2011).  
The acquired drug resistance of Mtb occurs through chromosomal mutations 
(Ford et al., 2011). These mutations usually happen in either the target or the activator 
gene for the drug (Sacchettini et al., 2008). Mutations are also observed in the promoter 
or intergenic regions, altering the gene expression levels of proteins related to the drug 
mechanism or the efflux pump systems (Calgin et al., 2013; Muller et al., 2011). For 
example, INH and ETH are both prodrugs that need to be activated in the cell, and INH 
resistant (INH
R
) and ETH resistant (ETH
R
) strains mostly carry mutations in the 
activator gene of these prodrugs, katG and ethA, respectively. Typically, 20-80% of the 
INH
R
 clinical isolates carry mutations in the katG gene. The most common katG 
mutation is the Ser315Thr mutation, which causes a deficiency in INH activation 
(Campbell et al., 2011; Suarez et al., 2009; Zhao et al., 2006). Similarly, 51% of ETH
R
 
isolates carry mutations in the ethA gene (Brossier et al., 2011; Morlock et al., 2003).   
On the other hand, 15-40 % of the INH
R




target gene of this drug inhA (such as S94A mutation) or within the inhA promoter 
(Zhang et al., 2005b). The S94A mutation results in a decreased affinity of the enzyme 
for the activated form of the drug (INH-NAD(H) adduct) (Vilcheze et al., 2006), while 
the promoter related mutations cause overexpression of the InhA protein leading to 
resistance (Rouse et al., 1995). Since INH and ETH both target InhA, mutations or 
overexpression of InhA cause cross-resistance to INH and ETH. Other INH
R
 strains have 
also been reported with mutations in the ndh and ahpC genes encoding for NADH 
dehydrogenase II and alkyl hydroperoxidase, which modulate the INH activity, NAD 
metabolism (by increased NADH/NAD
+
 ratios), and act as a marker of resistance, 
respectively (Miesel et al., 1998; Wilson and Collins, 1996). PZA is also a prodrug 
activated by the nicotinamidase/pyrazinamidase enzyme pncA, and PZA resistance is 
acquired through mutations in the pncA gene (Scorpio and Zhang, 1996). Resistance to 
RIF and fluoroquinoles occurs through mutations in the target genes rpoB and gryA/B, 
which encode for the RNAP β-subunit and DNA gyrase, respectively (Sandgren et al., 
2009). RpoB mutations occur at the amino acid positions Asp435, His445, and Ser450 of 
the of RNAP β-subunit, altering the affinity of the enzyme for the drug (Gill and Garcia, 
2011). The most common GyrA mutations are found at the amino acid positions Ala90 
and Asp94, preventing the drugs from effectively binding the enzyme (Campbell et al., 
2011).    
TB drug resistance presents a major global health problem by threatening the 
efforts of TB control. There is an urgent need for discovery and development of new 




of the TB treatment. Another challenge of completely eradicating TB is the ability of the 
bacteria to survive in the host in a non-replicating persistent or chronic state of infection 
despite the use of antibiotics. Mtb has the ability to adapt to the acidic, lytic, and nutrient 
poor environment inside the activated macrophages, which leads to persistence (Monack 
et al., 2004). Furthermore, the local drug concentration inside the granulomas might not 
be adequate to cause bacterial death, or some population of the bacteria might adopt a 
psyhiological state that makes them less susceptible to the used drugs (Sacchettini et al., 
2008). While some individuals can beat the primary infection by immune response 
without becoming sick, others are unable to eradicate the Mtb. Latent TB can reactivate 
after many years of the primary infection due to the dormant bacteria. It then leads to an 
active, progressive disease especially in immune-compromised people (Gomez and 
McKinney, 2004). Drug-resistance and persistence together lead to the development of 
chronic infection.  
According to the World Health Organization (WHO), a new TB infection occurs 
every second and it is estimated that one-third of the world’s population is infected with 
latent TB. In 2011, 1.4 million people died from TB, including 430,000 people co-
infected with HIV (Zumla et al., 2013b). TB is one of the leading causes of mortality in 
developing countries (Zaman, 2010).  The majority of the MDR-TB cases (~60%) are 
seen in Brazil, China, India, the Russian Federation, and South Africa. Of the new TB 
cases, 3.7% (~0.5 million people) are diagnosed as MDR-TB. However, this percentage 
rises up to 20% for previously reported cases (Abubakar et al., 2013). The WHO issued 




drug resistance and persistence, causing the resurgence of TB and making it such a 
difficult disease to eliminate (Sacchettini et al., 2008). These factors combine to make 
TB a serious global health threat. 
 
Drug discovery efforts against Mtb 
Determination of the genomic sequence of the virulent Mtb H37Rv strain in 1998 
opened a new era for anti-tubercular drug discovery (Mitra, 2012).  Among 4000 genes, 
around 40% were annotated with known functions, 44% were predicted with putative 
functions, and ~16% were designated as unique to this organism due to the lack of 
homology to the existing databases (Cole et al., 1998). Identification of the genes 
essential for the growth of the bacteria in various conditions suggested new drug targets 
for the development of novel anti-bacterial agents (Sassetti et al., 2003).  In order to 
decipher the Mtb biology to facilitate drug discovery, the Tuberculosis Structural 
Genomics Consortium (TBSGC) was founded in 2000, and aimed to determine the 
structures of functionally important proteins and potential drug targets for Mtb (Chim et 
al., 2011; Ioerger and Sacchettini, 2009). To date, more than 750 protein crystal 
structures were determined for Mtb and deposited in the Protein Data Bank (PDB, 
http://www.rcsb.org), and ~250 of these structures were contributed by TBSGC 
members (Chim et al., 2011). Once the structure of a target protein is solved, it can be 
used to understand the molecular basis of cellular processes and macromolecular 




structure-based drug design studies (as will be demonstrated in Chapter V of this 
dissertation).  
Three main strategies are followed toward drug development and to overcome 
drug-resistance against Mtb: i) identifying new drugs against the existing/validated drug 
targets, ii) identifying new drug targets that will be targeted by novel compounds, and  
iii) synergistic combination of new and existing drugs (Green and Garneau-Tsodikova, 
2013). The known and validated targets include DNA gyrase and components of the cell 
wall, cell membrane, and mycolic acid biosynthesis. Target based high-throughput 
screening (HTS) through a biochemical assay and structure-based drug design are the 
two conventional methods for the identification of hit/lead compounds against a 
validated target. These two approaches for identification of inhibitors for the Mtb enoyl-
reductase enzyme InhA will be demonstrated in chapters IV and V, respectively, of this 
dissertation. Conversely, identification and validation of new drug targets starts with the 
identification of an active compound against the organism in a whole-cell based HTS, 
followed up with additional experiments (forward chemical genetics, expression 
profiling, or chemical proteomics) to identify and verify the molecular target of the 
compound (Chan et al., 2010). The newly identified and promising drug targets for Mtb 
are the components of ATP homeostasis (such as the ATP synthase proton pump), the 
pantothenate synthesis pathway (such as pantothenate synthetase and pantothenate 
kinase), the enzymes in the shikimate pathway (such as dehydroquinase), the urease 




the glyoxylate shunt, and the drug transporters (such as the trehalose monomycolate 
transporter MmpL3) (Chim et al., 2011).       
The recent developments in anti-TB drug discovery include the identification of 
new fluoroquinolones (for example, MFX, levofloxacin (LFX), gatifloxacin (GTX)), 
nitroimidazole compounds (PA-824 and OPC67683), and 1,2-ethylenediamine 
derivatives (SQ109) (Table 1-1). Fluoroquinolones are a class of compounds effective 
against many bacterial species. They target the DNA gyrase and inhibit DNA 
supercoiling, which is especially important for DNA replication (Anand et al., 2011). 
They possess in-vivo and in-vitro bactericidal activity against drug-resistant Mtb and are 
included among the second-line TB drugs in the current tuberculosis therapy (Moadebi 
et al., 2007). PA824 and OPC67683, the 5-nitrorimidazole derivatives, are prodrugs with 
no cellular targets identified, and are potent against the drug-resistant and persistent 
bacteria. They are currently under Phase II and III clinical trials (Manjunatha et al., 
2006; Singh et al., 2008). Bedaquiline is an ATP synthase inhibitor that is potent against 
drug-sensitive and resistant bacteria (Andries et al., 2005). It was approved by the US 
Food and Drug Administration (FDA) as an anti-TB drug in 2012. It is the only new 
drug in the last 50 years that has been approved for TB treatment; however, its use is 







Targeting the actively replicating drug-susceptible and drug-resistant Mtb through 
the inhibition of mycolic acid biosynthesis pathways 
Mtb is a non-motile, rod-shaped, acid-fast, and aerobic bacterium belonging to 
the actinomycetales order of the actinobacteria class. Mtb is a slow growing organism 
with ~ 20 h of doubling time and contains a high G-C content (65%) in its genome (Cole 
et al., 1998). Mtb cells are impervious to gram staining or any other bacteriological stain 
due to the nature of the mycobacterial cell envelope. The mycobacterial cell envelope 
does not contain an outer membrane similar to the gram-negative bacteria, but has a 
unique cell wall structure that acts as an external permeability barrier. The mycobacterial 
cell wall is essential for mycobacterial viability, survival, and accounts for the intrinsic 
resistance of the bacteria to many chemical disinfectants, therapeutics and bactericidal 
agents (Brennan and Nikaido, 1995; Jarlier and Nikaido, 1994). In addition to the 
uniqueness of its structure and composition, the biosynthetic enzymes responsible for the 
synthesis of the characteristic features of the mycobacterial cell wall do not have 
homologs in mammalian systems. Therefore, the Mtb cell envelope is the preferred and 
promising source of molecular targets for drug discovery (Tomioka et al., 2008).  
 
Mtb cell wall 
The mycobacterial cell wall is composed of three covalently linked layers: 
peptidoglycan, arabinogalactan, and mycolic acids, which are often referred as the 
mycolyl-arabinogalactan-peptidoglycan complex (mAGP) (Figure 1-2). The 




units of N-acetyl-β-D-glucosaminyl-(14)-N-glycolylmuramic acid crosslinked by L-
alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine peptide chains (Schroeder et 
al., 2002). The arabinogalactan layer is composed of arabinan (D-Arabinofuranose) and 
galactan (alternating 5- and 6- linked β-D-Galactofuranose units) chains that are linked 
to the peptidoglycan through a phosphodiester linkage. Mycolic acids are attached to the 
branched hexaarabinofuranosyl termini of the arabinogalactan layer and constitute more 
than 40% of the weight of the cell wall (Schroeder et al., 2002). In addition to being 
covalently bound to the arabinogalactan layer, mycolic acids are also found in the cell 
wall in non-covalently bound forms such as trehalose 6,6’-dimycolate (TDM, cord 
factor). Lipoarabinomannan (LAM), phosphatidyllinositol mannosides (PIMs), trehalose 
monomycolates (TMMs), phenolic glycolipids (PGLs), and phthiocerol dimycocerosates 
(PDIMs) are the other extractable lipids present in the mycobacterial cell wall that play 








Figure 1-2. Schematic representation of the mycobacterial cell envelope. The figure 
is reproduced in part from Gokhale R.S. et al. (2007). Nat. Prod. Rep. 24(2), 267-277, 




Mycolic acid biosynthesis 
The hallmark components of the mycobacterial cell wall are the mycolic acids, 
which are essential for mycobacterial survival and the key to its virulence (Dubnau et al., 
2000). Mycolic acids are made of very long α-branched β-hydroxy fatty acids (C60-C90) 
and are divided into three different structural classes: the most abundant (~60%) α-
mycolic acids, the next most abundant (~30%) methoxymycolic acids, and the least 
abundant (~10%) ketomycolic acids (Schroeder et al., 2002). The α-mycolates contain 




ketomycolates both contain a cis-cyclopropane or an α-methyl trans-cyclopropane in the 
proximal position of the mero chain (Figure 1-3). The methoxymycolates and 
ketomycolates differ by the presence of an α-methyl methyl-ether, or an α-methyl ketone 




Figure 1-3. Chemical structures of the mycolic acids from M. tuberculosis. The 
figure is adapted from Takayama K et al. (2005). Clin. Microbiol. Rev. 18, 81-101, and 




In mycobacteria, the biosynthesis of mycolic acids is accomplished by two 
concerted type I (FAS-I) and type II (FAS-II) fatty acid biosynthetic pathways. The 




the medium-length (C16-C26) acyl-CoA chains. FAS-I functions as a single enzyme with 
multiple domains carrying discrete functions (Molle et al., 2010). In contrast, the FAS-II 
system is composed of multiple enzymes functioning successively. FAS-II elongates the 
FAS-I fatty acyl products leading to the production of meromycolates (C56). Following 
the introduction of various functional groups to the meromycolate chain by cyclopropane 
synthases, the condensation of the FAS-I (C26-acyl-CoA) and FAS-II (C56-
meromycolate) products by Pks13 (a polyketide synthase enzyme) yields the final 
product known as the mycolic acids (Bhatt et al., 2007b).  
Specifically, the FAS-II system elongates the acyl-CoA products of FAS-I by 
using the substrate malonyl-AcpM, which is generated from malonyl-CoA and 
phosphopantothenylated holo-AcpM by the FabD enzyme (Takayama et al., 2005). In 
the first cycle of FAS-II, the malonyl-AcpM and the FAS-I acyl-CoA product are 
condensed to a β-ketoacyl-AcpM by the FabH enzyme (Figure 1-4). The product of this 
condensation reaction is then reduced by the β-ketoacyl-AcpM reductase enzyme MabA. 
After that, the product is dehydrated by the β-hydroxyacyl-AcpM dehydratase enzyme 
HadABC, and finally reduced by the enoyl-AcpM reductase enzyme InhA (Figure 1-4) 
(Sacco et al., 2007). The resulting acyl-AcpM carries two more carbons when compared 
with the starting material, and it is fed into the next cycle as the substrate in the 
condensation reaction with malonyl-AcpM. However, this time the reaction is catalyzed 
by the KasA/KasB β-ketoacyl-AcpM synthases instead of FabH (Bhatt et al., 2007b). 
The successive iterations of the FAS-II cycle lead to the production of a very long chain 






Figure 1-4. The FAS systems of mycobacteria. The FAS-I produces the medium-
length (C16-C26) acyl-CoA chains and these precursors are used in FAS-II, producing the 
meromycolates (C56). INH, ETH, TRC and TLM which inhibit InhA and KasA/B, 
respectively, are also shown above the enzymes they target. The figure is reproduced 
from Bhatt et al. (2007). Molecular Microbiology. 64, 6, 1442–1454, with permission of 








FAS-II system components as drug targets 
Mycolic acids are essential for the integrity of the mycobacterial cell wall and 
play role in virulence and drug resistance (Singh et al., 2011). The enzymes in mycolic 
acid biosynthesis are also essential for the survival of mycobacteria (Bhatt et al., 2007b; 
Sacco et al., 2007). These enzymes represent excellent drug targets since no FAS-II 
system is present in humans (Kuo et al., 2003; Lu and Tonge, 2008; Payne et al., 2001). 
Components of the FAS-II system are conserved among many pathogens. Thus, 
selecting these enzymes as drug targets is also a useful strategy for broad spectrum 
antibiotic development (Lu and Tonge, 2008). Inhibitors that were designed to work 
against the enzymes of this pathway were experimentally shown to be suitable, potential 
antibacterial targets (Payne et al., 2001).  
 
InhA 
The enoyl reductase enzyme is one of the most studied enzymes as an 
antibacterial drug target in the FAS-II pathway. InhA is the trans-2-enoyl-ACP 
reductase and it catalyzes the last step in the elongation cycle of the FAS-II pathway 
while reducing the 2,3 double bond of trans-2-enoyl-ACP in an NADH dependent 
manner (Quemard et al., 1995). Recently, we have identified that InhA activity is 
regulated post-translationally by phosphorylation, and we elucidated the molecular basis 
of this regulation by X-ray crystallography (Molle et al., 2010). This study will be 




InhA has been identified as the primary cellular target of the anti-tubercular 
drugs isoniazid (INH), ethionamide (ETH), and also the anti-bacterial compound 
triclosan. The characterization of InhA as the molecular target of the frontline anti-
tubercular drug INH and the second-line drug ETH was achieved after extensive genetic 
and biochemical analysis. Furthermore, there are several lines of evidence proving that 
InhA is the primary target of INH and ETH. First, the inactivation of M. smegmatis InhA 
and INH treatment results in similar inhibition of the mycolic acid biosynthesis, 
accumulation of saturated FAS-I end products, and similar morphological changes in the 
cell wall leading to cell lysis (Oliveira et al., 2007; Vilcheze et al., 2000).  Next, 
overexpression of InhA in M. smegmatis, M. bovis, and Mtb causes 20- and 10-fold 
resistance to INH and ETH, respectively (Larsen et al., 2002). Also, clinical isolates 
resistant to INH contain mutations in the inhA gene and are cross-resistant to ETH 
(Morlock et al., 2003). Finally, the transfer of a single point mutation allele, S94A, of 
InhA to Mtb confers clinically relevant resistance levels to INH and ETH, and it inhibits 
mycolic acid biosynthesis (Vilcheze et al., 2006). Also, we have more recently 
demonstrated that InhA is the relevant molecular target of the antimycobacterial activity 
of INH, concluding the debates on the molecular target of this drug. This study will be 
discussed in Chapter II. 
Even though INH and ETH both inhibit InhA activity, neither one interacts with 
InhA directly; they are prodrugs needing activation inside the cell. The INH activation is 
done by the catalase-peroxidase enzyme, KatG. KatG oxidizes INH to an acyl radical, 




activation is done by a FAD containing monooxygenase, EthA, generating the ETH-
NAD adduct (Vilcheze et al., 2005). Both the INH-NAD and the ETH-NAD adducts are 
tight binding inhibitors of InhA (Ki ~5 nM) (Wang et al., 2007). Noticeably, ~50 % of  
the clinical isolates of MDR and XDR Mtb strains, which  are resistant to INH, carry 
mutations in the activator katG gene (Dessen et al., 1995; Kuo et al., 2003). The reported 
minimal inhibitory concentration (MIC) of INH against wild-type Mtb and the katG 
S315T strain is 1.5 μM vs. 200 μM (Kuo et al., 2003). In contrast, the majority of the 
ETH resistant strains carry mutations in the activator gene ethA and in the ethR gene, 
which encodes for a transcription repressor regulating the EthA expression negatively 
(Engohang-Ndong et al., 2004).     
The determination of the crystal structure of InhA in complex with the INH-
NAD adduct elucidated the mechanism of action of INH against InhA (Rozwarski et al., 
1998). The INH-NAD adduct binds to the cofactor binding site of the enzyme adjacent 
to the fatty acyl substrate binding pocket, interacting with the active site residues 
(Figure 1-5). Specifically, the pyridine ring of the isonicotinic acyl moiety makes 
aromatic stacking interactions with Phe149, hydrophobic interactions with the side 
chains of residues Gly192, Pro193, Leu218, Tyr158, and Trp222, and a water mediated 
interaction with Met155. When compared with the InhA:NADH structure, it is observed 
that the Phe149 side chain adopts a different conformation by flipping ~ 90° to interact 
with the pyridine ring of the INH-NAD adduct (Rozwarski et al., 1998). Rotation of the 
Phe149 ring opens up a new pocket deep down in the InhA active site and appeals as a 





Figure 1-5. Binding mode of the INH-NAD adduct to the InhA active site (PDB ID: 
1ZID). The INH-NAD adduct (purple sticks) binds to the cofactor binding pocket and 
interacts with the surrounding InhA residues such as Y158 and F149. F149 flips 
90°compared to the InhA:NADH structure opening a new pocket, which is occupied by 
the pyridine ring of the adduct.  
 
 
The mode of action of ETH against InhA is homologous to the INH mechanism 
of action. We determined the crystal structure of InhA in complex with the ETH-NAD 
adduct (Wang et al., 2007). Similarly to the INH-NAD adduct, the ETH-NAD adduct 
also binds to the cofactor binding site of the enzyme and the ethyl-isonicotinic-acyl 
moiety gets positioned to the new pocket accommodated by the flipping of the Phe149 




interactions with the Phe149 and is surrounded by the hydrophobic residues Tyr158, 
Met199, Trp222, Leu218, Met155, Met161, and Pro193 (Wang et al., 2007). Elucidation 
of the molecular mechanism of ETH action will be described in more detail in Chapter 
II.   
InhA is the cellular target of INH and ETH as well as the well known 
antibacterial compound triclosan. Triclosan (TRC) exhibits a broad spectrum activity 
against various gram-positive and gram-negative bacteria including P. falciparum, E. 
coli, and B. subtilis by inhibiting the bacterial FAS-II enoyl-reductase enzymes (Fang et 
al., 2010; Freundlich et al., 2009; Kuo et al., 2003; Parikh et al., 2000). Unlike INH and 
ETH, triclosan is not a prodrug and does not require activation before it interacts with 
InhA. The reported IC50 (inhibitory concentration for 50% inhibition of enzymatic 
activity) for TRC against InhA is 1.1 μM; however, the MIC against Mtb is around 138 
μM (40 μg/ml) (Freundlich et al., 2009). In addition, the bioavailability of TRC is quite 
low when compared with INH (Boyne et al., 2007), making it an attractive target for 
structure-based drug design to improve both the potency and the pharmacokinetic 
properties by chemical substitutions. Triclosan is composed of two phenyl rings (ring A 
and B) linked with an oxygen atom (Figure 1-6). The A ring is substituted with a 
hydroxyl at the 1-position and a chlorine at the 5-position. The B ring has two chlorine 
substitutions at the 2’- and 4’- positions. Substitutions at these positions were explored 
to elucidate the structure-activity relationship (SAR). The hydroxyl of the A ring and the 
chlorines at the 2’ and 4’ positions of the B ring were found to be important for the 




position with hydrophobic groups yielded better TRC derivatives (Freundlich et al., 




Figure 1-6. Binding mode of triclosan to the InhA active site (PDB ID: 1P45). 
Triclosan (TRC; blue sticks) interacts with NAD
+
 (gray sticks) and the InhA active site 
residues. Y158, F149 and some other residues interacting with TRC are shown.  
 
 
The mode of action of triclosan against InhA differs from INH and ETH. TRC is 
an uncompetitive inhibitor of InhA and requires the cofactor NAD
+
 to be bound to the 
enzyme. TRC binds to the substrate binding pocket of InhA, stacking on top of the 
nicotinamide ring of NAD
+




hydroxyl of this ring also makes H-bonding interactions with the 2’-hydroxyl of NAD
+
 
and the side chain of Tyr158. The rest of the TRC-InhA interactions are mediated 
through hydrophobic and van der Waals contacts between TRC and the residues Met103, 
Gly104, Met199, Phe149, Leu218, Ala157, Ile202, and Ile215 (Kuo et al., 2003). I will 
discuss our structure based drug design studies with triclosan analogs for the 
development of potent InhA inhibitors in Chapter V.  
Since InhA is an established target of INH, ETH, and TRC, and most of the 
MDR-TB strains are resistant to INH due to the loss of drug activation by KatG, InhA 
has been the focus of many drug-discovery efforts by both target-based HTS and 
structure-based drug design approaches. Several classes of compounds such as indole-5-
amides, pyrazole derivatives (Kuo et al., 2003), pyrrolidine carboxamides (He et al., 
2006), arylamides (He et al., 2007), imidazopiperidines (Wall et al., 2007) and a natural 
product pyridomycin (Hartkoorn et al., 2012) were identified as direct InhA inhibitors 
with sub-micromolar IC50 values. However, a majority of these compounds either 
showed no or very poor in-vivo activity. Some of these compounds even exhibited low 
membrane permeability against mycobacteria, limiting their use as anti-tubercular drugs 
(Lu et al., 2010). Therefore, more research is needed for identification of potent 
compounds that are active against InhA in vitro, and the drug-sensitive and drug-
resistant Mtb in vivo. We undertook a target based HTS drug discovery approach in 
collaboration with GlaxoSmithKline to develop and characterize novel and activation 




performed structure-based drug design using TRC as a template to develop InhA 
inhibitors, which will be covered in Chapter V.  
In order to overcome the ETH resistance and lower the amount of the effective 
dose necessary to avoid toxic side effects, alternative approaches such as developing 
inhibitor compounds that will block the EthR-DNA interaction and then promote EthA 
production were followed. These approaches were based on the facts that increased EthA 
expression increases the ETH sensitivity, and an ethR null mutant BCG strain exhibits 
higher sensitivity to ETH than the parent strain (Belardinelli and Morbidoni, 2013). 
These studies resulted in identification of potent compounds that boosted the ETH 
activity both in vitro cultures and in vivo models (Flipo et al., 2012; Willand et al., 
2009).   
 
KasA/KasB 
KasA and KasB both function as the β-ketoacyl-ACP synthase enzymes in the 
FAS-II elongation cycle. They catalyze the condensation reaction between malonyl-
AcpM and the growing acyl chain (Slayden and Barry, 2002). The KasA enzyme has 
been shown to be essential for mycobacterial survival by both conditional depletion and 
transposon experiments (Bhatt et al., 2005; Sassetti et al., 2003). Thiolactomycin (TLM) 
is a natural product produced by both Nocardia and Streptomyces species and has been 
shown to inhibit bacterial Kas enzymes, including the mycobacterial KasA and KasB 
proteins (Brown et al., 2003). The antimycobacterial activity of TLM against Mtb is 




bovis led to TLM resistance. However, it did not cause resistance to INH, ETH, isoxyl, 
or cerulenin, suggesting that the Kas enzymes are targeted by only TLM (Kremer et al., 
2000b).  
The crystal structure of Mtb KasA bound with TLM revealed the molecular basis 
of TLM interaction with KasA. TLM binds to the malonyl binding pocket of KasA 
forming two hydrogen bonds to the active site His311 and His345 residues (Figure 1-7). 
The isoprenoid moiety of TLM points to a lipophilic pocket and intercalates between 
two peptide bonds, Ala279-Pro280 and Gly403-Phe404, further stabilizing the 
interaction (Luckner et al., 2009). Binding of TLM to the active site, introduces a small 
conformational change (~0.9 Å) on the loop comprised by residues Phe402-Gly406, 
which contains the gate keeper residue Phe404 for the adjacent acyl channel (Figure 1-
7).  
To obtain more potent KasA inhibitors, several attempts were done on 
modification and optimization of the TLM scaffold, including adding more hydrophobic 
and longer substituents to the isoprenoid moiety. However, even subtle modifications at 
this position, disrupting the conjugated, planar structure, were not tolerated and the 
potency of the compound was lost (Kim et al., 2006; Kremer et al., 2000b). It was also 
proposed that the TLM molecule combined with a 40-50 carbon-long poly-ethylene-
glycol (PEG) might exhibit a good affinity toward the enzyme while increasing the 
solubility and the stability of the compound (Luckner et al., 2009). TLM and Kas 
enzymes are considered to be unexploited targets, considering the lack of cross-




et al., 2000b; Luckner et al., 2009; Singh et al., 2011). Therefore, they present potential 




Figure 1-7. Binding mode of thiolactomycin to the KasA active site (PDB ID: 
2WGE). Thiolactomycin (TLM; green sticks) interacts with the KasA active site 
residues His311 and His345. The isoprenoid moiety intercalates between the peptide 





HadABC and CMASs 
Thiacetazone (TAC) is a bacteriostatic anti-tubercular drug that has been widely 
used in combination with INH in Africa and South America (Davidson and Le, 1992). 
The antimycobacterial activity of TAC against Mtb is 0.1 μg/ml (Alahari et al., 2007). 




mycolic acid synthases (CMASs), which modify the double bonds at specific sites on 
mycolic acid precursors to form cyclopropane rings, were shown to be inhibited by 
TAC. Examination of the mycolic acid profiles of the TAC treated mycobacteria showed 
a significant loss of cyclopropanation in mycolates (accumulation of uncycloproponated 
mycolates). Also, overexpression of CMASs (cmaA2, mmaA2, and pcaA) resulted in 
increased resistance to TAC (Alahari et al., 2007). In addition, the HadA, HadB, and 
HadC proteins, which form the HadAB and HadBC heterodimers and function as the β-
hydroxyacyl-AcpM dehydratases in the FAS-II elongation cycle (Sacco et al., 2007), 
were recently proposed to be the molecular targets of thiacetazone (TAC). This was 
based on the experimental evidence that high levels of resistance to TAC were acquired 
upon overexpression of the hadABC operon and the isolated TAC-resistant mutants 
carried mutations in the hadABC genes (Belardinelli and Morbidoni, 2012). These 
results together suggest that TAC acts on the mycolic acid biosynthesis. Chemical 
analogues of TAC have been investigated against M. avium. Several of the analogues 
displayed better in vitro and in vivo activity than TAC (Bermudez et al., 2003). 
Structures of HadABC or CMASs in complex with TAC have not been determined yet. 
Determination of the molecular basis of TAC inhibition can aid the development of more 








Understanding persistence for targeting non-replicating Mtb 
Mtb is one of the most successful organisms at adapting to long-term residence in 
macrophage phagosomes, and this adaptation is essential for the survival, pathogenesis, 
persistence, and transmission of the bacterium (Schnappinger et al., 2003).  This is what 
gives the bacterium its ability to persist in the host in a non-replicating state despite the 
use of antibiotics, where it will remain latent and then reactivate years later when the 
immune system wanes (Gupta and Chatterji, 2005; Honer zu Bentrup and Russell, 2001). 
“Persisters” are the bacteria that remain viable after exposure to antibiotics while also 
exhibiting resistance to a majority of available antibiotics (Hopewell and Jasmer, 2005). 
It is important to decipher the biology of persistent bacteria, and to understand the 
transition in and out of this state, to be able to target the latent infection (Bacon and 
Marsh, 2007). Most of the antibiotics currently used in the TB therapy are only potent 
against replicating bacteria; therefore, discovery of effective drugs against persistent 
bacteria is crucial. Furthermore, understanding the physiology of persistent Mtb will aid 
the development of  new anti-TB agents (Sacchettini et al., 2008).  
 
Transcriptional response of Mtb in persistent state 
It is known that Mtb can prevent phagosomal maturation into phagolysosomes in 
order to avoid the hostile environment inside macrophages. Mature phagosomes expose 
the bacterium to the microbicidal agents including acids, lytic enzymes, oxygenated 
lipids, and reactive oxygen and nitrogen intermediates (ROI and RNI) such as the 
superoxide anion (O2
-






O2) and nitric oxide (NO)) (Bartos et al., 2004). Also, the phagosomal 
environment is poor in iron and nutrients. To counter this oxidative, nitrosative, hypoxic, 
and carbohydrate poor phagosomal environment, Mtb undergoes a number of 
physiological changes that include decreased replication rate, minimal metabolic 
activity, switching to anaerobic respiration, and usage of fatty acids as the main carbon 
source (Russell, 2005). Expression profiling and transcriptome analysis suggested that 
Mtb induces fatty-acid degradation enzymes, DNA repair proteins, and iron scavenging 
siderophore production in macrophages. The genes associated with the persistent state 
fall into three main categories: respiratory enzymes, fatty acid catabolism and metabolic 
enzymes, and stress-related response proteins. The differential expression of genes 
ensures that the bacteria can develop the necessary survival mechanisms against varying 
stress. 
The presence of the ROI and RNI, DNA damaging agents, and the lack of 
nutrients in the phagosome, induces a ‘stress’ response in bacteria. Under stress, 
mycobacteria, like all other bacterial species, proceeds to a non-replicating state by 
coordinately shutting-down the transcription of the genes for active metabolism, through 
a process called ‘stringent response’. During stringent response, the genes for ribosomal 
proteins, ribosomal RNAs (rRNA), and cell-wall biosynthesis are downregulated 
(Godfrey et al., 2002). The stringent response is initiated and mediated by the synthesis 
of the hyper-phosphorylated guanine, ppGpp and pppGpp, referred together as 
(p)ppGpp, through a  pyrophosphoryl transfer from ATP to GDP or GTP by the RelA 




destabilized by (p)ppGpp at selected promoters through direct binding to the RNAP 
secondary channel and coordinating to the active site Mg
+2
 atom of RNAP. The relA 
knockout Mtb strains deficient of (p)ppGpp production were found to be severely 
impaired in their ability to sustain persistent infection (Dahl et al., 2003), indicating the 
importance of this response mechanism for the long-term survival of Mtb. Mtb RelA is a 
bifunctional enzyme capable of both synthesis and hydrolysis of (p)ppGpp (Avarbock et 
al., 1999). In E. coli, synthesis and hydrolysis of (p)ppGpp is done by the RelA and 
SpoT enzymes, respectively (Murray and Bremer, 1996). However, it was discovered 
that (p)ppGpp production itself is not sufficient for the establishment of stringent 
response, and another protein encoded by the dksA gene was required in E. coli for this 
regulation (Paul et al., 2004a). Mtb does not have a DksA homolog by sequence analysis 
and no other component of the mycobacterial stringent response was identified. 
Recently, a functional homolog of E. coli DksA was identified in Mtb and annotated as 
CarD (Stallings et al., 2009). The CarD protein participates in the regulation of 
transcription under stress conditions; however, it has not been determined yet if it 
functions synergistically with (p)ppGpp in the same manner as DksA.     
In the hypoxic environment of the phagosomes, Mtb can use nitrate instead of 
oxygen as a terminal electron acceptor for anaerobic respiration (Trivedi et al., 2012). 
Nitrate dependent respiration was also found recently to protect the non-replicating 
bacteria from acid stress and the reactive nitrogen intermediates (Tan et al., 2010). 
Therefore, the Mtb nitrate reductases, narGHJI, and the putative nitrate/nitrite 




The narGHJI and narK2 genes are part of the DosR/S/T (Dos) dormancy regulon, which 
is a two-component signaling system composed of two sensor histidine kinases, DosS 
and DosT, and the cognate response regulator DosR (Chen et al., 2013). The Dos 
regulon regulates the expression of ~50 genes under hypoxic conditions and in response 
to nitric oxide, and it is especially important for the non-replicating bacteria (Hu and 
Coates, 2011). Other important members of this regulon include hspX, acr, acg, fdxA, 
and pfkB genes, which encode for a heat shock protein, an α-crystallin, a putative 
nitroreductase, ferredoxin, and phosphofructokinase, respectively (Voskuil et al., 2004; 
Zhang et al., 2012b).  
The RNI production by macrophages were shown to be essential for host defense 
during both acute and persistent infection in murine models (Chan et al., 2005 ). As a 
response to the ROI and RNI, Mtb produces ROI scavenging enzymes catalase-
peroxidase (KatG), superoxide dismutases (SodA and SodC), thioredoxin/thioredoxin 
reductase system (Trx-TrxR), truncated hemoglobins (trHbs), and  the peroxidase and 
peroxynitrite reductase complex (AhpC, AhpD, SucB, and Lpd) (Voskuil et al., 2011). 
In order to maintain a reduced environment, Mtb utilizes mycothiol instead of 
glutathione, which is believed to act as an antioxidant buffer system under oxidative 
stress, and was also shown to be required for the ethionamide susceptibility of Mtb (Ung 
and Av-Gay, 2006; Vilcheze et al., 2008). In the presence of H2O2 and NO, in addition to 
the Dos regulon, the genes regulated by the transcriptional regulators SigH, SigE, IdeR, 
and FurA were also found to be highly induced (Voskuil et al., 2011). Among these, 




degrades H2O2 to water and oxygen and is also involved in INH activation (Milano et al., 
2001). IdeR regulates a variety of proteins including putative transporters, siderophore 
synthesis, and  iron storage proteins (Rodriguez et al., 2002).   
The granuloma is rich in fatty acids and the energy metabolism of persistent Mtb 
switches from carbohydrates to lipids inside the macrophages. Enzymes for the β-
oxidation of fatty acids are utilized for the generation of acetyl-CoA that will be used in 
the tri-carboxylic acid (TCA) cycle (Kumar et al., 2011). Mtb replenishes the precursors 
required for gluconeogenesis by bypassing the two CO2 generating steps of the TCA 
cycle through the glyoxylate shunt, which converts isocitrate to glyoxylate and malate 
with isocitrate lyase and malate synthase enzymes, respectively. Isocitrate lyase (Icl) is a 
key enzyme for mycobacterial virulence and survival in the persistent state that the icl 
gene is upregulated during chronic infection and an icl knockout Mtb strain cannot 
establish persistent infection in mice (McKinney et al., 2000). The glyoxylate shunt is 
present in prokaryotes, fungi, and plants but not in mammals, which makes the enzymes 
of this pathway attractive drug targets. While it is challenging to target Icl due to its 
small and highly polar active site, the other enzyme of the glyoxylate shunt, malate 
synthase, has been shown to be a druggable target (Krieger et al., 2012; Sharma et al., 
2000). In addition to carbohydrate starvation, the phagosome environment is also poor in 
iron, which induces the upregulation of genes related to iron acquisition (mycobactin 
synthesis genes mbtA-L), iron transport, and iron storage (Reddy et al., 2012; Stokes and 





Overview of transcription  
RNA polymerase (RNAP) is responsible for the DNA-directed synthesis of 
RNA, called transcription. While eukaryotes have multiple RNAPs, each functioning to 
synthesize a different class of RNA, bacteria have a single RNAP. The bacterial RNAPs 
are comprised of four distinct subunits, alpha (α2), beta (β), beta prime (β’) and omega 
(ω), forming the core enzyme. A fifth subunit, sigma factor (σ), reversibly associates 
with the RNAP, forming the holoenzyme during transcription initiation (Figure 1-8). 
Currently, the crystal structures are available for the bacterial (E.coli, Thermus 
thermophilus and Thermus aquaticus) core RNAP (Zhang et al., 1999a), holoenzyme 
(Murakami, 2013; Murakami et al., 2002b; Vassylyev et al., 2002), holoenzyme with a 
“fork junction” DNA mimicking the open-complex (Murakami et al., 2002a), 
transcription initiation (Zhang et al., 2012a), and the elongation complexes (Vassylyev et 
al., 2007). The structure of the Mtb core/holo RNAP or any of its subunits has not been 
determined. 
 The architecture of the bacterial RNAPs is conserved among different species; 
however, it has been observed that the structural conservation among RNAPs is 
significantly greater than the sequence conservation (Darst, 2001). The overall structure 
of the bacterial RNAPs resembles a crab claw, where the β and β’ subunits form the two 
pincers creating a deep channel (primary or active-site channel) with a width of 27 Å 
(Darst et al., 2002). The primary channel accommodates the double-stranded DNA and 
the DNA-RNA hybrid. The two α subunits are located at the opposite surface of the 




while they interact with the promoter DNA and transcription activators through their C-
terminal domains (Geszvain and Landick, 2005). The ω subunit interacts with the 
carboxy terminal tail of the β’ subunit and participates in RNAP assembly (Mathew and 
Chatterji, 2006). The RNAP molecule is approximately 150 Å long, 115 Å, tall and 110 
Å wide in size (Darst, 2001). The top and bottom of the main channel is connected by a 
β’ helical segment called the bridge helix. The active site is located at the base of the 
main channel formed between the pincers, where one or two Mg
2+
 ions are chelated by 
the three conserved aspartate residues of the β’ subunit opposite to the bridge helix and 
several water molecules (Vassylyev et al., 2002). The active site is highly conserved 
among species and is equipped with the structural elements required for the catalysis and 
maintaining of the nucleic acid scaffolds. Comparison of the different RNAP structures 
revealed the conformational flexibility of the enzyme and identified the rigid core and 
mobile domains. While the α-N-terminal domains, ω subunit, β and β’ regions around 
the active site form the rigid core modules, the β and β’ pincer domains (protrusion (β1), 
lobe (β2), and β’-clamp) are mobile and can open/close the main channel, providing the 
grip on the dsDNA. The other mobile domain is the β-flap which covers the RNA exit 
channel (Geszvain and Landick, 2005). Conformational changes in these mobile 
domains are observed upon transition of RNAP from the core to the holo enzyme 






Figure 1-8. Structure of the bacterial RNAP. The crystal structure of the Thermus 
thermophilus transcription initiation complex is shown. Molecular surfaces for the α, β, 
β’, ω and σ subunits are shown in yellow, magenta, gray, orange and cyan colors, 
respectively. The β’-bridge helix connecting the bottom and the top of the main channel 
is colored green. The template and non-template dsDNA are shown in ribbon and sticks 
in dark blue. The active site is located deep inside the main chain between the β and β’ 




Transcription starts with binding of the holoenzyme to the specific promoter sites 
on the dsDNA that is selected by the σ-factor, forming the RNAP close-complex (RPc). 
Next, about 17 base pairs (bp) around the transcription start site get separated (melted) 
by the holocomplex, leading to the formation of the RNAP open-complex (RPo), and the 




interact with the downstream dsDNA in the initiation complex and participate in the 
formation and stabilization of the open-complex (Geszvain and Landick, 2005; Zhang et 
al., 2012a). Before processive RNA production starts, RNAP usually undergoes cycles 
of short (2-15 nucleotides) transcript formation and release known as the abortive 
transcription (Goldman et al., 2009). Once the nascent RNA chain becomes 
approximately ten nucleotides, RNAP can escape the promoter, the σ factor dissociates, 
and the core RNAP proceeds toward the chain elongation forming the transcription 
elongation complex (TEC). During elongation RNAP translocates both itself and the 
melted transcription bubble along the DNA template. The NTP substrates are fed to the 
active site through a secondary channel, which is lined within the β’ subunit, forming a 
funnel from the surface of the enzyme to the active center (Darst, 2001). The newly 
synthesized RNA exits through the RNA-exit channel, which is covered by the β-flap 
and β’-lid regions. In prokaryotes, transcription termination occurs through one of two 
processes. It can occur when RNAP reaches a characteristic termination sequence/signal, 
which leads to the formation of a stem-loop RNA structure that will pause and release 
RNAP by disrupting the nucleic acid-protein interactions. Termination can also happen 
through the binding of Rho, which is a transcription termination factor, to the growing 
RNA chain, and pausing RNAP while unwinding the DNA-RNA hybrid (Darnell and 







Transcription regulation by RNAP interacting proteins 
Gene regulation and transcription control is mainly mediated by the transcription 
factors and transcription regulators that interact with the RNAP and the promoter DNA 
sequences to alter the transcription activity. While the majority of the transcription 
factors bind to specific DNA sequences with their characteristic DNA binding domains 
and facilitate or block the RNAP-promoter DNA interactions (activators and repressors), 
some transcription regulators solely interact with RNAP, and some are involved in the 
structuring of the bacterial nucleoid (nucleoid-associated proteins). The Mtb genome 
encodes ~190 transcription regulators of which ~140 are uncharacterized/putative 
transcription factors, 13 are sigma factors, 11 are two-component systems, and 5 are 
unpaired response regulators (Manganelli et al., 2004). During the varying stages of 
infection, different transcription regulators are utilized to ensure differential gene 
expression as a response to the environmental conditions (Raman et al., 2004). Below, 
the Mtb RNAP-interacting transcription regulators that are important for the 
establishment of the persistent infection will be discussed.  
 
Sigma factors 
Sigma factors are indispensable components of the transcription machinery that 
provide promoter specificity. The Mtb genome encodes for 13 σ factors that all belong to 
the σ70 class, which is E. coli’s principal σ factor (Manganelli et al., 2004). Each 
mycobacterial sigma factor (sigA-M) has its own specificity and is expressed under 




primary σ factor, sigA (σA), is responsible for the transcription of housekeeping genes, it 
is essential for bacterial viability, and it is constantly expressed. The other sigma factors, 
sigB, sigC, sigD, sigE, sigF, sigH, and sigJ, were found to be induced upon various 
stress conditions, starvation, and within the macrophages. Therefore, they are associated 
with persistent infection and virulence (Smith et al., 2005). This is especially true for σD, 
σE, and σH, which regulate the genes related to the persistent infection. These genes 
include the rel operon, icl, and the genes encoding for fatty acid degradation enzymes 
(such as fadE24), DNA repair proteins, thioredoxin and thioredoxin reductase (Rodrigue 
et al., 2006). Mtb strains with mutant σF, σB, and σJ display attenuated virulence and are 
more sensitive to various stresses, suggesting their involvement in adaptation to the 
stationary phase (Rodrigue et al., 2006). The σ function is usually regulated by anti-
sigma factors, which bind to σ and inhibit its interaction with RNAP and the promoter 
DNA. Four different anti-σ-factors were identified from the Mtb genome that regulate 
the functions of σE, σF, σH, and σL (Smith et al., 2005).  
The σ70 related σ-factors contain up to four conserved regions (regions 1,2,3 and 
4), which can further be divided into sub-regions (sub-regions 1.1-1.2, 2.1-2.4, 3.0-3.2 
and 4.1-4.2), and classified into four different groups (groups 1,2,3 and 4) based on their 
structural and functional organizations (Geszvain and Landick, 2005). Mtb σA, σB, and 
σF belong to groups 1, 2, and 3, respectively, and contain at least three conserved regions 
(regions 2, 3, and 4). The rest of the ten mycobacterial σ-factors belong to group 4, and 
are also described as the extracytoplasmic function (ECF) σ-factors, containing only 




the crystal structures of the RNAP holoenzyme from Tth, E. coli and Taq revealed the 
details of the sigma-RNAP interactions (Murakami, 2013; Murakami et al., 2002b; 
Vassylyev et al., 2002). It has also been observed from the crystal structures of initiation 
complexes that the sequence specific interactions between RNAP and the promoter DNA 
are provided by the conserved regions of the σ-subunit (Murakami et al., 2002a). The 
major contact interface between the core RNAP and σ occurs between the coiled-coil 
region of the β’ clamp and the conserved σ sub-region 2.2 (Vassylyev et al., 2002). The 
other contacts are between the σ sub-region 3.1 and the β-subunit β1 protrusion domain, 
the σ sub-region 3.2 and the β’ rudder, lid loops and the C-terminus of the β subunit, and 
the σ sub-regions 4.1 and 4.2 with the β flap and β’ zinc finger domain. The σ-promoter 
DNA interactions occur through the sub-regions 2.4, 2.3, 3.0, and 4.2, which are 
involved in the -10 promoter recognition, transcription bubble melting, and the extended 
-10 element and the -35 promoter recognition, respectively (Rodrigue et al., 2006). The 
sub-region 4.2 was also shown to interact with other transcription regulators such as 
WhiB3 (Steyn et al., 2002).   
 
RbpA 
RbpA is a 14 kDa protein found only in actinomycetes and was first identified in 
Streptomyces coelicolor. It was found that in Mtb, during the stationary phase under 
starvation, the expression of the rbpA gene was upregulated ~8 fold (Betts et al., 2002). 
In M. Smegmatis, RpbA was associated with increased tolerance and resistance to 




mechanisms such as the competition of RbpA with rifampicin for the binding site, 
inducing allosteric conformational changes in the rifampicin binding site while 
influencing the drug’s binding affinity, and an indirect mechanism affecting the 
membrane permeability (Hu et al., 2012). Recently, it was identified that RbpA 
functions as a σ specific transcriptional activator and it regulates the access of the 
primary and stress related σ-factors, σA and σB but not σF, to the core RNAP during the 
stress response and stationary phase (Bortoluzzi et al., 2013; Hu et al., 2012) 
The NMR solution structure of RbpA revealed a well-defined core domain 
comprised of four β-strands and highly flexible N- and C-terminal regions. It was shown 
that RbpA interacts with σA and σB σ2 domains through these unstructured N- and C-
terminal regions (Bortoluzzi et al., 2013; Tabib-Salazar et al., 2013). Two different 
studies suggested that RbpA interacts with the RNAP β-subunit. However, one study 
proposed RbpA binds close to the RNAP active site where rifampicin binds, while the 
other study proposed the sandwich-barrel hybrid motif of the β-subunit on RNAP 
surface is the interaction interface (Dey et al., 2010; Hu et al., 2012). These studies 
suggest that RbpA stabilizes the σ binding to the core RNAP and facilitates open-
complex formation in order to promote transcription. Being an essential transcription 
regulator and playing an important role in the σ cycle makes RbpA a promising target to 








Microarray experiments to identify genes that are regulated differently under 
stress conditions resulted in identification of the Rv3583c gene of Mtb. Rv3583c encodes 
for a 17 kDa protein, which is a putative transcriptional factor that is annotated as CarD. 
CarD expression was found to be upregulated 4-8 fold when the bacteria was grown 
under oxidative stress, starvation, and in the presence of DNA damaging agents. CarD 
depleted strains failed to regulate the rRNA and ribosomal protein levels, pointing out its 
involvement in the stringent response mechanism (Stallings et al., 2009). The ability of 
Mtb CarD to complement the DksA function in a ∆dksA E. coli strain verified its 
involvement in rRNA and ribosomal protein transcription regulation and suggested that 
it was a functional homolog to E. coli DksA. In-vivo studies also demonstrated that 
absence of the CarD protein diminishes the persistent Mtb infection in mice. In addition, 
the CarD protein was essential both in-vivo and in-vitro conditions for mycobacterial 
growth under stress as well as under normal growth conditions. These findings all 
suggested that CarD has a pivotal role in the establishment of persistence. Understanding 
the biology of this protein can provide insights into Mtb’s adaptation to persistence and 
may offer new potential drug targets.   
The Mtb CarD protein belongs to the CarD-TRCF family of proteins. The N-
terminus of CarD proteins shows ~30% sequence identity to the Transcription Repair 
Coupling Factor (TRCF) RNAP interacting domain (RID). TRCF removes the stalled 
RNAP from a site of damaged DNA, recruits the DNA repair proteins, and interacts with 




CarD homologs are found in all mycobacterial species and they are highly conserved 
(>95%) among actinobacteria. On the other hand, no homolog is present in humans. Mtb 
CarD has ~30% sequence identity and ~50% sequence similarity to the CarD protein 
from Myxococcus xanthus, which is the first identified protein from this family. M 
.xanthus CarD is involved in the carotenogenesis pathway, which is responsible for the 
carotenoid synthesis upon exposure to blue light. M. xanthus CarD is part of a complex 
regulatory network, and interacts with both RNAP and CarG with its N-terminal protein-
protein interaction domain. It also interacts with the carQRS promoter DNA with its C-
terminal DNA interaction domain (Nicolas et al., 1996; Penalver-Mellado et al., 2006). 
The M. xanthus CarD DNA binding domain resembles the eukaryotic high mobility 
group A-1 (HMGA1) proteins, which interact with the minor grove of AT rich DNA 
sequences through their ‘RGRP’ protein sequence motifs called ‘AT hook’s. In contrast, 
Mtb CarD does not have an AT hook motif and only exhibits homology to the N-
terminal domain of M. xanthus CarD. Therefore, Mtb CarD is also classified as a CarD-
N-terminal-like (CdnL) protein (Garcia-Moreno et al., 2010).   
Similar to M. xanthus CarD, Mtb CarD was also reported to interact with the 
RNAP β-subunit (Stallings et al., 2009). Based on the homology models generated 
according to the homologous TRCF-RNAP interaction, it was predicted that CarD 
proteins interact with the N-terminus (approximately the first 120 residues) of the β-
subunit. For Mtb CarD, this interaction is crucial for transcription regulation and is 
required for mycobacterial survival and adaptation to stress conditions (Weiss et al., 




affects Mtb’s susceptibility to rifampicin. Loss of the CarD-RNAP interaction increases 
the sensitivity of mycobacteria to rifampicin (Weiss et al., 2012).  
Little is known about the mechanism of CarD regulation of RNAP. Recently, we 
have determined the crystal structure of Mtb CarD complexed with the RNAP β-lobes. 
The uncomplexed structure of the β-lobes was also solved to compare the 
conformational differences of RNAP in the bound and unbound states. We then 
investigated the CarD-DNA interaction (Gulten and Sacchettini, 2013). Another study 
was performed with a CarD homolog protein from Thermus thermophilus and suggested 
that CarD functions during transcription initiation as an activator by favoring 
interactions between RNAP and promoter DNA (Srivastava et al., 2013). Our structural 
studies of the Mtb CarD/RNAP complex and the insights gained through this complex 





DECIPHERING THE MECHANISM OF DRUG ACTION FOR ISONIAZID AND 





Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clinically 
effective in the treatment of Mycobacterium tuberculosis (Mtb), Mycobacterium leprae 
(M. leprae), and Mycobacterium avium (M. avium) complex infections. Although 
generally considered second-line drugs for tuberculosis, their use has increased 
considerably as the number of multidrug resistant and extensively drug resistant 
tuberculosis cases continues to rise. Despite the widespread use of thioamide drugs to 
treat tuberculosis and leprosy, their precise mechanisms of action remain unknown. 
Mycobacterium tuberculosis enoyl-acyl-ACP reductase (InhA) has been demonstrated to 
be the primary target of isoniazid (INH) and ETH. Recently, it was postulated that M. 
tuberculosis dihydrofolate reductase (DHFR) is also a target of INH, based on the 
findings that a 4R-INH-NADP adduct synthesized from INH by a nonenzymatic 
approach showed strong inhibition of DHFR in vitro, and overexpression of M. 
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tuberculosis dfrA in M. smegmatis conferred a 2-fold increase of resistance to INH. In 
the present study, a plasmid expressing M. tuberculosis dfrA was transformed into M. 
smegmatis and M. tuberculosis strains, respectively. The transformant strains were tested 
for their resistance to INH. Compared to the wild-type strains, overexpression of dfrA in 
M. smegmatis and M. tuberculosis did not confer any resistance to INH based on the 
MIC values. Similar negative results were obtained with 14 other overexpressed proteins 
that have been proposed to bind some form of INH-NAD(P) adduct. An Escherichia coli 
cell-based system was designed that allowed coexpression of both M. tuberculosis katG 
and dfrA genes in the presence of INH. The DHFR protein isolated from the 
experimental sample was not found bound with any INH-NADP adduct by enzyme 
inhibition assay and mass spectroscopic analysis. We also used whole-genome 
sequencing to determine whether polymorphisms in dfrA could be detected in six INH-
resistant clinical isolates known to lack mutations in inhA and katG, but no such 
mutations were found. The dfrA overexpression experiments, together with the 
biochemical and sequencing studies, conclusively demonstrate that DHFR is not a target 
relevant to the antitubercular activity of INH. In addition, using the cell-based activation 
method, we now have definitive evidence that both thioamides form covalent adducts 
with nicotinamide adenine dinucleotide (NAD) and that these adducts are tight-binding 
inhibitors of M. tuberculosis and M. leprae InhA. The crystal structures of the 
inhibited M. leprae and M. tuberculosis InhA complexes provide the molecular details of 
target–drug interactions. The purified ETH-NAD and PTH-NAD adducts both showed 




structures and mechanisms of action of these drugs provides insights into designing new 
drugs that can overcome drug resistance. 
 
Introduction 
In 1952, isoniazid (INH) was discovered to have bactericidal activity against 
Mycobacterium tuberculosis (Bernstein et al., 1952). Since then, it has been used as a 
potent front-line drug against tuberculosis (Bloch, 1977). On the other hand, INH is not 
effective against Mycobacterium leprae, the causative agent of leprosy, most likely due 
to the dysfunction of the M. leprae katG gene. Thioamide drugs, ethionamide (ETH) and 
pro-thionamide (PTH), were introduced in the 1960s, and they are structurally similar to 
INH (Figure 2-1). They have been widely used in the treatment of mycobacterial 
infections caused by Mycobacterium tuberculosis, M. leprae, and M. avium complex 
infections (Fajardo et al., 2006; Yajko et al., 1987). ETH and PTH are both bacteriocidal 
and are essentially interchangeable in a chemotherapy regimen. They are the most 
frequently used drugs for the treatment of drug-resistant tuberculosis and, therefore, are 
becoming increasingly relevant as the number of multidrug-resistant and extensively 
drug-resistant cases is increasing worldwide (CDC, 2006; Crofton et al., 1997). 
Moreover, ETH and PTH are also used in a combined chemotherapy regimen with either 
dapsone or rifampin to treat leprosy (Katoch et al., 1992). Although we have previously 
speculated about the mechanism of action of ETH in M. tuberculosis based on an 
analogy to isoniazid’s (INH’s) mode of action (Banerjee et al., 1994; Rozwarski et al., 








Figure 2-1. Chemical structure of ETH, PTH, and INH. Although these prodrugs 
have similar structures, INH is activated by a catalase-peroxidase, whereas ETH and 




The mechanism of action of INH has been studied for more than 50 years. 
Through lipid profiling, INH was found to inhibit mycolic acid biosynthesis in M. 
tuberculosis (Winder et al., 1970). In addition, the INH-induced inhibition of mycolic 
acid biosynthesis was demonstrated to correlate with the bactericidal activity of INH 
(Takayama et al., 1972). Further analysis of the lipids of INH-treated M. tuberculosis 
indicated that the elongation of fatty acids beyond C26 was inhibited, which suggested 
that the target of INH is an enzyme in fatty acid elongation (Takayama et al., 1975). 
Similar to INH, ETH and PTH also inhibit mycolic acid biosynthesis (Takayama et al., 




endogenous catalase/peroxidase (Zhang et al., 2005a). The mode of INH action 
remained unclear until an INH-NAD adduct was identified as the bound inhibitor in the 
active site of InhA, the enoyl-acyl ACP reductase involved in long-chain fatty acid 
biosynthesis, by protein crystallography (Rozwarski et al., 1998). It was hypothesized 
that KatG cleaves the hydrazide on INH to an isonicotinoyl radical, which then reacts 
with NAD to form an adduct that binds to and inhibits InhA (Timmins and Deretic, 
2006). The crystal structure of InhA bound with the adduct indicates that an 
isonicotinoyl moiety was covalently attached to the 4-position of the nicotinamide ring 
of NAD cofactor in an S configuration. The chemical structure of the INH-NAD adduct 
was found to be consistent with the molecular weight obtained by the mass analysis 
(Rozwarski et al., 1998). Later studies demonstrated that INH-NAD adduct could be 
generated by a KatG-catalyzed oxidation in the presence of NAD (Lei et al., 2000; 
Wilming and Johnsson, 1999), which strongly inhibits InhA (Ki = 5 nM) to block 
mycolic acid biosynthesis (Rawat et al., 2003; Rozwarski et al., 1998; Vilcheze et al., 
2006). Similar to INH, ETH and PTH are also prodrugs that require activation to exert 
antitubercular activity. KatG mutant strains resistant to INH are sensitive to ETH, 
indicating that ETH has a different activator (Fattorini et al., 1999; Morlock et al., 2003). 
Mutations of a gene designated ethA were repeatedly found in the clinical isolates 
resistant to ETH (DeBarber et al., 2000; Morlock et al., 2003). Like KatG, the 
overexpression of ethA in M. smegmatis resulted in substantially increased ETH 
sensitivity (Baulard et al., 2000). This evidence suggested that ethA is critical for the 




Villiger reaction to detoxify aromatic and long-chain ketones (Fraaije et al., 2004). The 
enzyme is membrane associated and has a tendency to form large oligomers after 
purification (Fraaije et al., 2004; Vannelli et al., 2002). The monooxygenase activity of 
the purified EthA is very low (kcat = 0.00045 s
−1
), suggesting that the enzyme may 
require other proteins or cellular components to be completely functional (Fraaije et al., 
2004). The active form of ETH has never been detected or isolated in vitro, although 
some inactive metabolites produced by the catalytic oxidation of ETH by EthA have 
been studied by TLC and HPLC (DeBarber et al., 2000).  
Mutations within the protein-coding and promoter regions of inhA are frequently 
observed in clinical isolates resistant to INH (Guo et al., 2006; Telenti, 1998). An S94A 
mutation in InhA, which was originally identified in an INH-resistant M. smegmatis 
strain, was later found in three M. tuberculosis clinical isolates that conferred resistance 
to both INH and ETH (Banerjee et al., 1994; Morlock et al., 2003). The S94A allele of 
inhA has been transferred into M. tuberculosis by a specialized linkage transduction, 
which was sufficient to confer 5-fold resistance to INH (Vilcheze et al., 2006). 
Moreover, overexpression of inhA in M. tuberculosis was found to confer 10-fold 
resistance to INH (Larsen et al., 2002). Indeed, several M. tuberculosis clinical isolates 
resistant to INH contain mutations in the inhA gene, and all have been found to be cross-
resistant to ETH (Lei et al., 2000). These genetic observations support that InhA is the 
primary target of INH. 
 Although genetic and biochemical studies have provided convincing evidence 




proposed (Mdluli et al., 1998; Timmins et al., 2004). Previously, FAS-II elongation 
enzyme KasA was proposed to be the primary target of INH based on the mutations 
found in kasA of some clinical isolates and the formation of a complex between AcpM, 
KasA and INH (Mdluli et al., 1998). However, later it was demonstrated that InhA 
inhibition but not KasA inhibition induces the formation of this complex, and only InhA 
but not KasA gets inhibited by KatG activated INH in vitro (Kremer et al., 2003). 
Recently, 17 proteins other than InhA were identified from M. tuberculosis lysate that 
could tightly bind to an affinity matrix derived from INH-NADP or INH-NAD adducts 
by proteomic analysis (Argyrou et al., 2006a). Among these proteins, M. tuberculosis 
dihydrofolate reductase (DHFR) was shown to be strongly inhibited by an INH-NADP 
adduct in vitro (Ki app = 1 nM) in a separate study (Argyrou et al., 2006b). This INH-
NADP adduct was synthesized by incubating INH and NADP in the presence of Mn(III) 
as a catalyst. The crystal structure of the complex indicated that an acyclic 4R INH-
NADP adduct was selectively bound in the active site of DHFR. In addition, 
overexpression of dfrA in M. smegmatis caused a 2-fold increase of resistance to INH 
compared to the wild-type (Argyrou et al., 2006b). These observations were taken to 
suggest that M. tuberculosis DHFR is also a target of INH (Argyrou et al., 2006a; 
Argyrou et al., 2006b). 
There are several observations which conflict with the proposal that DHFR might 
be a target of INH. First, the MIC difference (2-fold) between the dfrA overexpressed M. 
smegmatis strain and the wild-type strain is not significant compared to the error of this 




tuberculosis. Although it is an essential gene for nucleotide biosynthesis in many other 
organisms (Gangjee et al., 2007; Kompis et al., 2005), disruption of dfrA by transposon 
mutagenesis was found not to attenuate M. tuberculosis infection in mice (Sassetti and 
Rubin, 2003). Third, the endogenous formation of the 4R INH-NADP adduct by KatG 
catalysis has not been demonstrated.  
In this study, we elucidated the mechanism of drug action of ETH and PTH 
against M. tuberculosis and M. leprae using a cell based activation approach. To 
determine whether M. tuberculosis DHFR is a molecular target of INH, we investigated 
(i) whether overexpression of dfrA under relevant conditions confers resistance to INH 
in M. smegmatis and M. tuberculosis, (ii) whether the INH-NADP adduct is an activated 
INH product generated by KatG catalysis inside the cell, and (iii) whether mutations in 
dfrA could be observed in INH-resistant clinical isolates.  
 
Results and discussion 
 
Identification of the active form of ETH 
To identify the active form of ETH, we and others have attempted to use purified 
EthA to activate ETH and inhibit InhA in vitro but have never been able to observe any 
InhA inhibition (unpublished data). This might be due to the fact that purified EthA 
forms large oligomers (200-600 kDa) and has a very low enzymatic activity in vitro 
(Fraaije et al., 2004). Purification of EthA is only possible in the presence of detergents 




or hydrophobic segments that could contribute to membrane anchoring is recognized 
from the protein sequence (Fraaije et al., 2004). It is possible that other proteins or 
cellular components are required for the full EthA activity. Because in vitro activation of 
the drugs ETH and PTH has not been possible by either chemical or enzymatic 
approaches, we developed a cell-based activation method. In this system, recombinant 
Mtb or M.leprae EthA and InhA were co-overexpressed in the same Escherichia coli 
cell, and ETH or PTH was added to the culture to test whether the drugs would inhibit 
InhA upon activation. Although ETH and PTH are both potent drugs against M. 
tuberculosis (MIC = ~0.5 μg/ml) (Quemard et al., 1992), they do not affect E. coli 
growth, even at very high concentrations (100 μg/ml), which is primarily caused by the 
absence of an EthA homologue in E. coli. 
InhA and EthA from M. tuberculosis were coexpressed in E. coli BL21 (DE3) in 
the presence of 100 μg/ml ETH. InhA was rapidly purified, and an in vitro enzyme assay 
was performed. InhA isolated from the experimental sample had <1% of the specific 
activity of InhA purified without the addition of ETH under the same assay condition. 
Mass analysis of denatured InhA from the experimental sample indicated the presence of 
a small molecule with a molecular weight of 798.2. This corresponds to the exact 
molecular weight of an ethyl-isonicotinic-acyl-NAD covalent adduct. Moreover, pure 
fractions of this small molecule showed strong inhibition to native InhA in vitro (Ki = 7 
± 5 nM), which is as potent as the INH-NAD adduct, the active form of INH (Ki = 5 
nM) (Vilcheze et al., 2006). When PTH was used in the same coexpression experiment, 




exact weight of a propyl-isonicotinic-acyl-NAD adduct. This compound is also 
extremely potent against InhA in vitro (Ki = 2 ± 0.8 nM for Mtb InhA; Ki= 11 ± 6 nM 
for M.leprae InhA). 
Other than ETH and PTH, thioamide drugs such as thiacetazone and isoxl have 
been shown to be activated by EthA EthA (DeBarber et al., 2000). The same cell-based 
method was applied to test thiacetazone. InhA and EthA were co-overexpressed in the 
presence of TAC and InhA was purified to test the enzymatic activity. The isolated InhA 
was not inhibited under the same assay condition. As expected, mass analysis did not 
show the existence of any tightly bound inhibitor. These results indicate that, unlike 
ETH or PTH, thiacetazone does not target InhA, even though all of these thioamides are 
activated by EthA in M. tuberculosis.  
 
Structures of Mtb and M.leprae InhA with ETH-NAD and PTH-NAD adducts 
We have determined the crystal structures of M. tuberculosis InhA in complex 
with the ETH-NAD and the PTH-NAD adducts, and M. leprae InhA in complex with the 
PTH-NAD adduct to 2.2, 2.5 Å and 2.1 Å resolution, respectively. Mtb and M. leprae 
InhA proteins are highly similar in sequence and overall structure (90% sequence 
identity; RMSD = 1.3 Å for Cαs). The active site residues are also conserved. Unbiased 
electron density maps of each complex clearly indicated the presence of a modified 
NAD with an ethyl-isonicotinic-acyl or propyl-isonicotinic-acyl group covalently 
attached to the 4 position of the nicotinamide ring in a 4S configuration (Figure 2-2A). 




obtained by the mass analysis. Similar to the structure of InhA bound with the adduct 
INH-NAD (Rozwarski et al., 1998), the ethyl-isonicotinic-acyl, or the propyl-
isonicotinic-acyl, moiety is found in a hydrophobic pocket that was formed by the 
rearrangement of the side chain of Phe
149
 (Figure 2-2B–D). The ethyl-isonicotinic acyl 
or the propyl-isonicotinic-acyl group also forces the side chain of Phe
149
 to rotate ~90°, 
forming an aromatic ring-stacking interaction with the pyridine ring (Figure 2-3A). The 

















, and is adjacent and 
partly overlapped with the fatty acyl substrate-binding site. Indeed, the atoms common 
to ETH-NAD, PTH-NAD, and INH-NAD are in nearly identical positions. The only 
difference is the extra ethyl or propyl group at the 2 position of the pyridine ring of ETH 
or PTH. The ethyl group contributes to the binding of ETH-NAD adduct by forming π-
stacking interactions with the aromatic side chain of Tyr
158
 at a distance of ~3.3 Å. It is 
also within van der Waal interaction distances with side chains of Leu
218
 (3.3 Å) and 
Met
155
 (3.2 Å). The hydrogen-bonding interactions between the phosphate group of the 
adduct and residues of the nucleotide-binding site are well conserved. Therefore, it is 
very likely that mutations, such as S94A, that decrease the binding of NAD(H) and the 
INH-NAD adduct would also weaken the binding of ETH-NAD and PTH-NAD (Figure 









Figure 2-2. Active sites of the M. tuberculosis enoyl-acyl ACP reductases bound to 
inhibitors and the bound inhibitor. A) The crystal structure of PTH-NAD superimposed onto 
the simulated annealing omit electron density map contoured at 1 σ. Carbon atoms are gray, 
oxygen atoms are red, nitrogen atoms are blue, and phosphor atoms are orange. The 2-propyl-
isonicotinic acyl group is covalently attached to the 4 position of the nicotinamide ring of 
NADH in a 4S configuration. B) Cross section through the surface of the InhA active site with 
bound INH-NAD. C) Cross section through the surface of the InhA active site with bound ETH-
NAD showing that the 2-ethyl-isonicotinic acyl moiety protrudes into a hydrophobic binding 
pocket created by the rearrangement of the side chain of Phe
149
 (shown behind the transparent 
surface), which is similar to INH-NAD. D) Cross section through the surface of the InhA active 
site with bound PTH-NAD, which has a similar binding mode to INH-NAD and ETH-NAD. The 
carbon atoms of the adduct inhibitors and Phe
149








Figure 2-3. M. tuberculosis InhA with bound inhibitors. A) Superposition of active 
sites of the M. tuberculosis InhA:NADH structure and the InhA:ETH-NAD structure, 
showing the side chain of Phe
149
 rotated 90° once the ETH-NAD adduct binds to the 
enzyme. The carbon atoms of residues and NADH in the InhA:NADH structure are 
cyan. The carbon atoms of residues and ETH-NAD in the InhA:ETH-NAD structure are 
gold. B) The stereo view of the active sites of the M. leprae InhA:PTH-NAD structure. 
The carbon atoms of residues and PTH-NAD adduct are gold and cyan, respectively. 
Other atoms are colored according to the atom type (red, oxygen atoms; blue, nitrogen 











The structures reveal that the active forms of ETH and PTH inhibit M. leprae 
InhA in a similar way to M. tuberculosis InhA. Although no clinical or experimental 
mutant of M. leprae InhA has been reported thus far, based on the binding mode of the 
PTH-NAD adduct, it is very likely that the mutations of InhA found in ETH-resistant M. 
tuberculosis mutant strains, such as S94A, would also confer resistance of M. leprae to 







Figure 2-4. Selected interactions between ETH-NAD and the active site of InhA. A 
conserved water molecule, TIP20, forms a hydrogen bond interaction with the nitrogen 
atom of the 2-ethyl-isonicotinic acyl moiety of the inhibitor at a distance of 2.9 Å. The 
other water molecule, TIP2, is in the center of a hydrogen bonding network, which 
interacts with the oxygen atom of the phosphate group of the adduct and the hydroxyl 
group of Ser
94




It has been proposed that a free radical metabolite intermediate could be 
generated through EthA oxidation of ETH, similar to the activation of INH. However, no 
active species that inhibit InhA were isolated in vitro (DeBarber et al., 2000), which 
suggests that an unknown cell component, either a protein or cell membrane, is required 
for the formation of the adduct by the free radical intermediate. We believe that the 
inactive metabolites isolated in previous attempts could result from side reactions and 




thioamide is oxidized by EthA. Tokuyama et al. demonstrated that a thioamide could be 
used as a precursor of a synthon equivalent to an imidoyl radical in converting 
thioamides to corresponding indole derivatives. Bu3SnH/Et3B has been used as a free 
radical initiator in pure organic solvent (Tokuyama et al., 1999). Similarly, we postulate 
that ETH is converted to an imidoyl radical, and this imidoyl radical subsequently 
attacks NAD
+
 to form an adduct, which is then converted to ethyl-isonicotinic-acyl-NAD 
adduct after hydrolysis to release the amine group. It is also possible that the imidoyl 
anion is the intermediate before forming the adduct with NAD (Figure 2-5). However, 
based on the current evidence, we are not certain if this reaction is catalyzed by EthA 








Figure 2-5. Possible reaction mechanisms for the activation of ETH and the 
formation of ETH-NAD. Two plausible mechanisms for the activation of ETH are 
shown. Either route will lead to the observed ETH-NAD adduct, retaining a tetrahedral 
carbon at position 4 of the nicotinamide ring. 
 
 
INH-NADP adduct formation was not observed in an E. coli-based activation system 
coexpressing katG and dfrA. 
 In the previous study, a synthetic INH-NADP adduct derived from INH 
demonstrated strong inhibition of M. tuberculosis DHFR in vitro (Ki app = 1 nM) 
(Argyrou et al., 2006b). However, the INH-NADP adduct was synthesized by using an 




not truly reflect an enzyme-mediated process inside the cell. To better mimic the in vivo 
activation of INH, a cell-based activation system was designed to examine the KatG-
catalyzed adduct formation and the inhibition of DHFR by the adduct. In this system, 
katG and dfrA were coexpressed in E. coli in the presence of INH to investigate whether 
the activated drug would inhibit DHFR. To construct this system, katG and dfrA were 
cotransformed into the E. coli BL21(DE3) strain and selected on 50 μg of kanamycin 
and carbenicillin/ml. The E. coli strain containing katG and dfrA genes was grown and 
induced in the presence and absence of INH, respectively. After the coexpression of both 
genes was confirmed by SDS-PAGE, recombinant KatG and DHFR proteins were 
readily purified. 
Mass spectroscopy was used to determine whether DHFR purified from the 
experimental sample was bound with any inhibitor. Before the mass spectroscopic 
analysis, the purified DHFR was concentrated and then denatured, followed by filtration 
to separate small molecules from the denatured protein. The MALDI mass spectrum of 
the filtrate, which ranged between 200 and 1,200 Da, was carefully analyzed. We were 
not able to identify any compound that has a molecular mass corresponding to an INH-
NADP adduct. The peaks shown on the spectrum most likely resulted from the cofactor 
NADP and some small fragments of the protein. 
An enzyme assay was performed to determine the activity of purified DHFR. 
DHFR isolated from the experimental sample was found to be fully active (specific 




) compared to the enzyme purified from expression in the 




DHFR in vitro, it would tightly bind to DHFR if the adduct is indeed generated by KatG 
catalysis inside the cell. However, both the activity assay result and the mass analysis 
indicated that no detectable amount of the INH-NADP adduct had bound to DHFR. The 
coexpressed KatG from the same experimental sample was purified and assayed for its 









) (Lei et al., 2000), which 
confirmed that the lack of the INH-NADP adduct did not result from the absence of 
KatG activity. Therefore, the acyclic 4R INH-NADP adduct is not an activated INH 
product generated by KatG catalysis inside the E. coli cell-based system. Thus far, KatG 
is the only identified activator of INH, and it is very unlikely that INH could be activated 
by another unknown protein to form the INH-NADP adduct in M. tuberculosis. As a 
result, we conclude that the synthetic INH-NADP adduct is not biologically relevant to 
INH inhibition.  
 
INH-NAD adduct was detected in the E. coli-based activation system coexpressing 
katG and inhA 
 It has been shown that KatG activates INH and catalyzes the formation of an 
INH-NAD adduct in vitro (Timmins and Deretic, 2006; Wilming and Johnsson, 1999). 
In order to demonstrate that this KatG-catalyzed INH-NAD adduct formation and its 
inhibition of InhA can be reproduced in the E. coli-based system, both katG and inhA 
were transformed into E. coli and coexpressed in the presence of INH. InhA was rapidly 




InhA isolated from the experimental sample had 15% of the specific activity of InhA 
purified without the addition of INH under the same assay condition. The bound 
inhibitor was isolated by denaturing the InhA purified from the experimental sample, 
and a 1 μM concentration of the inhibitor led to complete inhibition of native InhA. The 
crystal structure of InhA in complex with the inhibitor was solved to 2.4 Å resolution. In 
the active site of InhA, an unbiased electron density map clearly indicated the presence 
of a modified NAD with an isonicotinic-acyl group covalently attached to the 4-position 
of the nicotinamide ring in a 4S configuration, which is consistent with the previously 
identified INH-NAD adduct (Rozwarski et al., 1998). This is the first time that the 
activation of INH by KatG and the formation of the INH-NAD adduct has been 
demonstrated in a whole-cell environment. This confirms that our E. coli cell-based 
system is capable of activating the prodrug INH.  
 
Overexpression of dfrA does not confer resistance to INH 
The most direct evidence to support that DHFR is a target of INH comes from 
the observation that overexpression of dfrA in M. smegmatis conferred a 2-fold increase 
in resistance to INH (Argyrou et al., 2006b). Therefore, we first reexamined whether 
overexpression of this protein using a strong promoter in M. smegmatis would lead to 
increased resistance to INH. Use of cosmids harboring a gene on a multicopy plasmid 
along with its native promoter might be a desired approach to overexpress putative 
targets. However, this can result in a failure to observe overexpression whether the 




promoter-specific effect, a novel T7-based expression system was developed for the 
efficient expression of proteins in mycobacteria. In brief, an M. smegmatis strain 
(mc
2
4517) was generated by integrating a plasmid expressing the T7 polymerase under 
the acetamidase-inducible promoter into the genome at the mycobacteriophage L5 
attachment site. M. tuberculosis genes were cloned under the T7 promoter on a separate 
episomal plasmid pYUB1062. Protein expression was induced by the addition of 0.2% 
acetamide. To ensure overexpression of dfrA and inhA, protein lysates were analyzed on 
SDS gels, and a high level of expression was observed within 6 h of induction as a 
distinct band corresponding to the expected size compared to the uninduced control 
(Figure 2-6). The strains overexpressing dfrA (mc
2
5097) and inhA (mc
2
5089) were then 
tested for their susceptibility to INH and ETH and the results obtained are summarized 
in Table 2-1. The MIC for the inhA overexpression strain mc
2
5089 increased more than 
60-fold to 300 μg/ml for INH, compared to the wild-type strain. In contrast to InhA, we 
did not observe any increase in MIC for mc
2
5097, the strain overexpressing DHFR, 
which had been reported to confer 2-fold resistance to INH when induced in M. 
smegmatis with an acetamidase promoter (Argyrou et al., 2006b). Other than DHFR and 
InhA, 16 additional proteins from M. tuberculosis were identified in a previous study 
(Argyrou et al., 2006a) that bound to an INH-NAD or INH- NADP adduct in vitro. We 
applied the same T7 promoter system to successfully overexpress 14 of these genes in 
M. smegmatis, but none of them could confer resistance to INH or ETH (Table 2-1). 
Since this analysis was done in liquid culture, we also tested the ability of the strains to 





Figure 2-6. Overexpression of the proteins in M. smegmatis confirmed by SDS-
PAGE analysis. Lanes: M, marker; 1, vector; 2, Rv0155 (PntAA, 40 kDa); 3, Rv1484 
(InhA, 29.5 kDa); 4, Rv2763c (DfrA, 17.4 kDa); 5, Rv1996 (34.9 kDa); 6, Rv2623 (32.7 
kDa); 7, Rv2766c (FabG5, 30.8 kDa); 8, Rv2858 (AldC, 50 kDa); 9, uninduced Rv2763c 








Table 2-1. MICs determined in 7H9 broth by serial dilution method after 
overexpressing the INH-NAD binding proteins from M. tuberculosis H37Rv in M. 
smegmatis. 






4517 parental strain) 4.7 9.4 
Rv1484 (InhA) 300 150 
Rv2763c (DfrA) 4.7 9.4 
Rv3248c (SahH) 4.7 9.4 
Rv0753c (MmsA) 4.7 9.4 
Rv1187 (RocA) 4.7 9.4 
Rv0155 (PntAA) 4.7 9.4 
Rv2623 (universal stress protein) 4.7 9.4 
Rv1996 (universal stress protein) 4.7 9.4 
Rv0468 (FadB2) 4.7 9.4 
Rv2691 (CeoB/TrkA) 4.7 9.4 
Rv0091 (Mtn/Sah) NA NA 
Rv2858c (AldC) 4.7 9.4 
Rv1059 (unknown) 4.7 9.4 
Rv0926c (unknown) 4.7 9.4 
Rv3777 (probable oxidoreductase) 4.7 9.4 
Rv2971 (probable oxidoreductase) NA NA 
Rv2766 (FabG5) 4.7 9.4 
Rv2671 (RibD) 4.7 9.4 
a








matis strain containing the overexpressed DHFR (mc
2
5072) failed to grow on an INH-
containing plate, while the strain overexpressing InhA (mc
2
5071) showed complete 
resistance. To find out whether DHFR was indeed expressed, the strain containing the 
overexpressed DHFR was plated on medium containing the known DHFR inhibitor 
trimethoprim. Strain mc
2
5072 (DHFR overexpresser) was able to grow on medium 
containing 50 or 150 μg of trimethoprim/ml. In contrast, the parental strain mc
2
5069 or 
the strain overexpressing InhA (mc
2
5071) failed to grow on trimethoprim-containing 
plates. One possible explanation for the difference between our findings and those 
reported previously (Argyrou et al., 2006b) might be that the growth inhibition 
experiment in the previous study was carried out at 30°C, which is not optimal for 
growth, whereas the growth inhibition experiments in our study were performed at 37°C. 
Our observation that the overexpression of M. tuberculosis InhA but not DHFR confers 
resistance to INH and ETH in M. smegmatis using this new expression system is 
consistent with InhA being the primary target of INH and ETH. Even though DHFR has 
been shown to bind an INH-NADP adduct in vitro, this phenomenon is not sufficient to 







Figure 2-7. Growth of the wild-type M. smegmatis strain and transformed strains 
overexpressing DHFR or InhA on media containing the known DHFR inhibitor 




A second overexpression experiment was conducted using the H37Rv strain of 
M. tuberculosis, which is more disease relevant, compared to M. smegmatis. The M. 
tuberculosis H37Rv strain was transformed with the pMV261::dfrA plasmid. The MIC 
of INH for the M. tuberculosis strain overexpressing dfrA is identical to that of the wild-
type H37Rv strain (0.06 μg/ml). On plates with three times the MIC for INH, no growth 
of the M. tuberculosis strain overexpressing dfrA was observed. In contrast, the M. 




the previous report that the MIC for M. tuberculosis overexpressing inhA (1.0 μg/ml) 
increased 20-fold compared to the wild-type H37Rv strain (MIC 0.06 μg/ml) (Larsen et 
al., 2002). Therefore, similar to what we observed in our M. smegmatis experiment, 
overexpression of dfrA did not prevent growth inhibition of M. tuberculosis by INH, 
which genetically demonstrates that M. tuberculosis DHFR is not a relevant target of 
INH. 
 
Absence of polymorphisms in dfrA in INH-resistant clinical isolates  
As an alternative approach to determining whether DHFR might be a relevant 
target of INH, we used whole-genome sequencing to determine whether mutations in 
dfrA could be observed in INH-resistant clinical isolates. If DHFR were a target of INH, 
then it might be expected that mutations might occur in dfrA in INH-resistant clinical 
isolates lacking mutations in inhA or katG. Although mutations in inhA or katG and their 
promoters account for most cases of resistance to INH, the remaining 10 to 25% of cases 






Figure 2-8. Growth of M. tuberculosis H37Rv strains overexpressing DHFR or 
InhA on media containing INH (0.2 μg/ml) or kanamycin (100 μg/ml). Spots: A, 
pMV261::inhA (InhA overexpresser); B, pMV261 (plasmid only); C to F, four 




We sequenced the genomes of six clinical isolates that were INH resistant but 
known not to have relevant mutations in inhA, katG, or their promoters. The six strains 
were sequenced by using an Illumina Genome Analyzer II (see Materials and Methods). 
The depth of coverage (i.e., the number of reads overlapping each site, averaged over the 
whole genome) was 36.9x to 49.4x for each strain, providing high confidence in the final 
base calls. This method has been used successfully to identify known and novel 
mutations associated with resistance to INH, rifampin, pyrazinamide, kanamycin, 
ofloxacin, streptomycin, etc., in many other strains sequenced in our lab. 




earlier (Argyrou et al., 2006a) were searched for polymorphisms. The 100-bp regions 
upstream of the operon containing each gene were also searched for possible SNPs in the 
promoter region that might affect expression level. None of the six clinical isolates 
harbored any mutations in dfrA or its promoter (Table 2-2). Furthermore, few 
nonsynonymous mutations were found in any of the other 16 genes identified as 
potential proteins that can bind an INH-NAD(P)H adduct. Strain 5358 showed the most 
mutations, due to its evolutionary distance from the others (5358 belongs to the M. bovis 
family), but most of the mutations in strain 5358 were also observed in the genome for 
INH-sensitive M. bovis BCG, implying that they are not responsible for INH resistance. 
The only sites where there are potentially relevant differences (i.e., nonsynonymous and 
not in BCG) are a 931-bp deletion of mtn in 5400, aldC(T21A) in 5297, the a-64c 
promoter mutation upstream of Rv1059, the 1-bp frameshift mutation in Rv1059 in 
5297, and Rv3777:P101A in 5297. 
For completeness, other genes traditionally associated with INH resistance were 
also searched, including katG, iniC, ndh, ahpC, etc. (Hazbon et al., 2006), but no known 
mutations responsible for INH resistance could be identified (Table 2-3). Two strains 
showed mutations in katG (F129S in strain 5400 and G285V in strain 5324), and one 
strain has a mutation in efpA (Q513R in strain 5324). None of these mutations has been 
previously reported in INH-resistant strains. The katG F129S mutation is located at the 
dimer interface, and the katG G285V mutation is located at the mouth of the active site 
entrance, so their effect on INH activation is unclear. Mutations in mshA, which 




Table 2-2. Mutations in genes identified as potential INH-NAD(P) binders
a 
   Mutation in strain    
5071 5072 5297 5324 5358 5400 M.bovis 
BCG 
 Protein        
Rv2763c/dfrA None None None None None None None 
Rv3248c/sahH None None None None None None None 
Rv0753c/mmsA None None None None None None None 
Rv1187/rocA None None None None None None None 
Rv0155/pntAa A274A None None None None None None 
Rv2623  None None None None None None None 
Rv1996  None None None None None None None 
Rv0468/fadB2 None None None None L87L None L87L 
Rv2691/ceoB T117A T117A T117A T117A T117A T117A T117A 
Rv0091/mtn None A155P None Q174Q None 931-bp 
deletion 
None 






None None None None None 
Rv3777  None None P101 None None None None 
Rv3777  V160A V160A V160A V160A V160A V160A V160A 
Rv3777  L63L L63L L63L L63L L63L L63L L63L 
Rv0926c  None None None None None None None 
Rv2766c/fabG5 None None None None None None None 
Rv2671/ribD None None None None None None None 
Rv2971  None None None None N152H None N152H 
a
Argyrou et al. (Argyrou et al., 2006a). Mutations are indicated relative to the amino 
acid in the H37Rv reference sequence. Mutations that are shared with M. bovis BCG are 
assumed not to cause isoniazid resistance. 
b







Table 2-3. Mutations in genes traditionally associated with INH resistance
a
 
    Mutation(s) in strain:   
5071 5072 5297 5324 5358 5400 M.bovis    
BCG Protein 
Rv1484/inhA None None None None None None None 
Rv1908c/katG None None None G285V R463L F129S R463L 
Rv1909c/furA None None None None A46V None A46V 
Rv1854c/ndh None None None None G313R None G313R 




Rv0341/iniB None None None None None None None 
Rv0343/iniC None None None None None None None 
Rv3139/fadE24 None None None None None None None 
Rv2245/kasA None None None None None None None 
Rv2246/kasB None None None None None None None 
Rv2428/ahpC None None None None None None None 
Rv2242 None None None None A363T None A363T 
Rv0340 None None None None None None None 
Rv1592c I322V I322V I322V I322V I322V I322V I322V 
Rv1772 None None None None Deletion None Deletion 
Rv2846c/efpA None None None Q513R T15R None T15R 
Rv0486/mshA N111S N111S None N111S None N111S None 
a
 Mutations are indicated relative to the amino acid in the H37Rv reference sequence. 











ETH resistance, but the N111S allele appears in the Erdman strain, which is as 
susceptible to these drugs as H37Rv (Vilcheze et al., 2008). Although the true cause of 
INH resistance in these six strains remains undetermined, the lack of mutations in dfrA 
and the 16 other putative INH-NAD(P)-binding proteins suggests that they are unlikely 
to be targets of INH. We also have sequenced the dfrA gene in six additional M. 
tuberculosis strains known to be INH-resistant but with no known relevant mutations. 
None of these had a mutation in the dfrA gene. Consistent with our findings, a recent 
large-scale screening of 127 INH-resistant M. tuberculosis isolates from Singapore by 




Cloning, expression, and purification 
The M. tuberculosis dfrA, katG and inhA genes were cloned as previously 
described (Argyrou et al., 2006b; Dessen et al., 1995). M. tuberculosis ethA was cloned 
from genomic DNA (National Institutes of Health contract N01-AI-75320; Colorado 
State University). The amplified product was inserted into pET28b using the NdeI and 
NotI restriction sites. M. leprae ethA and inhA were cloned from genomic DNA. The 
amplified product of M. leprae ethA was inserted into pET15b using the NdeI and 
BamHI restriction sites. M. leprae inhA was inserted into pET30b using the NdeI and 
HindIII restriction sites. 




and M.leprae inhA and ethA were singly and doubly transformed into E. coli BL21(DE3) 
(EMD Bioscience, catalog no. 69387-3). The strains containing both plasmids were 
cultured in LB-Miller medium containing 50 μg/ml kanamycin and 50 μg/ml 
carbenicillin at 37°C until OD600 reached 0.5. Expression of both genes was induced for 
20 h at 16°C by addition of 1 mM isopropyl β-D-thiogalactopyranoside. At the same 
time of induction, 100 μg/ml of INH or ETH or PTH was also added to the culture. The 
same protocol was used for the strains containing just the dfrA or inhA plasmids.  
Recombinant M. tuberculosis DHFR and KatG was purified according to a 
previously described method (Argyrou et al., 2006b; Zhao et al., 2006). Recombinant 
InhA was purified according to the method described in Chapters III and IV. The 
coexpression and purification of M. leprae ethA and inhA were conducted using 
protocols similar to those used for the M. tuberculosis enzymes. 
 
Mass spectroscopy analysis for adduct identification  
InhA purified from the experimental strain containing both inhA and ethA genes 
was concentrated and heated for 40 s at 100°C. After the heat treatment, ETH-NAD or 
PTH-NAD was separated from denatured enzymes by filtration, using a centricon device 
(cutoff size = 30 kD). The concentration of ETH-NAD and PTH-NAD was determined 
by its absorbance at 260 and 326 nM (Lei et al., 2000). The molecular weight of both 
adducts was determined by matrix-assisted laser desorption/ionization (MALDI) 
performed on an ABI Voyager-DE STR (AME Bioscience): ETH-NAD, calculated 




799.2 and found weight = 799.2 (positive mode); PTH-NAD, calculated weight = 811.2 
and found weight = 811.3 (negative mode). Mass spectrometry analysis for DHFR was 
performed in a similar way. Purified DHFR was heated for 60 s at 100°C. After the heat 
treatment, denatured enzyme was separated by filtration, using a Centricon (cutoff, 3 
kDa). The filtrate was used for MALDI experiment.  
 
DHFR, KatG and InhA enzymatic activity assays  
All assays were carried out on a Cary 100 Bio Spectrophotometer at 25°C. 
DHFR assays are performed by monitoring the oxidation of NADPH and reduction of 
dihydrofolate (DHF) at 340 nm. Reactions were initiated by adding DHFR (10 nM) to 
assay mixtures containing NADPH (10 μM), DHF (4.5 μM), and phosphate buffer (pH 
7.5, 50 mM). The KatG activity was assayed as previously described (Zhao et al., 2006). 
InhA activity was monitored by oxidation of NADH at 340 nm. Reactions were initiated 
by adding 50 μM of substrate dodecenoyl-CoA to assay mixtures containing 1 nM InhA, 
100 μM NADH, and 3–2,000 nM of adduct inhibitors. The IC50 was determined from the 
dose-response plot of enzyme fractional activity as a function of inhibitor concentration. 
Ki was obtained by dividing the IC50 value by 1 + [S1]/Km1 + [S2]/Km2, where [S1] and 








Crystallization of InhA in complex with the INH-NAD, ETH-NAD and PTH-NAD 
adducts  
Crystallization was accomplished by the hanging-drop vapor diffusion method. 
Mtb or M. leprae InhA in complex with INH-NAD, ETH-NAD or PTH-NAD was 
cocrystallized in hanging droplets containing 2 μl of protein solution at 10 mg/ml and 
with 2 μl of buffer (12% 2-methyl-2,4-pentanediol, 4% dimethyl sulfoxide, 0.1 M 
HEPES, and 0.025 M sodium citrate) at 16°C  against 1 ml of the same buffer. Diamond 
or cubic shaped protein crystals appeared 4 days later. 
 
Data collection and processing 
Data were collected at 121 K using cryoprotection solution containing reservoir 
solution with an additional 30% MPD. Crystals of M. tuberculosis InhA:INH-NAD, 
InhA:ETH-NAD and M. leprae InhA:PTH-NAD diffracted x-rays to 2.4, 2.2 and 1.8 Å 
using the beamline 23-ID at the Advanced Photon Source (Argonne National 
Laboratory, Argonne, IL). Diffraction data were collected from a single crystal with 1° 
oscillation widths for a range of 120°. Crystals of M. tuberculosis InhA:PTH-NAD were 
diffracted to 2.5 Å using a Raxis image plate detector coupled to a Rigaku x-ray 
generator using a copper rotating anode (CuKα, λ = 1.54 Å). The data were integrated 
and reduced using HKL-2000 (HKL Research, Inc.) (Otwinowski and Minor, 1997). 
 
Structure determination and model refinement 




those of the native enzyme. Initial phases were obtained by molecular replacement using 
the apo-InhA structure (1ENY) and refined with CNS software (Brunger et al., 1998). Fo 
– Fc and 2Fo – Fc electron density maps were calculated, and an additional density 
resembling the inhibitor was found. The ligand was fit into the additional density, and 
the whole model was rebuilt using XtalView (McRee, 1999). During the final cycles of 
the refinement, water molecules were added into peaks above 3 σ of the Fo − Fc electron 
density maps that were within hydrogen-bonding distances from the appropriate protein 
atoms.  
 
T7-based expression system for mycobacteria 
  
Construction of M. smegmatis expression strain, mc
2
4517 
pT7Pol26 was digested with BamHI to excise the RNA polymerase gene of 
bacteriophage T7. The 2.7-kb BamHI DNA fragment was ligated to BamHI-digested 
pSD26 plasmid, and the orientation was confirmed by digestion with the appropriate 
restriction enzymes. The DNA fragment of an acetamidase promoter fused to T7 
polymerase was then cloned into pMV306, to generate pYUB1232. The expression 
strain mc
2





Construction of expression plasmids 




NarI/SspI DNA fragment (948 bp) from pET30a plasmid and the NarI/EcoRV DNA 
fragment (4,026 bp) of pMV206. Shuttle vector pYUB1062 contains an oriE for 
replication in E. coli, oriM for replication in mycobacteria, a hygromycin cassette for 
antibiotic selection, a T7 promoter/terminator, and a histidine tag region for the 
purification of overproduced protein. The various M. tuberculosis genes were cloned 
into pYUB1062 using NdeI or NcoI as the upstream site and an appropriate down-stream 
site.  
 
Expression of INH-NAD- or INH-NADP-binding proteins from M. tuberculosis 
M. smegmatis mc
2
4517 cells were transformed with plasmids expressing INH-
NAD- or INH-NADP-binding protein of M. tuberculosis. A single bacterial colony was 
grown in all cases at 37°C to an A600 of 0.6 to 0.8 in Middlebrook 7H9 broth medium 
supplemented with 0.2% Tween 80, 0.05% glycerol, kanamycin (20 μg/ml), and 
hygromycin B (100 μg/ml). Cell cultures were diluted 1:100 in 50 ml of the same liquid 
medium and cells were grown to mid-exponential phase (A600 0.5 to 0.6) at 37°C at 120 
rpm before induction with acetamide. The bacterial cultures were divided into equal 
volumes, and 0.2% (wt/vol) acetamide was added to the one of the aliquots (the other 
aliquot was used as a control). Expression of protein was determined after 6 h of 
induction by analyzing the cell-free protein extract by 10 to 20% SDS-PAGE. 
 
MIC determination 




of 0.6 and then induced with 0.2% acetamide for 6 h until the OD reached 1.0. The cells 
were then diluted by 10
5
-fold and incubated in 200 μl of 7H9 medium containing INH 
(0, 0.6, 1.2, 4.7, 9.4, 18.6, 37.5, 75, 150, and 300 μg/ml) in a 96-well plate. The plates 
were incubated at 37°C and observed after 72 h. The MIC was determined as the 
concentration of drug at which no visible growth was observed. MICs for M. 
tuberculosis strains were determined by using an MTT assay (Martin et al., 2005). The 
concentrations of INH tested were 0, 0.015, 0.03, 0.06, 0.12, 0.24, 0.48, 0.96, 1.92, and 
3.84 μg/ml. 
 
Sequencing of clinical isolates  
Six INH-resistant clinical isolates (strains 5071, 5072, 5297, 5324, 5358, and 
5400) were obtained for whole-genome sequencing. The clinical isolates were collected 
from Mexico between 1991 and 1996 by the Laboratory of Clinical Microbiology, 
Instituto Nacional de Ciencias Me´dicasy Nutricio´n Salvador Zubira´n, Mexico City, 
under an IRB-approved protocol. Five of the six strains were genotyped as belonging to 
SNP cluster group SCG_3b, whereas strain 5358 belongs to the M. bovis family based 
on spoligotyping. MICs for INH ranged from 0.2 to 8.0 μg/ml compared to 0.03 μg/ml 
for H37Rv. 
Genomic DNA was extracted by using a CTAB (cetyltrimethylammonium 
bromide) protocol as previously described (Larsen et al., 2007). The DNA library was 
constructed by using a genomic DNA sample preparation kit (Illumina). The sample was 




fragments comprised of 3 or 5 overhangs were converted into blunt ends, using T4 DNA 
polymerase and Klenow enzyme. Klenow 3 -to-5 exonuclease minus was used to add an 
“A” base to the phosphorylated 3 blunt end of the DNA fragments so that the fragments 
could be ligated to the adaptors, which have a single “T” base overhang at their 3 end. 
The ligated DNA was then size selected on a 2% agarose gel. DNA fragments of 300 bp 
were excised from the preparative portion of the gel. DNA was then recovered by using 
a Qiagen gel extraction kit and PCR amplified to produce the final DNA library. A total 
of 5 pmol of DNA from each strain was loaded onto a different lane of the sequencing 
chip (eight lanes total), and the clusters were generated on the cluster generation station 
of a Genome Analyzer II using the Illumina Cluster generation kit. Bacteriophage X174 
DNA was used as a control. 
The sequencing reaction was run for 36 cycles (tagging, imaging, and cleavage 
of one terminal base at a time), and four images of each tile on the chip were taken in 
different wavelengths for exciting each base-specific fluorophore. Image analysis and 
base-calling were done by using v0.3 of the Illumina GA Pipeline software. 
The 36 bp reads that were generated for each strain were mapped (aligned) 
against H37Rv as a reference sequence (or M. bovis in the case of strain 5358, which 
was the closest reference strain by spoligotyping). Apparent differences (at sites where 
the consensus base from overlapping reads differed from the expected base in the 
reference sequence), along with sites where coverage was low or observed bases were 
heterogeneous, were identified, and local contig-building was used to resolve them into 






Additional unpublished results  
 
Coexpression experiments for InhA-EthA, Dhfr-KatG and Dhfr-EthA 
Initial coexpression trials for InhA and EthA or Dhfr and KatG were performed 
using a duet expression vector. The corresponding genes were successively cloned into 
the multiple cloning sites of the pETDuet (Novagen) vector. Each gene sequence was 
verified by DNA sequencing. Individual colonies harboring the InhA-EthA, Dhfr-KatG, 
or Dhfr-EthA pETDuet plasmids were inoculated into Luria broth (LB) medium. 
Coexpression was tested in both small (5 ml) and large scale (2 L) cultures. The cells 
were grown till the log phase and were induced with IPTG at 18 °C and 37 °C.  Samples 
were aliquoted from each flask and subjected to SDS-PAGE analysis. However, it was 
found that coexpression from a single plasmid did not yield either a good amount of 
protein expression or soluble protein (Figure 2-9B). Therefore, coexpression 
experiments were performed by co-transformation of two individual plasmids carrying 
each gene into the same E. coli cell. Mtb and M.leprae InhA and EthA, or Mtb Dhfr and 
KatG were cloned into individual expression vectors with different antibiotic selection 
markers (pET15b with carbenecillin marker and pET28b or pET30b (Novagen) with 
kanamycin marker), which were simultaneously cotransformed to E. coli BL21(DE3) 
cells. This approach yielded sufficient amount of soluble InhA, Dhfr and KatG proteins 






Figure 2-9. Recombinant coexpression of Mtb Dhfr and KatG proteins in E.coli. A) 
Plasmids carrying Dhfr and KatG genes were co-transformed to E.coli BL21(DE3) cells. 
Two individual colonies carrying both plasmids were inoculated into LB medium and 
protein expression was induced by 1 mM IPTG. Over-expression of both proteins (Dhfr- 
17.5 kDa and KatG- 80 kDa) was clearly visible in the SDS-PAGE gel. B) Dhfr and 
KatG genes were cloned into pETDuet vector and the presence of both inserts were 
verified by DNA sequencing. Four individual colonies were inoculated into LB medium 
and expression was induced by 1 mM IPTG. As seen from the SDS-PAGE gel, there was 
no over-expression for either protein. For both panels, NI represents before IPTG 
induction (non-induced), I is after IPTG induction (induced).     
 
 
We have shown that both INH and ETH target InhA by forming structurally 
similar adducts with NAD
+
. Since it was proposed that Dhfr was inhibited by the INH-
NADP adduct, we tested if the same hypothesis can hold for ETH, which is a structural 
analog of INH. Similar to the Dhfr/KatG coexpression experiment, Dhfr and EthA were 
coexpressed in the presence of 100 μg/ml ETH, to determine if the cell activated ETH 
can inhibit Dhfr. However, despite the optimization of induction time, temperature and 
the expression host cell line, no soluble Dhfr protein was obtained when it was 




also not target Dhfr, as we have shown that the INH-NAD adduct does not bind to Dhfr 




Figure 2-10. Recombinant coexpression of Mtb Dhfr and EthA proteins in E.coli. A) 
The plasmids carrying the dhfr and ethA genes were co-transformed to E. coli 
BL21(DE3) cells. A single colony carrying both plasmids was inoculated into 5 ml LB 
medium and protein expression was induced by 1 mM IPTG. Over-expression of both 
proteins (Dhfr- 17.5 kDa and EthA- 55 kDa) was clearly visible in the SDS-PAGE gel. 
B) Dhfr and EthA were overexpressed in the presence of ETH. Cells were lysed by 
French press and spinned at 16K rpm. The lysate (L), supernatant (S) and pellet (P) were 
run on a SDS-PAGE gel. As concluded from the gel, the majority of the Dhfr protein 
was in pellet (insoluble).   
 
 
Inhibition of InhA activity by the cell-activated ETH 
After coexpression of Mtb InhA and EthA in the presence of 100 μg/ml ETH, 
InhA was purified and the enzymatic activity was monitored. As a control experiment, 
either InhA was singly expressed in the presence of ETH or InhA and EthA were 




sample (InhA+EthA+ETH) displayed very low (<1%) enzymatic activity (Figure 2-11). 
In contrast, the control experiments, where InhA and EthA were coexpressed in the 
absence of ETH, or InhA was singly expressed in the presence of ETH, showed that 
InhA activity was retained in these situations (Figure 2-11). This demonstrated that ETH 
was a pro-drug and it could not inhibit InhA without activation by EthA. In addition, 
InhA inhibition was solely due to the in vivo activated ETH molecule (ETH-NAD 





Figure 2-11. InhA inhibition after coexpression with EthA in the presence of ETH. 








Isoniazid (INH) and ethionamide (ETH) have been used for the treatment of M. 
tuberculosis and M. leprae infections, the causative agents of tuberculosis and leprosy 
diseases, respectively. Both INH and ETH are prodrugs requiring activation inside the 
cell. The mechanism of action for INH has been established. INH is activated by the 




the 4-position of 
the nicotinamide ring in an S
 
configuration. In contrast, the active form of ETH has not 
been demonstrated before this study. The enoyl-reductase enzyme, InhA, has been 
shown to be the molecular target of both drugs. Recently, it was proposed that the 
dihydrofolate reductase enzyme, Dhfr, of Mtb was also a target of INH, based on the 
findings that a non-enzymatically generated 4R-INH-NADP adduct strongly inhibited 
Dhfr in vitro, and Dhfr overexpression in M. Smegmatis confered 2-fold resistance to 
INH. In this study, an E. coli cell-based activation system was developed, which allowed 
the coexpression of the activator and the target gene of a drug in the presence of the drug 
compound. To determine the active form of ETH, Mtb and M. leprae InhA and EthA 
proteins were co-overexpressed in the presence of ETH, and the active form of ETH was 
isolated and characterized by mass spectrometry and X-ray crystallography. It was 
demonstrated that ETH displayed a similar mode of action as INH, and the biologically 
active form of ETH was consisted of an ETH-NAD
+
 adduct in a 4S configuration. 
Similarly, to test whether Dhfr and InhA were molecular targets of INH, Dhfr/KatG or 
InhA/KatG proteins were coexpressed in the presence of INH. Mass spectrometry and 




INH-NAD(P) adduct. In addition, it was verified that overexpression of the Dhfr protein 
in M. Smegmatis and Mtb did not confer resistance to INH, and INH resistant clinical 
isolates did not carry polymorphisms in the dfrA gene. These findings conclusively 






CHAPTER III  





The remarkable survival ability of Mycobacterium tuberculosis in infected hosts 
is related to the presence of cell wall-associated mycolic acids. Despite their importance, 
the mechanisms that modulate expression of these lipids in response to environmental 
changes are unknown. Here we demonstrate that the enoyl-ACP reductase activity of 
InhA, an essential enzyme of the mycolic acid biosynthetic pathway and the primary 
target of the anti-tubercular drug isoniazid, is controlled via phosphorylation. Thr-266 is 
the unique kinase phosphoacceptor, both in vitro and in vivo. The physiological 
relevance of Thr-266 phosphorylation was demonstrated using inhA phosphoablative 
(T266A) or phosphomimetic (T266D/E) mutants. Enoyl reductase activity was severely 
impaired in the mimetic mutants in vitro, as a consequence of a reduced binding affinity 
to NADH. Importantly, introduction of inhA_T266D/E failed to complement growth and 
mycolic acid defects of an inhA-thermosensitive Mycobacterium smegmatis strain, in a 
similar manner to what is observed following isoniazid treatment. This study suggests 
that phosphorylation of InhA may represent an unusual mechanism that allows M. 
                                                 

 Reprinted with permission from “Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth 
of Mycobacterium tuberculosis” by Gulten G., Molle V., Vilchèze C., Veyron-Churlet R., Zanella-Cléon 
I., Sacchettini J.C., Jacobs W.R., Kremer L., 2010. Molecular Microbiology, 78(6), 1591–1605, Copyright 





tuberculosis to regulate its mycolic acid content, thus offering a new approach to future 
anti-tuberculosis drug development. 
 
Introduction 
Mycolic acids are the major and distinguishing molecular components of the 
Mycobacterium tuberculosis cell envelope. These very long α-alkyl β-hydroxyl fatty 
acids are found either unbound as esters of trehalose or glycerol that are extractable with 
organic solvents or attached to the terminal penta-arabinofuranosyl units of 
arabinogalactan, the polysaccharide that, together with peptidoglycan, forms the 
insoluble cell-wall skeleton (McNeil et al., 1991). These lipids play an important role in 
the formation of an outer membrane and in cell-wall impermeability, virulence, immune 
evasion (Bhatt et al., 2007a; Bhatt et al., 2007b; Dao et al., 2008; Dubnau et al., 2000; 
Glickman et al., 2000; Rao et al., 2006) and the distinctive acid-fast staining of M. 
tuberculosis (Bhatt et al., 2007a). Recent studies have also revealed free mycolic acids in 
M. tuberculosis biofilms (Ojha et al., 2008). Mycolic acid synthesis is tightly related to 
cell division, as evidenced by the fact that isoniazid (INH) and ethionamide (ETH), two 
antitubercular drugs, inhibit mycolic acid biosynthesis, resulting in cell lysis (Takayama 
et al., 1972). This metabolic pathway thus represents an important reservoir of targets for 
new drugs (Dover et al., 2008), which are more critical than ever since the emergence of 
multidrug-resistant and extremely drug-resistant strains of M. tuberculosis.  
Biosynthesis of mycolic acids depends on two distinct fatty acid synthases: the 




is a single polypeptide that performs de novo biosynthesis of medium-length acyl-CoAs 
(C16 and C24–C26) (Bloch, 1975; Zimhony et al., 2004). These are used as primers by the 
FAS-II system and are iteratively condensed with malonyl- Acyl Carrier Protein (ACP) 
in a reaction catalysed by mtFabH, the β-ketoacyl-ACP synthase III of M. tuberculosis 
(Brown et al., 2005; Choi et al., 2000; Scarsdale et al., 2001). During the second step of 
the elongation cycle, the resulting β-ketoacyl-ACP product is reduced by MabA, the 
NADPH-dependent β-ketoacyl reductase of M. tuberculosis (Banerjee et al., 1998; 
Marrakchi et al., 2002). The resulting β-hydroxyacyl-ACP is then dehydrated by a set of 
dehydratases, HadABC (Brown et al., 2007; Sacco et al., 2007), and finally reduced by 
the NADH-dependent 2-trans-enoyl-ACP reductase, InhA (Quemard et al., 1995). The 
succeeding steps of condensation of the elongating chain with malonyl-ACP units are 
performed by the β-ketoacyl-ACP synthases KasA and KasB (Bhatt et al., 2007a; 
Kremer et al., 2002; Schaeffer et al., 2001), leading to very long-chain meromycolyl-
ACPs (up to C56), which are the direct precursors of mycolic acids (Kremer et al., 2000a; 
Takayama et al., 2005).  
InhA belongs to the family of short-chain dehydrogenases/reductases (Dessen et 
al., 1995; Quemard et al., 1995). Genetic studies have revealed that inhA is essential in 
mycobacteria (Vilcheze et al., 2000). Thermal inactivation of InhA in a Mycobacterium 
smegmatis strain carrying an inhA-thermosensitive allele resulted in inhibition of 
mycolic acid biosynthesis and cell lysis in a manner similar to that seen in INH-treated 
bacteria (Vilcheze et al., 2000). It is now clear that INH is activated by the catalase 




resulting INH-NAD adduct inhibits InhA (Rozwarski et al., 1998), leading to 
accumulation of long-chain fatty acids, inhibition of mycolic acid biosynthesis and 
ultimately cell death (Vilcheze et al., 2000). INH resistance also involves several genes 
but only mutations in inhA have a dominant phenotype, whereas all other mechanisms of 
resistance (katG, ndh, msh, nat) are recessive (Vilcheze and Jacobs, 2007). The inhA 
gene product was originally identified as a putative target for INH and ETH in M. 
smegmatis (Banerjee et al., 1994). An increasing body of evidence has since pointed to 
InhA as the primary target of the two drugs (Kremer et al., 2003; Larsen et al., 2002; 
Vilcheze et al., 2000; Wang et al., 2007), culminating in the demonstration that transfer 
of an inhA S94A mutant allele in M. tuberculosis was sufficient for conferring resistance 
to both INH and ETH and establishing InhA as the clinically relevant target of INH 
(Vilcheze et al., 2006). InhA is one of the best-validated targets for the development of 
antitubercular agents. Further studies on INH, as well as on other small-molecule 
inhibitors of InhA, hold significant promise for the delivery of novel anti-tubercular 
agents effective against drug-resistant M. tuberculosis (am Ende et al., 2008; Freundlich 
et al., 2009; He et al., 2007; He et al., 2006; Oliveira et al., 2007; Tonge et al., 2007; 
Vilcheze and Jacobs, 2007). This prompted us to seek new alternatives for InhA 
inactivation, ultimately leading to mycolic acid and cell growth inhibition. Indeed, 
mycolic acid biosynthesis and cell division are very likely to be related (Lacave et al., 
1989; Lacave et al., 1987; Takayama et al., 1972). We hypothesized that the activity of 
InhA might be controlled by post-translational modification in M. tuberculosis. This idea 




regulated by Ser/Thr protein kinase (STPK)-dependent phosphorylation, providing the 
first information on the molecular mechanism(s) involved in mycolic acid regulation 
through phosphorylation of a FAS-II enzyme (Veyron-Churlet et al., 2010) and (ii) the 
fact that genes encoding the two FAS-II reductases, MabA and InhA, are in the same 
operon in the M. tuberculosis genome (Banerjee et al., 1998; Cole et al., 1998).  
Many of the stimuli encountered by M. tuberculosis are transduced via sensor 
kinases in the membrane, allowing the pathogen to adapt to survive in hostile 
environments. In addition to the classical two-component systems, M. tuberculosis 
contains 11 eukaryotic-like STPKs (Av-Gay and Everett, 2000; Cole et al., 1998). There 
is now an increasing body of evidence suggesting that, in M. tuberculosis, many STPKs 
are involved in regulating metabolic processes, transport of metabolites, cell division or 
virulence (Molle and Kremer, 2010). Signalling through Ser/Thr phosphorylation has 
recently emerged as a key regulatory mechanism in pathogenic mycobacteria (Molle and 
Kremer, 2010; Wehenkel et al., 2008).  
As a first step to decipher an original molecular mechanism for future drug 
development by specifically targeting InhA, this study was undertaken to determine 
whether InhA represents a new substrate of M. tuberculosis SPTKs and to investigate 
whether phosphorylation negatively regulates InhA activity and consequently mycolic 









 InhA is phosphorylated in vitro by multiple Ser/Thr kinases (STPK)  
By analogy with the mode of action of INH, we reasoned that inhibition of 
mycolic acid biosynthesis might occur in vivo via post-translational modifications of 
InhA capable of reducing the enoyl reductase (ENR) activity of the enzyme. This 
prompted us to examine whether InhA could be modified by phosphorylation, a reaction 
that changes the physicochemical properties of defined Ser or Thr residues by 
introducing negative charges, which can ultimately affect the overall activity of the 
protein. This was first investigated in vitro in the presence of purified STPKs (PknA to 
PknL). The kinase domains of several transmembrane kinases from M. tuberculosis were 
expressed as GST-tagged fusion proteins and purified from Escherichia coli as reported 
earlier (Molle et al., 2006). The purified kinases were incubated with InhA and [γ-
33
P]-
ATP, resolved by SDS-PAGE and their phosphorylation profiles analysed by 
autoradiography. The presence of intense radioactive signals indicated that InhA was 
phosphorylated by multiple kinases, including PknA, PknB, PknE and PknL (Figure 3-
1A). No signal was observed in the presence of PknF, PknH or PknK, all of which 
displayed various autokinase activities as reported earlier (Molle et al., 2006). These 
results clearly indicate that InhA is a specific substrate and interacts with various STPKs 
in vitro, suggesting that this key protein of the mycolic acid biosynthetic pathway might 






Figure 3-1. M. tuberculosis InhA is phosphorylated in vitro by Ser/Thr kinases on 
residue Thr-266. A) In vitro phosphorylation of InhA by multiple kinases. Eight 
recombinant STPKs (PknA to PknL) encoded by the M. tuberculosis genome were 
expressed and purified as GST fusions and incubated with purified His-tagged InhA and 
radiolabelled [γ-
33
P]-ATP. The quantity between the STPKs varied from 0.2 to 1 μg in 
order to obtain the optimal autophosphorylation activity for each specific kinase. 
Samples were separated by SDS-PAGE, stained with Coomassie blue (upper panel) and 
visualized by autoradiography after overnight exposure to a film (lower panel). Upper 
bands reflect the autophosphorylation activity of each kinase and the lower bands 
correspond to the phosphorylation signal of InhA. B) Mass spectrometric analysis of 
PknB-phosphorylated InhA. MS/MS spectrum of the triply charged ion [M+3H]
3+
 at m/z 
1051.51 of peptide (241–269) (monoisotopic mass: 3151.52 Da). Unambiguous location 
of the phosphate group on Thr-266 was shown by observation of the ‘y’ C-terminal 
daughter ion series. Starting from the C-terminal residue, all ‘y’ ions lose phosphoric 
acid (-98 Da) after the Thr-266 phosphorylated residue. C) In vitro phosphorylation of 
the InhA_T266A mutant. Purified InhA_WT and InhA_T266A were incubated with 
PknB and [γ-
33
P]-ATP. Samples were separated by SDS-PAGE, stained with Coomassie 











InhA is phosphorylated on a unique threonine residue  
Mass spectrometry was used to identify the number and nature of the 
phosphorylation sites on InhA. Such a method has been successfully used to elucidate 
the phosphorylation sites in a sequence-specific fashion for several M. tuberculosis 
STPK substrates (Barthe et al., 2009; Canova et al., 2009; Veyron-Churlet et al., 2009; 
Veyron-Churlet et al., 2010). InhA was incubated with unlabelled ATP in the presence 
of PknB (one of the most active kinases for InhA, Figure 3-1A) and subjected to mass 
spectrometric analysis after tryptic and chymotryptic digestion. Spectral identification 
and phosphorylation determination were achieved with the paragon algorithm from the 
ProteinPilot® 2.0 database-searching software (Applied Biosystems) using the 
phosphorylation emphasis criterion against a homemade database that included the 
sequences of InhA and derivatives. The phosphopeptides identified by the software were 
then validated by manual examination of the corresponding MS/MS spectra. Manual 
validations were performed based on neutral loss of H3PO4 from the precursor ion and 
the assignment of major fragment ions to b- and y-ion series or to the corresponding 
neutral loss of H3PO4 from these ions. The sequence coverage of the protein was 94% 
and phosphorylation occurred only on peptide (241–269) with an 80 Da mass increment 
from 3071.53 Da (theoretical MW) to 3151.52 Da (monoisotopic mass). The MS/MS 
spectra unambiguously confirmed the presence of a phosphate group on Thr-266 
(Figures 3-1B and A-1A). Then, in order to prevent in vitro phosphorylation on Thr-
266, this residue was changed to alanine by site-directed mutagenesis. The 




His-tagged protein in E. coli BL21(DE3)Star harbouring pETPhos_inhA_T266A. The 
resulting InhA_T266A mutant protein was purified and incubated with PknB in the 
presence of [γ-
33
P]-ATP. Following separation by SDS-PAGE and analysis by 
autoradiography, total abrogation of the phosphorylation signal was observed compared 
with InhA_WT (Figure 3-1C). Similar results were obtained when InhA_T266A was 
incubated in the presence of either PknA, PknE or PknL (data not shown), indicating that 
Thr-266 represents the phosphoacceptor for all four kinases.  
Taken together, these results indicate that Thr-266 represents the unique 
phosphorylation site in InhA and suggest that phosphorylation of this residue is likely to 
play a critical role in the regulation of InhA activity.  
 
In vivo phosphorylation of InhA  
To corroborate the in vitro results, it was necessary to confirm the 
phosphorylation state of the InhA protein in vivo. The inhA gene was cloned into the 
pMK1 mycobacterial expression vector under the control of the strong promoter hsp60 
(Table A-1). The resulting construct was used to transform Mycobacterium bovis BCG 
Pasteur in order to allow over-production of recombinant His-tagged InhA, which was 
purified and subjected to 2D-gel electrophoresis. As shown in Figure 3-2A, two spots, 
presumably corresponding to the non-phosphorylated form followed in the acidic 
direction by a mono-phosphorylated form of InhA, were clearly detected. Definitive 
identification and localization of Thr-266 as the unique phosphorylation site in InhA in 




BCG cultures. LC-MS/MS identified an 80 Da mass increase corresponding to the 
peptide (241–269), supporting the conclusion that InhA is phosphorylated in vivo in M. 
bovis BCG (Figures 3-2B and A-1B). Together, these results confirm that Thr-266 
corresponds to the primary phosphorylation site both in vitro and in vivo.  
 
ENR activity is strongly reduced for the InhA_T266D and InhA_T266E 
phosphomimetic mutants  
Earlier studies showed that the acidic Asp or Glu amino acids qualitatively 
mimic the effect of phosphorylation with regard to functional activity. Following a 
strategy successfully used to demonstrate the role of phosphorylation on the condensing 
activity of mtFabH (Veyron-Churlet et al., 2009) and the β-ketoacyl-ACP reductase 
MabA (Veyron-Churlet et al., 2010), we first expressed and purified the 
phosphomimetics InhA_T266D and InhA_T266E. Next, we determined the in vitro ENR 
activity of these mimetics and compared their enzymatic activity with those of 
InhA_WT in the presence of increasing concentrations of trans-2-dodecenoyl-CoA (DD-
CoA). Figure 3-3A clearly shows a strongly reduced activity of the two phosphomimetic 
mutants. The effect of mutation at T266 on the enzymatic activity was then calculated as 
the remaining per cent activity. The phosphoablative InhA_T266A protein showed very 
similar catalytic activity to the wild-type enzyme, indicating that this residue is not 






Figure 3-2. In vivo phosphorylation of InhA in mycobacteria. A) Phosphorylation 
profile of InhA purified from recombinant M. bovis BCG carrying the pMK1_inhA_WT. 
Bacteria were lysed and the soluble fraction was incubated with Ni-NTA agarose beads 
to purify the His-tagged InhA. The protein preparation was loaded on a 7 cm immobiline 
strip (Bio-Rad, pH 5–8) and electrophoresed on a Protean IEF Cell (Bio-Rad) for the 
first dimension and on a 10% SDS-PAGE for the second dimension, then stained with 
Coomassie blue. The grey circles represent the different phosphorylated isoforms, as 
indicated: np, non-phosphorylated; 1P; mono-phosphorylated. B) Mass spectrometric 
analysis of InhA purified in vivo. MS/MS spectrum of the triply charged ion [M+3H]
3+
 
at m/z 1051.51 of peptide (241–269) (monoisotopic mass: 3151.52 Da). The phosphate 
group on T266 was unambiguously located by observing the ‘y’ C-terminal daughter ion 
series. Starting from the C-terminal residue, all ‘y’ ions lose phosphoric acid (-98 Da) 








InhA_T266E and InhA_T266D mutants showed only ~30% residual enzymatic 
activity. Subsequent enzymatic studies were focused on Asp and Glu mutants to 
determine the reason behind this significant loss of function. Initial velocity studies with 
Asp and Glu mutants suggested that both followed a random order reaction mechanism 
with preferred NADH binding prior to DD-CoA binding, which was reported previously 
for wild-type InhA (Parikh et al., 1999; Quemard et al., 1995) (Figures 3-3A and 3-3C). 
This preferred-ordered pathway towards NADH binding resulted in sigmodial initial 
velocity curves as the NADH concentrations were varied at a fixed DD-CoA 
concentration (Figure 3-3A, right panel). On the other hand, when the concentration of 
DD-CoA was varied at fixed concentrations of NADH, a pattern similar to substrate 
inhibition was observed (Figure 3-3A, left panel). The steady-state kinetic parameters, 
kcat and Km, calculated for DD-CoA for InhA_WT, InhA_T266A, InhA_T266D and 
InhA_T266E mutants are presented in Table 3-1. Both Asp and Glu mutants exhibited 
Km values for DD-CoA very similar to those of the wild-type and T266A mutant 
enzymes but kcat and Vmax values for the wild type and Ala mutant showed three- to 
fourfold higher catalytic turnover and maximum velocity compared with the 
phosphomimetic mutants. kcat/Km, which defines the substrate specificity, is almost the 
same for all four enzymes. This suggests that the overall observed decrease in the 
activity (100% wild type versus 30% mutants) is not due to the deficiency in the DD-






Figure 3-3. Enoyl reductase (ENR) activity of InhA_WT and mutant derivatives. 
InhA_WT and the single mutants carrying a Thr→Ala, a Thr→Asp or a Thr→Glu 
mutation at position 266 were purified from recombinant E. coli, dialysed and assayed 
for ENR activity. A) Enzymatic activity in the presence of 150 μM NADH and 
increasing concentrations of DD-CoA (left panel). Initial velocity for the wild-type and 
mutant enzymes measured as the NADH concentration was varied at a fixed DD-CoA 
concentration (50 μM) is presented in the right panel. B) Activity of the various InhA 
variants in the presence of 100 μM NADH and 50 μM DD-CoA. The activity of 
InhA_WT was arbitrarily set at 100%. Values are means of triplicates and are 
representative of three sets of experiments with independent protein preparations. Error 
bars represent the standard error. C) Proposed preferred pathway reaction mechanism for 
InhA_T266D and InhA_T266E enzymes. Both of the enzymes bind preferably to NADH 
first, followed by DD-CoA binding. Since the enzymes kinetically prefer NADH binding 
first, decreased affinity towards NADH can affect the overall in vitro activity of the 








Figure 3-3 Continued.  
 
 
Fluorescence experiments clearly indicated that both Asp and Glu mutants had 
three- to fourfold decreased binding affinity for NADH while InhA_T266A displayed 
approximately twofold reduction compared with InhA_WT as judged by the Kd values 
(Table 3-1). This suggests that T266 is an important residue for NADH binding and 
mutation of this residue can affect the binding of the enzyme to NADH. However, the 
overall effect on enzymatic activity is not linearly related to the fold decrease in NADH 
binding affinity since T266A is catalytically as active as the wildtype enzyme. Because 
phosphomimetic mutant enzymes kinetically prefer NADH binding first, the overall 
activity for these mutant proteins were affected significantly by the decreased affinity 
towards NADH. It is therefore very likely that the change in the NADH binding affinity 





Table 3-1. Steady-state kinetic parameters Km, kcat, Vmax and kcat/Km for DD-CoA, 
for wild-type and mutant InhA enzymes. 

















InhA_WT 100 40.9 ± 15.4 320.4 ± 52.7 11.4 ± 1.9 9.9 ±   2.7 1.5 ± 0.2 
InhA_T266A 102.6 ± 7.8 52.3 ± 3.6 427.4 ± 34.4 15.3 ± 1.2 8.2 ± 0.2 3.5 ± 0.4 
InhA_T266D 31.4 ± 6.3 19.6 ± 5.6 87.3 ± 4.4 3.1 ± 0.1 6.0 ± 2.7 4.7 ± 0.6 
InhA_T266E 29.5 ± 1.2 20.3 ± 4.9 149.4 ± 11.9 4.1 ± 0.8 6.9 ± 2.3 6.0 ± 0.6 
 
Dissociation constants for NADH are presented. The values were determined in triplicate and the 
average numbers calculated from three different experiments are represented. For each InhA 
enzyme, kcat/Km was calculated from three independent experiments and the mean kcat/Km is 
presented. Values are mean ± standard error.  
 
 
Local structural changes generated by Thr-266 mutations  
Recombinant InhA_WT, InhA_T266D and InhA_T266E proteins were purified 
from E. coli and subjected to crystallographic studies. In the InhA_WT structure, the 
OG1 atom of T266 interacts with the NE2 atom of Q267 (3.08 Å) and carbonyl oxygen 
of G263 (2.74 Å) (Figure A-2). For the T266D/E mutants, due to the loss of the Thr 
residue, this direct H-bonding interaction between residues T266 and Q267 is lost. 
Instead, a new water molecule (H2O #9 and #5 for InhA_T266D and InhA_T266E 
mutants respectively) is introduced between residues 266 and 267 (Figure A-2). 
Regarding the InhA_T266D structure, this makes H-bonding interactions with the NE 
atom of Q267 (3.01 Å), the carbonyl oxygen of G263 (2.74 Å) and the carbonyl oxygen 
of T254 from the neighboring subunit (2.77 Å). In InhA_T266E these interaction 
distances are 3.0 Å, 2.71 Å and 2.79 Å respectively. Notably, the direct interaction 




structures. On the other hand, OD1 and OD2 atoms of D266 interact with NE2 and ND1 
of H265 (3.07 Å and 3.45 Å respectively), causing a ~15 degree flip in the H265 ring. 
For E266, the distances are: OE1 of E266 with NE2 of H265 4.4 Å; ND1 of H265 3.04 
Å; OE2 of E266 with ND1 H265 3.5 Å and NE2 of H265 3.8 Å. OE2 of E266 and OD2 
of D266 also H-bonds with the carbonyl oxygen of T254 from the neighbor subunit (3.0 
Å), which is not present in the wild-type InhA:NADH structure (3.7 Å) (Figure A-2). In 
summary, mutation of Thr→Asp or Thr→Glu led to local structural changes limited to 
the surrounding of the mutated residue. 
 
Growth defect of fast- and slow-growing mycobacteria overexpressing InhA 
phosphomimetic proteins  
Mycobacterium smegmatis mc
2
155 was transformed with pMK1 derivatives 
allowing constitutive expression of the different inhA alleles under the control of the 
strong hsp60 promoter (Table A-1): inhA_WT, the phosphoablative inhA_T266A or the 
phosphomimetic inhA_T266D and inhA_T266E. Transformed mycobacteria were 
selected on Middlebrook 7H10 plates. As shown in Figure 3-4A, which illustrates the 
morphology and size of M. smegmatis colonies after 4 days’ incubation at 37°C, it is 
clear that overexpression of InhA_T266A did not impair growth of M. smegmatis as 
compared with the strain overproducing InhA_WT. In contrast, overexpression of either 
InhA_T266D or InhA_T266E was accompanied by a decrease in the growth rate 
compared with the strains overexpressing InhA_WT or InhA_T266A (Figure 3-4A). 




(Figure A-3). Taken together, these results indicate that overexpression of the 
phosphomimetic InhA alleles severely altered mycobacterial growth in both fast- and 
slow-growing mycobacterial species. Our results show that the impaired ENR activity of 
InhA_T266D or InhA_T266E is likely to be responsible for this growth defect, 
presumably by inhibiting FAS-II activity, either interacting with other FAS-II system 
enzymes or forming non-functional oligomers. Because InhA acts as a tetramer in 
mycobacteria, overproduction of InhA_T266D or InhA_T266E may lead to 
unproductive InhA multimers, which may coexist with functional InhA multimers.  
The hypothesis that the impaired in vitro activity of InhA_T266D or 
InhA_T266E is linked to a different oligomerization state than InhA_WT can, however, 
be excluded since both mutant enzymes formed only tetramers in solution as 
demonstrated by gel-filtration chromatography (data not shown), and by the fact that we 
could crystallize and determine the structures of the tetrameric InhA_T266D and T266E 
mutants (Figure A-4). Western blot analysis from M. smegmatis and M. bovis BCG 
cultures revealed both the endogenous and the recombinant InhA proteins in each strain, 
which can be clearly distinguished by the presence (recombinant InhA) or absence 











Figure 3-4. Overexpression of the various InhA variants and effect on growth in M. 
smegmatis. A) Electrocompetent M. smegmatis mc
2
155 was transformed with the empty 
pMK1 construct, the pMK1_inhA_WT, pMK1_inhA_T266A, pMK1_inhA_T266D or 
pMK1_inhA_T266E to allow constitutive expression of the various inhA alleles under 
the control of the strong hsp60 promoter. Transformed mycobacteria were plated and 
incubated at 37°C for 3 days. B) InhA expression levels in the InhA-overproducing M. 
smegmatis mc
2
155 strains. Western blot analysis of M. smegmatis mc
2
155 cultures 
overexpressing the phosphoablative inhA_T266A and phosphomimetic inhA_T266D and 
inhA_T266E alleles were harvested, resuspended in PBS and disrupted. Equal amounts 
of crude lysates (20 μg) were loaded onto a 4–12% acrylamide gel, subjected to 
electrophoresis and transferred onto a membrane for immunoblot analysis using rabbit 








Although the recombinant InhA forms are produced in large excess compared 
with the endogenous InhA, the presence of significant amounts of endogenous protein 
may explain the partial growth defect in the phosphomimetic strains. The growth 
impairment also hampers further examination and evaluation of the possible link 
between growth defect and mycolic acid biosynthesis inhibition in the mycobacterial 
strains overproducing the phosphomimetic mutants. We then explored whether this 
could be demonstrated by generating isogenic strains carrying either the phosphoablative 
or the phosphomimetic inhA alleles in M. tuberculosis.  
 
Transfer of T266D or T266E point mutations in InhA is lethal to M. tuberculosis  
Using specialized linkage transduction (Vilcheze et al., 2006) we could transfer a 
single-point mutant allele (T266A) into inhA in M. bovis BCG and M. tuberculosis 
H37Rv (Figure 3-5A), indicating that introduction of the phosphoablative inhA allele 
was not lethal. In addition, the growth curves of M. tuberculosis bearing either the 
inhA_WT or the inhA_T266A allele were similar, indicating that introduction of the 
T266A mutation did not alter growth of M. tuberculosis (data not shown). In contrast, 
and despite several attempts, we could not transfer the T266D or T266E alleles (Figure 
3-5A) into a wild-type genetic background, suggesting that these single mutations were 
lethal to M. bovis BCG and M. tuberculosis strains. To test this hypothesis, we 
performed allelic replacements using M. tuberculosis inhA merodiploid strains 
constructed by integrating a functional copy of inhA into the chromosome of M. 




chromosomal site. Gene replacements were carried out using specialized linkage 
transduction as described above. Interestingly, only in the presence of a complementing 
copy of the wild-type inhA were we able to introduce the T266D or T266E mutation into 
both the M. tuberculosis H37Rv and the M. tuberculosis CDC1551 merodiploid strains, 
as shown by Southern blot (Figure 3-5B) and PCR analyses (data not shown). Sequence 
analysis confirmed the presence of the expected inhA alleles in the various strains (data 
not shown).  
Taken together, these results indicate that a single T266D or T266E point 
mutation within InhA confers lethality on M. tuberculosis. They also strongly suggest 








Figure 3-5. Construction and analysis of M. tuberculosis inhA_T266A, 
inhA_T266D and inhA_T266E isogenic strains. A) Schematic representation of the 
specialized transduction phage. A replicating shuttle phasmid phAE159 containing 
inhA carrying the T266A, T266D or T266E mutation, sacB, a hyg resistance cassette, 
and hemZ was used to transduce M. bovis BCG or M. tuberculosis H37Rv. When 
recombination occurs before the point mutation, this results in a recombinant strain 
carrying the T266A, T266D or T266E mutation. Hygromycin-resistant transductants 
are screened by PCR and the presence of the desired mutations is confirmed by 
sequencing. The results of introducing phosphoablative (T266A) or phosphomimetic 
(T266D, T266E) mutations into the chromosomal inhA gene in the various strains are 
indicated: +, isogenic strain obtained; -, no isogenic strain obtained; ND, not 
determined. B) Allelic exchange replacement in InhA merodiploid strains. 
Merodiploid strains of M. tuberculosis H37Rv (Rv::inhA) and CDC1551 (1551::inhA) 
were obtained following transformation with the integrative construct pMV361_inhA. 
These strains were used as receptor strains for specialized transduction, as described 
above. Hygromycin- and kanamycin-resistant strains were screened by PCR and 
sequencing. Southern blot analysis using the inhA probe of the corresponding BamHI 
restriction profiles of DNA from Rv::inhA + phAE159::inhA(T266E) (lane 1), 
Rv::inhA + phAE159::inhA(T266D) (lane 2), H37Rv + phAE159::inhA(T266E) (lane 
3), H37Rv + phAE159::inhA(T266D) (lane 4), H37Rv + phAE159::inhA(T266A) 
(lane 5), H37Rv (lane 6), CDC1551 + phAE159::inhA(T266D) (lane 7), CDC1551 + 
phAE159::inhA(T266E) (lane 8), 1551::inhA (lane 9), 1551::inhA + 
phAE159::inhA(T266D) (lane 10) and 1551::inhA + phAE159::inhA(T266E) (lane 11). 






Figure 3-5 Continued. 
 
 
Lack of ENR activity complementation with the InhA phosphomimetic mutants in 
InhA-thermosensitive mutant strain 
To investigate whether cell death occurring in a phosphomimetic strain is 
associated with inhibition of mycolic acid biosynthesis, we took advantage of using an 
inhAthermosensitive (Ts) mutant of M. smegmatis (m
2
2359) carrying an inhA_V238F 
allele (Vilcheze et al., 2000). At a non-permissive temperature (42°C), thermal 




leading to a drastic morphological change and cell death in a manner similar to the result 
in INH treated cells (Vilcheze et al., 2000). M. smegmatis m
2
2359 was therefore 
transformed with either the empty pMK1 vector or the pMK1 derivatives, allowing 
constitutive expression of the different inhA alleles, and selected for kanamycin 
resistance. Cultures were grown at the permissive temperature (30°C), then plated and 
grown at either 30°C or 42°C for 4–5 days. Figure 3-6A shows that cells transformed 
with constructs carrying either the inhA_WT or inhA_T266A alleles could grow on 
Middlebrook plates at the non-permissive temperature, indicating that functional 
complementation occurred. In sharp contrast, neither the inhA (T266D) nor the inhA 
(T266E) alleles restored growth at 42°C, indicating that introduction of these mutations 
was lethal in the absence of functionally active InhA (Figure 3-6A). These phenotypes 
cannot be attributed to an eventual alteration of the expression levels of the various InhA 
mutants, as demonstrated by Western blot analysis (Figure 3-6B). Comparable 
expression levels of the various InhA variants were found at either 30°C or 42°C. 
Moreover, due to the presence of an additional His-tag in the pMK1_InhA-derived 
constructs, it became possible to distinguish the recombinant variants (InhA_WT, 
T266A, T266D and T266E) from the endogenous protein (InhA_V238F) in the various 
strains. Importantly, following a temperature shift to 42°C, only the strains 
overexpressing InhA_WT or InhA_T266A could grow in broth medium, whereas those 
harbouring either the empty pMK1 plasmid or the pMK1-inhA_T266D/E constructs 
failed to grow (Figure 3-6C). Overall, these results indicate that the T266D or T266E 




endogenous protein) cannot complement thermal inactivation of InhA_V238F at the 
non-permissive temperature.  
The usefulness of these strains prompted us to examine whether this lethal 
phenotype was related to de novo mycolic acid biosynthesis inhibition. This was 
achieved by shifting the temperature of the various strains to 42°C prior to labelling with 
[1-
14
C]-acetate. After a further 3 h incubation at 42°C, cells were harvested and fatty 
acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs) were extracted 
and separated by thin layer chromatography (TLC). As shown on the autoradiogram, and 
consistently with a previous study (Vilcheze et al., 2000), mycolic acid biosynthesis was 
almost completely abrogated in M. smegmatis mc
2
2359 carrying the empty pMK1 at 
42°C (Figure 3-6D). In contrast, M. smegmatis mc
2
2359 transformed with either 
pMK1_inhA_WT or pMK1_inhA_T266A displayed a wild-type mycolic acid profile at 
both 30°C and 42°C. Importantly, synthesis of mycolic acids in the phosphomimetic 
strains was severely impaired at the non-permissive temperature. Synthesis of α- and 
epoxy-mycolates was almost completely abrogated. The shorter-chain α′-mycolates, only 
present in this particular mycobacterial species, appeared less affected, as could be 
observed also when M. smegmatis cultures were treated with INH (Figure 3-6D). This 
observation is consistent with previous studies reporting that α′-mycolates are less 
affected than the other mycolic acid subtypes after treatment with FAS-II-inhibitory 






Figure 3-6. Functional complementation of M. smegmatis m
2
2359 with InhA_WT or 
InhA_T266A but not with phosphomimetics InhA_T266D or InhA_T266E. A) An 
inhA(Ts) mutant of M. smegmatis (mc
2
2359) resistant to INH was transformed with 
pMK1, pMK1_inhA_WT, pMK1_inhA_T266A, pMK1_inhA_T266D or 
pMK1_inhA_T266E and grown either at the permissive temperature (30°C) or at the 
non-permissive temperature (42°C). B) InhA expression levels. The various InhA levels 
of the parental strain and complemented mc
2
2359 strains were analysed by 
immunoblotting using rabbit anti-InhA antibodies. Cells were grown at the permissive 
temperature (30°C) or shifted at the non-permissive temperature (42°C), harvested, 
resuspended in PBS and disrupted. Equal amounts of crude lysates were loaded onto a 
4–12% acrylamide gel, subjected to electrophoresis and transferred onto a membrane for 
immunoblot analysis. Endogenous (InhA_V238F) and recombinant InhA proteins are 
indicated by arrowheads. C) Growth curves of the strains described in (A) in Sauton 
broth medium, following temperature shift at 42°C. D) De novo biosynthesis inhibition 
of mycolic acids. Cultures of M. smegmatis mc
2
2359 harbouring pMK1, 
pMK1_inhA_WT, pMK1_inhA_T266A, pMK1_inhA_T266D or pMK1_inhA_T266E 
were grown at 30°C. The cultures were shifted to 42°C for 3 h and labelled by adding [1-
14
C]-acetate (1 μCi ml
-1
). After 3 h at 42°C, cultures were harvested and FAMEs and 
MAMEs were extracted and analysed by one-dimensional TLC using petroleum 
ether/acetone (95/5, v/v). Detection of the radiolabelled FAMEs and MAMEs was 
performed by autoradiography, exposing the TLC plates to X-ray films for 24 h. α, α′ 












Figure 3-6 Continued. 
 
 
Overall, these results clearly indicate that, in the absence of a functional 
endogenous protein, the T266D or T266E mutants cannot restore mycolic acid 
production, leading to mycobacterial growth inhibition. Importantly, this mycolic acid 
profile was reminiscent of that observed in INH-treated cultures (Vilcheze et al., 2000), 
leading to the conclusion that phosphomimetic mutants of InhA inhibit mycolic acid 






In this study, a combination of genetic, biochemical and structural approaches 
was used to provide, for the first time, evidence that phosphorylation of InhA negatively 
regulates de novo biosynthesis of mycolic acids in M. tuberculosis. We found that 
phosphorylation occurred both in vitro and in vivo on a unique residue, identified as Thr-
266, although InhA was not identified in the recent phosphoproteomic study performed 
on M. tuberculosis (Prisic et al., 2010). Moreover, enzymatic analyses clearly indicated 
reduced ENR activity of InhA phosphomimetic mutant proteins, suggesting that 
phosphorylation may negatively regulate mycolic acid production. This hypothesis is 
supported by the following three facts: transfer of single T266D or T266E mutations into 
M. tuberculosis was lethal, unless an additional copy of inhA was present in a merodiplid 
strain; overexpression of InhA_T266D/E severely impaired growth in both fast- and 
slow-growing mycobacterial species; and T266D or T266E phosphomimetic proteins 
could not complement thermal inactivation of InhA_V238F at the non-permissive 
temperature in an inhA(Ts) mutant of M. smegmatis, leading to strong inhibition of α- 
and epoxy-mycolic acid production and growth arrest. It is noteworthy that, during 
review of our manuscript, an independent study has been accepted for publication (Khan 
et al., 2010), presenting very similar results and conclusions by demonstrating that (i) 
InhA was phosphorylated in vivo at Thr-266, (ii) phosphorylation of InhA resulted in 
decreased enzymatic activity, and (iii) an InhA_T266E mutant was unable to rescue a M. 
smegmatis conditional inhA gene replacement mutant. Therefore, from both studies it 




important mechanism controlling mycolic acid biosynthesis and largely supports and 
extends the emerging theme that Ser/Thr phosphorylation plays a critical role in the 
regulation of cell-wall biosynthesis and cell division in mycobacteria (Molle and 
Kremer, 2010; Wehenkel et al., 2008).  
One hypothesis could be STPK-dependent phosphorylation of InhA is used by 
M. tuberculosis during the nonreplicating dormant state, known to correlate with a 
slowdown of cell division, energy metabolism and lipid biosynthesis (Betts et al., 2002). 
However, further studies are required to investigate whether InhA 
(hyper)phosphorylation participates in the inhibition of mycolic acid metabolism during 
the ‘persistent’ state.  
From a purely mechanistic perspective, our kinetic studies revealed that both 
InhA phosphomimetics followed a preferred-order pathway with NADH binding 
preceding DD-CoA binding. Both mutant proteins exhibited a three- to fourfold 
decreased binding affinity to NADH even though the mutation site was not at the 
cofactor binding pocket of InhA. Since there is a kinetic advantage when InhA binds to 
NADH first, it appears very likely that the overall activity for the mutant proteins was 
affected significantly by the decreased affinity towards NADH. T266 is very close to the 
C-terminal end of the protein (266 of 269 residues) and crystallographic studies 
indicated that mutation at this residue was not accompanied by significant differences in 
the secondary structure and did not alter the overall backbone conformation of the 
protein. Both T266E and T266D complexed with NAD
+
/NADH crystallized in the same 




(Table A-3). As for InhA_WT, all mutant proteins formed tetramers in solution as 
judged by the gel-filtration chromatography profile (data not shown), indicating that 
mutation of the Thr-266 residue does not alter the oligomeric state of the protein. 
Moreover, the comparison of the tetrameric structures generated by crystallographic 
symmetry-related molecules for the wild type and Asp/Glu mutants revealed that the 
Rmsd value between the superimposed structures was 0.3 Å (Figure A-4). Structural 
differences due to Thr→Asp or Thr→Glu replacements were limited to the surroundings 
of the mutated residue and introduced only subtle and local structural changes, 
perturbing the H-bonding network and introducing water molecules (Figure A-2). The 
active site of InhA protein was ~15– 20 Å away from the mutation site in InhA_T266 
(Figure A-5). Although no significant structural difference or conformational change 
was observed at either the active site residues or the substrate/cofactor binding pockets 
between native and mutants structures, it remains possible that mutations cause changes 
in the network of interactions and affect the interaction and communication between the 
subunits of the functional tetramer. This in turn may affect NADH binding affinity and 
the overall enzymatic activity of the phosphomimetic InhA mutants. Based on our 
enzymatic analyses, it is noteworthy that NADH binding is affected even though the 
mutation site is ~16 Å away from the cofactor binding pocket.  
InhA is one of the best-validated targets for antitubercular agents and several 
recent studies reported the development of new InhA inhibitors (am Ende et al., 2008; 
Freundlich et al., 2009; He et al., 2007; He et al., 2006; Oliveira et al., 2007; Tonge et 




unphosphorylated/phosphorylated InhA balance in favour of the phosphorylated isoform 
rapidly leads to mycolic acid cessation, as happens following INH treatment, and to 
mycobacterial growth inhibition. Therefore, an elegant hypothesis arising from the 
present work is that, by increasing the activity of the kinases, it may be possible to 
directly alter mycobacterial growth, opening new and original perspectives for future 
anti-tuberculosis drug development. Indeed, small molecules that modulate the activity 
of STPK may be of great therapeutic value in inhibiting M. tuberculosis growth. 
Bryostatin, a natural product synthesized by a marine bacterium, which activates 
eukaryotic intracellular STPKs (Hale et al., 2002), is one of these molecules. 
Interestingly, bryostatin acts directly on the Bacillus subtilis Ser/Thr kinase PrkC, which 
contains an extracellular domain able to bind to peptidoglycan fragments and this signals 
the bacteria to exit dormancy by stimulating germination (Shah et al., 2008). PrkC, like 
M. tuberculosis PknB, possesses the PASTA (Penicillin And Ser/Thr kinase Associated) 
domains, which are found in the extracellular portion of membrane associated STPKs 
and which have been proposed to bind to peptidoglycan and act as signalling molecules. 
In this context, bryostatin or other STPK-activating molecules, along with the recent 
structural determination of the M. tuberculosis PknB PASTA domains (Barthe et al., 
2010), may provide new therapeutic strategies to be developed against tuberculosis. 
From our results, it can also be inferred that STPK-induced phosphorylation of InhA 
would be active on M. tuberculosis clinical isolates carrying the inhA alleles (I21, S94 or 




phosphorylation occurs exclusively on Thr-266, a residue that has never been linked to 
INH resistance. 
The present study provides a foundation for further investigation of a seemingly 
important functional linkage between STPKs and the FAS-II system. It also provides 
conceptual advances in our understanding of the mycolic acid metabolic adaptation and 
regulatory events exploited by M. tuberculosis to adapt its mycolic acid cell-wall 
content. Although very challenging, future studies should now help to identify 
extracellular cues sensed by the different kinases and leading to InhA phosphorylation. 
This will not only allow us to understand how M. tuberculosis senses its environment 
and mediates its response in a co-ordinated manner to regulate mycolic acid 
biosynthesis, but also to possibly link InhA phosphorylation to the establishment of the 
non-replicating persistent state. One can also anticipate that similar strategies involving 
STPK-dependent mechanisms will be found to be used by pathogenic mycobacteria to 
regulate expression of other cell-wall lipids/glycolipids to respond to the various signals 




Bacterial strains, plasmid, phage and growth conditions 
Strains used for cloning and expression of recombinant proteins were E. coli 




grown in LB medium at 37°C. Media were supplemented with ampicillin (100 μg ml
-1
) 
or kanamycin (25 μg ml
-1
), as required. Mycobacterial strains used were M. smegmatis 
mc
2
155, M. bovis BCG Pasteur 1173P2 and M. tuberculosis H37Rv, Erdman and 
CDC1551. Mycobacteria were grown on Middlebrook 7H11 agar plates with OADC 
enrichment (Difco) or in Sauton’s medium containing 0.05% tyloxapol (Sigma) 
supplemented with kanamycin (25 μg ml
-1
) or hygromycin (50 μg ml
-1
) when required. 
The shuttle phasmid phAE159 (Bardarov et al., 2002) and the integrative plasmid 
pMV361 (Stover et al., 1991) were reported earlier.  
 
Cloning, expression and purification of recombinant InhA and mutant proteins 
 For in vitro kinase assays, the inhA gene was amplified by PCR using M. 
tuberculosis H37Rv genomic DNA as a template and a set of primers containing NdeI 
and NheI restriction sites (Table A-2). This amplified product was digested with NdeI 
and NheI and ligated into pETPhos (Canova et al., 2008), generating pETPhos_inhA_WT 
(Table A-1). Sitedirected mutagenesis was directly performed on this vector using 
inverse-PCR amplification with the self-complementary primers (Table A-2). All 
constructs were verified by DNA sequencing. Recombinant InhA proteins were 
overexpressed in E. coli BL21(DE3) and purified as described (Veyron-Churlet et al., 
2010). Fractions containing pure InhA proteins were pooled, dialysed when required and 
stored at -20°C until further use. For enzymatic or crystallographic studies, inhA_T266A, 
inhA_T266D and inhA_T266E were amplified from H37Rv genomic DNA using the 




(containing a HindIII site) (Table A-2). The amplified products were digested with NdeI 
and HindIII and ligated into pET30b (Novagen). Mutation sites were verified by DNA 
sequencing. Expression and purification of InhA_WT (Quemard et al., 1995), 
InhA_T266A, InhA_T266D and InhA_T266E proteins were performed in E. coli 
BL21(DE3) as described (Freundlich et al., 2009). 
 
Construction of the integrative pMV361_inhA and cosmid p004_inhA_hemZ 
inhA was amplified from H37Rv genomic DNA using primers inhAE1 and 
inhAH1 (Table A-2). The PCR fragment was cut with EcoRI and HindIII and cloned 
into EcoRI–HindIII-cut pMV361 (Table A-1), generating pMV361_inhA. To produce 
p004_inhA_hemZ, the hemZ gene was PCR-amplified from H37Rv genomic DNA using 
the RR and RL primers (Table A-2). inhA was then PCR-amplified using upstream LL 
primers and downstream LR-266A, LR-266D or LR-266E primers (Table A-2). PCR 
fragments were cut with Van91I, cloned into Van91I-cut p004 (Table A-1). All 
constructs were sequenced before use.  
 
Specialized transduction 
The transducing mycobacteriophages were prepared as described (Bardarov et 
al., 2002). Briefly, the recombinant cosmids p004_inhA_hemZ were cut with PacI and 
ligated to the PacI-cut shuttle phasmid phAE159. The resulting phasmids were packaged 




electroporated into M. smegmatis mc2155 and the resulting transducing phages were 
amplified to obtain high-titre phage lysates. M. bovis BCG and M. tuberculosis H37Rv, 
Erdman and CDC1551 strains (100 ml) were grown to log phase (OD600 about 1.0), spun 
down, washed twice with mycobacteriophage (MP) buffer (50 mM Tris, 150 mM NaCl, 
10 mM MgCl2, 2 mM CaCl2; 100 ml) and finally resuspended in MP buffer (10 ml). The 
cell suspension (1 ml) was mixed with high-titre phage lysate (1010–1011 pfu ml
-1
, 1 
ml) and incubated at 37°C for 4 h. After centrifugation, the cell pellet was resuspended 
in Middlebrook 7H9 medium (0.4 ml) and plated onto Middlebrook 7H10 plates 
containing 75 μg ml
-1
 hygromycin. Plates were then incubated at 37°C for 4 weeks and 
transductants screened by PCR using the primer pairs TW361 and TW398 (Table A-2) 
to verify that the inhA–hemZ region had been disrupted and TW 361 and p004R (Table 
A-2) to check the integration of the sacB–hyg cassette between inhA and hemZ. 
Confirmation of allelic exchange was by Southern blotting on genomic DNA of HygR 
transductants digested with BamHI and probed with inhA. 
 
In vitro kinase assay 
 In vitro phosphorylation was performed as described (Molle et al., 2003) with 4 
μg of InhA in 20 μl of buffer P (25 mM Tris-HCl, pH 7.0; 1 mM DTT; 5 mM MgCl2; 1 




P]-ATP corresponding to 65 nM (PerkinElmer, 3000 
Ci mmol
-1
), and 0.2–1.0 μg of kinase in order to obtain for each specific kinase its 




purification of the eight recombinant GST-tagged STPKs from M. tuberculosis were 
described previously (Molle et al., 2006).  
 
Mass spectrometry analysis 
Purified InhA_WT and mutant derivatives were subjected to in vitro 
phosphorylation by GST-tagged PknB as described above, except that [γ-
33
P]-ATP was 
replaced with 5 mM unlabelled ATP. Purified InhA from M. bovis BCG cultures was 
subjected to mass spectrometry without further treatment. Subsequent mass 
spectrometric analyses were performed as previously reported (Fiuza et al., 2008).  
 
Overexpression of InhA proteins in mycobacteria  
inhA was amplified by PCR using M. tuberculosis H37Rv chromosomal DNA as 
template and a set of primers containing an NdeI and an EcoRI restriction site (Table A-
2). This amplified product was then digested by NdeI and EcoRI and ligated into the 
pMK1 expression vector (Table A-1). The resulting construct was electroporated into M. 
bovis BCG and transformants were grown in broth medium and harvested for 
immunoblotting analysis as described previously (Kremer et al., 2003).  
 
ENR assay  
Enoyl reductase activity was monitored spectrophotometrically by following the 
change in absorption at 340 nm via the oxidation of NADH to NAD
+
. All reactions were 




7.5 using 80 nM of either wild-type or mutant enzyme. Kinetic parameters Km, kcat and 
Vmax for DD-CoA were determined at a fixed saturating concentration of NADH (150 
μM) while varying the concentration of DD-CoA (25– 100 μM) using the equation v = 
kcat[E]0[S]/(Km + [S]). The percentage of remaining activity was calculated by comparing 
the rate of the reaction of the mutant enzyme to the rate of the reaction of the wild-type 
enzyme in the presence of 50 μM DD-CoA and 100 μM NADH with wild-type enzyme 
activity set at 100%. 
 
Fluorescence measurements 
Binding constants of NADH to the wild-type, Asp and Glu mutant enzymes were 
obtained by measuring the protein fluorescence using a Cary Eclipse spectrofluorometer 
at 25°C. Excitation and emission wavelengths were 280 nm and 335 nm respectively. 
Emission was first monitored between 300 and 450 nm and 335 nm was selected as λmax. 
Approximately 0.7–0.76 μM protein solutions in 100 mM Pipes buffer pH 7.0 were 
titrated with various concentrations of NADH (0–20 μM). The contribution of NADH 
fluorescence to final fluorescence intensity was checked with a control experiment by 
titrating NADH into buffer in the absence of protein. The fluorescence intensities at λmax 
for a corresponding NADH concentration were corrected for dilution factors and NADH 
contributions before any calculations. At the concentrations used for InhA and NADH, 
the fluorescence intensity change due to inner filter effect was negligible. Kd values were 
calculated using the equation ∆F = ∆Fmax - Kd*(∆F/[NADH]), where F represents 




Complementation studies of the inhA(Ts) M. smegmatis strain 
Cultures of M. smegmatis strains mc
2
2359 (InhA(Ts), INHresistant) were grown 
at 30°C. Competent bacteria were prepared and transformed with pMK1, 
pMK1_inhA_WT, pMK1_inhA_T266A, pMK1_inhA_T266D or pMK1_inhA_T266E. 
Clones selected on kanamycin were grown in Sauton medium at 30°C to mid-log phase 
and plated at 30°C or 42°C for 3–5 days. 
 
Mycolic acid biosynthesis 
Cultures of M. smegmatis mc
2
2359 (InhA(Ts), INH-resistant) were grown to 
mid-log phase in Sauton medium at 30°C. The temperature was then shifted to 42°C for 
3 h and cultures were labelled by adding [1-
14
C]-acetate (1 μCi ml
-1
). After a further 3 h 
incubation at 42°C, cells were harvested and FAMEs and MAMEs were extracted as 
reported (Kremer et al., 2002). Equal amounts of counts were subjected to TLC using 
petroleum ether/acetone (95/5, v/v) and exposed overnight to a Kodak X-Omat film. As 
a control of mycolic biosynthesis inhibition, M. smegmatis mc
2
155 (InhA_WT, 
INHsensitive) was treated with 50 μg ml
-1
 INH for 3 h and labeled by adding [1-
14
C]-
acetate (1 μCi ml
-1









Additional unpublished results 
 
ENR assays with in vitro phosphorylated InhA 
In order to determine whether phosphorylation has any effect on InhA enzymatic 
activity, two serine-threonine kinases of Mtb, PknB and PknF, were used in an in vitro 
phosphorylation assay. As a negative control, two kinase-dead mutants of PknB 
(PknB
K40M
) and PknF (PknF
K41M
) were also included in the assays. The kinase domains 
were expressed in E. coli and purified to homogeneity as described previously (Molle et 
al., 2006). As seen from the in vitro phosphorylation experiments done with [γ-
33
P]-ATP 
(Figure 3-1A), InhA was phosphorylated by PknB but not by PknF. InhA and PknB/F 
were incubated at different molar ratios (1:20 or 1:10 kinase:InhA) at 37 °C in the 
presence of 1 mM ATP, 5 mM MgCl2, and 1 mM DTT in phosphate buffer pH 7.5. 
Control experiments lacking either kinase, ATP or both were also set in the same way. 1 
μl from this reaction mixture was aliquoted and InhA activity was monitored by the 
oxidation of NADH at 340 nm. However, the assay results were inconsistent and no 
difference in the InhA activity between the phosphorylation and control reactions was 
observed. Also, there was no correlation of InhA activity with the type of the kinase used 
in the assay; i.e., no difference was observed if the assay was performed with the wild-
type or K40M/K41M mutant kinases. There may be a couple of reasons for the 
inconsistency in these experiments. The first issue was the stability of InhA in the 
phosphorylation reaction mixture. It was observed that InhA protein heavily precipitated 




not have equal amount of InhA protein to be used in the enzymatic assay. Also, since the 
efficiency of the phosphorylation reaction (phosphorylated/non-phosphorylated InhA 
ratio) was not known, it was difficult to compare the enzymatic activity from a mixture 
of phosphorylated and non-phosphorylated protein. Therefore, to overcome these issues, 
the phosphomimetic T266D and T266E mutants of InhA were generated. Even though 
aspartate and glutamate do not mimic the size of a phospho group perfectly, they do 
mimic the negative charge. Mimicking of serine and/or threonine phosphorylation by 
aspartate or glutamate has been widely used in the literature (Leger et al., 1997; Veyron-
Churlet et al., 2009; Veyron-Churlet et al., 2010).       
 
Intrinsic fluorescence quenching experiments 
The affinity of the wild-type and mutant InhA proteins for NADH was 
determined by the intrinsic fluorescence quenching. InhA has four tryptophan residues, 
two of which (Trp222 and Trp230) lie close to the NADH binding pocket. It has been 
observed that InhA undergoes conformational changes upon transition from the apo form 
to the NADH bound form (Dias et al., 2007). Particularly, the substrate binding loop of 
the enzyme (residues 196-219) gets ordered and moves ~2 Å upon NADH binding (Dias 
et al., 2007). In addition, there are multiple tyrosine residues positioned close to the 
NADH binding pocket (especially the catalytic Tyr158), which may also contribute to 
the intrinsic protein fluorescence. Therefore, quenching of the intrinsic fluorescence by 




Initial excitation and emission scans showed that InhA had an excitation 
maximum at 280 nm. The emission was monitored between 300-450 nm and 335 nm 
was selected as the λmax. At this emission wavelength, NADH did not contribute to the 
fluorescence intensity since the λexcitation and λemis for NADH were around 340 nm and 
450 nm, respectively.  
 As the NADH concentration was increased, a decrease was observed in the 
fluorescence (Figure 3-7A). When the wild-type and the T266D and T266E mutant 
proteins were compared, it was observed that the fluorescence quenching (the difference 
between Fmax and Fobserved; i.e., ∆F) was greater for the wild-type enzyme than the 
mutants (Figures 3-7B and 3-7C). This indicated that NADH bound tighter to the wild-
type enzyme. The Kd values for NADH binding were calculated from the fluorescence 







Figure 3-7. Intrinsic fluorescence quenching experiments for the wild-type and 
mutant InhA enzymes. A) Fluorescence quenching of wild-type InhA by NADH 
titration. The fluorescence intensity decreased as the concentration of NADH (0-54.5 
µM) increased. Each titration is indicated with a different line color and the 
corresponding NADH concentrations are given on the right of the chart. B and C) 
Comparison of the fluorescence quenching of the wild-type and the T266 mutant InhA 
proteins. ∆Fwt was greater than ∆FT266A, ∆FT266D  and ∆FT266E, indicating that NADH 

















InhA has a pivotal role in mycolic acid synthesis and it is essential for 
mycobacterial viability (Vilcheze et al., 2000). Being the molecular target of isoniazid 
and ethionamide, it still is one of the best-validated targets for antitubercular drug 
discovery. Therefore, understanding InhA regulation is quite important.  
Phosphorylation/dephosphorylation is considered a central signal transduction 
mechanism that allows regulation of different cellular processes like growth, 
differentiation, mobility, and survival (Stock et al., 1989). It was recently shown that in 
Mtb, members of the FASII system, MabA, FabH, KasA, KasB and HadABC, were 
substrates of multiple serine-threonine kinases (STPK), and their functions were 
regulated by phosphorylation. While for the KasA, FabH, MabA, and HadABC enzymes 
phosphorylation decreased the enzymatic activity, for the KasB enzyme phosphorylation 
positively affected (increased) the activity (Molle and Kremer, 2010). In this study, it 
was demonstrated that InhA was also phosphorylated at a single threonine residue by the 
STPKs. Phosphorylation regulated the InhA function negatively. Kinetic studies and 
fluorescence experiments performed with the phosphomimetic T266D and T266E 
mutants showed that they retained only 30% of the enzymatic activity, which was due to 
their reduced affinity for NADH. The crystal structures of the wild-type and 
T266D/T266E mutants revealed the local structural changes around the mutated residue 
and indicated no significant conformational changes in the protein backbone and at the 
active site. InhA functions as a tetramer and it is possible that mutation of T266 alters 




though the residue T266 lay ~16 Å away from the NADH binding site, mutation of this 
residue affected the cofactor binding and the enzyme activity significantly.  
The effect of InhA phosphorylation on cell viability and growth was also 
demonstrated by genetic experiments. The M. smegmatis and M. bovis strains over-
expressing the phosphomimetic InhA proteins displayed growth defects compared with 
the strains harboring the wild-type or the phosphoablative plasmids. The transfer of a 
point T266A mutation into the inhA gene in Mtb indicated that introduction of the 
phosphoablative allele was not lethal and did not have any effect on cell growth. In 
contrast, the transfer of T266D or T266E point mutations to the inhA gene was not 
feasible, suggesting that these alleles were lethal for Mtb. These results together implied 
that the presence of the phosphomimetic proteins became lethal for the cell because of 
the decreased InhA activity.   
It is intriguing that all of the FASII enzymes are regulated by phosphorylation. 
Why does Mtb choose to phosphorylate all of the enzymes belonging to the same 
pathway? One suggested explanation is that altering the activity of these enzymes will 
lead to a tightly regulated system, which will allow adaptation to various growth 
conditions (Molle and Kremer, 2010). While phosphorylation of each individual FASII 
enzyme does not abolish the enzymatic activity completely, the cumulative effects of the 






CHAPTER IV  
ACTIVATION-FREE INHIBITOR DISCOVERY STUDIES FOR INHA 
 
Overview 
 The enoyl-reductase enzyme of the FASII system in Mtb, InhA, which is the 
biological target of the anti-tubercular drug isoniazid, has been shown to be essential for 
mycobacterial viability. Inhibition of InhA activity leads to the accumulation of FASI 
end products, which results in the disruption of mycolic acid biosynthesis, causing 
mycobacterial cell death. Considering that no FASII system is present in humans, InhA 
has been the focus of many drug discovery efforts since the 1990s. However, despite 
several reports on identification of potent InhA inhibitors, many of which were also 
effective in vivo against Mtb, INH remains the only first-line drug targeting InhA in the 
current TB treatment. The majority of the INH resistant Mtb clinical isolates were found 
to develop resistance through the mutations in the INH activator katG gene, which 
underlines the importance of the discovery of activation-free inhibitors.  
 In this work, we report novel InhA inhibitors that do not require activation by 
KatG. A target-based high-throughput screening (HTS) performed by GlaxoSmithKline 
(GSK) among a library of a million compounds resulted in the identification of a 
previously unexplored class of InhA inhibitors displaying good potency. These 
compounds effectively inhibited InhA enzymatic activity at nanomolar concentrations. 
The structural basis of InhA inhibition by this new class of GSK inhibitor compounds 




with the GSK compounds shed light on the binding mode of these inhibitors, providing 
future assistance for further inhibitor development. Subsequent chemical optimizations 
yielded InhA inhibitor lead compounds, which exhibited potent activity against drug-
sensitive and drug-resistant Mtb strains with good pharmacokinetic properties. They 
represent a promising class of inhibitors for future studies.   
 
Introduction 
Although the drugs currently used to treat  tuberculosis (TB) were discovered 
more than 50 years ago, TB still accounts for 1.4 million deaths every year (Zumla et al., 
2013b). While the majority of the TB cases are treatable with the current regimen of 
drugs, nevertheless, the rising incidences of multi-drug resistant and extensively drug 
resistant cases worldwide is threatening to nullify our advances in the fight against this 
disease. The current TB treatment regimen is long, complex and has several adverse 
effects, so lack of adherence is not unusual, leading to suboptimal responses (treatment 
failure and relapse), emergence of resistance, and continuous spread of the disease. In 
the last forty years there has been only one new drug approved for TB (Andries et al., 
2005). Thus, there is a critical need for the development of drugs with shorter, simpler 
regimens as well as novel mechanisms of action that can be used for the treatment of the 
drug-resistant forms of the disease.  
  Both target-based and phenotypic screening approaches have been employed for 
the identification of new anti-tubercular drug leads (Kondreddi et al., 2013; Magnet et 




for the latter (Rao et al., 2013; Remuinan et al., 2013), target-based approaches have 
encountered very limited success as previously demonstrated in the antibacterial field 
(Payne et al., 2007). Rather than invalidating the target-based approaches per se, this 
situation highlights the disconnect between the concepts like genetic validation of target 
essentiality and the amenability of that target to small molecule drug discovery. 
Confidence that inhibition of a single target will allow resolution of an infection cannot 
be fully supported by genetic validation of essentiality. A deeper understanding of the 
systems biology and the mechanisms underlying the antibiotic killing are important for 
the discovery of new antimicrobial therapies through the target-based approaches. 
Additionally, for reasons that are not always obvious, some targets are clearly more 
chemically tractable than others. For example, protein and cell wall synthesis and DNA 
gyrase have delivered multiple classes of published leads and marketed drugs, whereas 
there are no known inhibitors for many other essential gene products, despite a long 
history of antibacterial research (Kohanski et al., 2010; North et al., 2013; Payne et al., 
2007). In the antitubercular field, only a very limited number of targets such as InhA, 
RpoB, DNA Gyrase, ATP synthase, and DprE1 have been shown to be targeted by 
potent bactericidal drugs or promising leads. 
Isoniazid (INH) is a frontline anti-TB drug targeting InhA and it is an essential 
component of the TB treatment regimen. It has been administrated to more than 40 
million people saving millions of lives. Its outstanding bactericidal effect rapidly blocks 
the bacterial transmission and significantly improves the patient’s condition after a few 




has remained elusive for many years. INH penetrates the tubercle bacilli by passive 
diffusion and is activated by the bacterial anti-oxidant enzyme KatG to a range of 
reactive species including the isonicotinoyl radical, which forms an adduct with the 
nicotinamide adenine dinucleotide (NAD
+
). This adduct inhibits the enoyl-ACP 
reductase enzyme encoded by the inhA gene leading to the block of mycolic acid 
biosynthesis. The dependency on KatG activation for the INH-mediated killing is also 
the source of the main clinical weakness associated with the use of INH, as between 40-
95% of INH-resistant Mtb clinical isolates develop mutations in katG, leading to a 
decreased activation of INH to its active form. While mutations are also detected in 
clinical isolates within the inhA promoter region, these can be successfully treated in 
most instances by increasing the dose of isoniazid. 
On the basis of the mode of action of INH, it has been proposed that direct 
inhibitors of Mtb enoyl-ACP reductase would retain the outstanding antitubercular-cidal 
profile of INH while overcoming most of the problems associated with its pro-drug 
nature, such as the resistance and toxicity issues. Also, compounds inhibiting InhA 
without requiring activation by KatG could be active under anaerobic conditions, given 
the fact that the catalase-mediated activation is suppressed by hypoxia. Novel classes of 
direct InhA inhibitors have been identified previously using high-throughput screening 
strategies. They include the indole-5-amides (Kuo et al., 2003), the pyrazole derivatives 
(Kuo et al., 2003), the pyrrolidine carboxamides (He et al., 2006), the arylamides (He et 
al., 2007), and the imidazopiperidines (Wall et al., 2007). Additionally, the natural 




of these compounds showed a lack of correlation between the enzymatic inhibition and 
the whole cell activity, had moderate potencies or narrow selectivity windows, making 
them unsuitable for further progression as drug leads. 
GlaxoSmithKline, under the sponsorship of the TB Alliance has carried out a 
high-througput screen against InhA using the GSK compound collection and has 
identified the thiadiazole series as the most promising small molecule anti-tubercular 
family. The structural basis of InhA inhibition by the thiadiazoles has been determined 
by X-ray crystallography. In the present study, we present the novel lead compound and 
its attractive anti-tubercular properties. 
 
Results and discussion 
 
Biochemical and antimicrobial characterization of the hit structure GSK826625A 
Several screening campaigns were run against InhA with an overall 0.63% of 
true hits after the removal of the quenchers. The campaign covered a total of 1.9 million 
compounds (HTS details to be published elsewhere) unearthing GSK826625A 
(GSK625A) and GSK826613A (GSK613A) (Table 4-1) as the most attractive 










Table 4-1. Structures and activities of the hit compounds GSK613A and GSK625A. 
Compounds were assessed for activity against M. tuberculosis H37Rv and against a 
broad-spectrum bacterial panel, cytotoxicity in HepG2 cells, clearance (in vitro and in 







InhA IC50 8 nM 4 nM 
MIC H37Rv 2 μM 1 μM 
MIC shift o/e > 4 fold > 4 fold 
Antibacterial 
panel 
≥64 μg/mL ≥64 μg/mL 
HepG2 cytotox > 100 μM > 100 μM 
In vitro Cli 
mouse 
11.9 mL/min.g 14.9 mL/min.g 
In vitro Cli 
human 
2.9 mL/min.g 2.8 mL/min.g 
In vivo Cli mice 157mL/min/Kg 120 mL/min/Kg 





pyrazol-1-yl)ethyl)-1,3,4-thiadiazol-2-amine) was progressed to enzymatic mode of 
action studies. GSK613A was a selective inhibitor against Mtb enoyl-ACP reductase and 
it was inactive against human FAS. Steady state competition experiments showed that 




was uncompetive with NADH, consistent with inhibitors binding to a pre-formed 




Figure 4-1.Inhibition of InhA by members of the thiadiazole family. Double 
reciprocal plots in the absence of inhibitor (○) and in the presence of 3 nM (●), 15 nM 
(□), 40 nM (■) and 80 nM (△) inhibitor compound. The patterns of inhibition observed 




Whole cell mode of action confirmation in InhA overexpressor 
In clinical isolates, over-expression of InhA translates into INH and ETH 
resistance, which confirms that the enoyl ACP-reductase is the main antitubercular target 
for both drugs (Vilcheze et al., 2006). Similarly, two Mycobacterium smegmatis and M. 




constructed and the susceptibility of these strains for the compounds were tested in order 
to verify that the whole-cell activity of the inhibitors was mediated mainly or solely by 
the inhibition of InhA. A reproducible shift in minimum inhibitory concentration (MIC) 
values higher than 4-fold in strains overexpressing the target was considered as an 
indication that the antitubercular activity was mainly mediated by InhA inhibition. The 
thiadiazoles GSK625A and GSK613A met this criterion (Table 4-1). 
 
Structure of the InhA: GSK625A complex 
InhA was co-crystallized with GSK625A and GSK2136490A (GSK490A) in the 
presence of the cofactor NAD
+
. GSK490A is an analog of GSK625A, and lacks the 
halide substituted phenyl ring attached to the pyrazole ring (Figure 4-2). GSK490A 
displayed ~6000 fold less inhibitory activity (IC50 = 28 μM) against InhA compared with 
the GSK625A (IC50 = 4 nM). The reason behind this potency difference was revealed by 
crystallography.  
  The enzyme:inhibitor complex crystallization was successful only in the 
presence of the cofactor NAD(H) in agreement with the uncompetitive character of these 
inhibitor compounds (Figure 4-1). Crystals of the InhA:NAD
+
:GSK490A ternary 
complex were determined to be in the P6222 space group with one molecule in the 
asymmetric unit (ASU), whereas the crystals of the InhA:NAD
+
:GSK625A complex 
belonged to the P212121 space group with four molecules in the ASU. Both structures 
were solved by molecular replacement using the previously determined InhA:NADH 




2.9 Å, respectively. The structures were refined to Rwork of 19% and 20%, and Rfree of 
21% and 23%, respectively, with excellent stereochemistry (Table 4-2). 
The crystal structures revealed that both compounds bound to the hydrophobic 
substrate binding pocket of InhA, which was surrounded by the residues Met103, 
Phe149, Tyr158, Ala198, Met199, Ile202, Leu207 and Ile215. Comparison of the 
InhA:GSK inhibitors and the InhA:NAD
+
:C16-fatty acyl substrate analog structure 
(PDB ID: 1BVR) (Rozwarski et al., 1999) revealed that the aromatic rings of the GSK 
compounds occupied the same pocket as the thioester and the trans double bond portion 
of the C16-substrate analog (Figure 4-2A), and they positioned proximate to NAD
+
, 
which is in agreement with the competitive behavior of the inhibitors relative to the 






















Table 4-2. Data collection and refinement statistics for the InhA:GSK625A  and 
InhA:GSK490A structures. Highest resolution shells are given in parenthesis.  
 
 InhA: GSK490A InhA:GSK625A 
Data collection   
Space group P6222 P212121 
Cell dimensions 
a, b, c (Å) 





97.9, 97.9, 139.4 
90.0, 90.0, 120.0 
 
 
90.2, 104.2, 190.8 
90.0, 90.0, 90.0 
Wavelength (Å) 1.542 1.542 
Resolution (Å) 24.2-2.0 (2.01) 47.7-2.91 (2.91) 
Completeness (%) 99.7 (99.9) 97.7 (95.5) 
Redundancy 8.3 (8.0) 3.9 (3.8) 
I/Iσ 21.8 (3.0) 13.9 (1.8) 
Rsym (%) 2.8 (35.2) 6.1 (57.4) 
Refinement   
Resolution 23.2-2.01 34.7- 2.91 
No. reflections 26922 39444 



































Figure 4-2. Binding mode of the thiadiazoles to the InhA active site. A) A cross-section 
through the surface of the active site of InhA. InhA:NAD
+
:GSK structures (490 (purple) and 625 
(green), respectively) are superposed with the InhA:NAD
+
:C16-fatty acyl substrate analog 
(orange) structure. As seen from the figure, the GSK compounds occupied the substrate binding 
pocket. B-C) Key interactions between the GSK compounds 490 and 625 and the InhA active 
site. Compounds interacted with NAD
+
 (gray) and M98 via H-bonds; with G96, F97, M103, 
F149, M161, I202, and L207 through hydrophobic and van der Waals interactions. GSK625 has 
additional hydrophobic and van der Waals interactions with G104, A157, Y158, A198, and 
M199 compared with GSK490, which results in more than 1000 fold better potency. Atom 
coloring is oxygen red; nitrogen blue; sulfur yellow; chlorine and fluoride green. H-bonds are 




  The specificity and potency of the thiadiazoles for InhA was provided by the 
interactions with both NAD
+
 and the protein backbone. GSK625A and GSK490A 
interacted with the cofactor NAD(H) via π-π stacking interactions through their pyrazole 
rings (3.6 - 4 Å) (Figure 4-2). In addition, the nitrogen of the pyrazole ring made a 
hydrogen bond to the 2’ hydroxyl of the ribose moiety of NAD
+
 (2.7 and 3.2 Å).  The 
other key interactions were the direct H-bonding between (i) the nitrogen of the 
thiadiazole ring and the amide NH of Met98, and (ii) the nitrogen linking the pyrazole 
and the thiadiazole rings and the carbonyl oxygen of Met98 (2.4 & 2.9 Å, respectively) 
(Figure 4-2). Met98 was the only residue that participated in a direct hydrogen bonding 
interaction with the thiadiazoles.  
Hydrophobic and van der Waals interactions between the inhibitors and the side 
chains of the residues Gly96, Phe97, Met103, Phe149, Met161, Ile202, and Leu207 
dominated the ligand-protein interactions for both compounds (Figure 4-2). This was 
not surprising since the inhibitors occupied the hydrophobic substrate binding pocket. 
Compared with the GSK490A, the halide substituted aryl group of GSK625A made 
additional hydrophobic and van der Waals interactions with Gly104, Ala157, Tyr158, 
Ala198, and Met199. In particular, the fluoride atom of GSK625A interacted with 
Gly104. This can explain a shift of three orders of magnitude in the enzymatic potency 
of the two thiadiazoles (GSK490A IC50=28 μM; GSK625A IC50=4 nM).  
Noticeably, neither GSK490A nor GSK625A caused a significant conformational 
change in the main chain backbone of InhA (rmsd is 0.5 Å), or perturbed the position or 




the substrate binding loop (especially the helix between the residues 208-226) moved 2.2 
Å away from the active site (the distance between the Cαs of Glu209) compared with the 
InhA: NAD(H) structure, due to the presence of the halide substituted phenyl moiety of 
the inhibitor. Unlike the INH-NADH adduct, GSK compounds did not cause the flipping 
of the Phe149 side chain, thus they did not interact with the isonicotinic acid binding 
pocket. The catalytic residue Tyr158 also adopted the identical position as in the 
InhA:NAD(H) structure (PDB ID: 3OEW) (Molle et al., 2010). It is worth noting that 
Tyr158 did not make any hydrogen bonds with the GSK inhibitors and it participated in 
ligand binding only through van der Waals interactions (4.2-5.4 Å). In contrast to the 
previously identified InhA inhibitors such as pyrolidine carboxamides (He et al., 2006), 
Genzyme10850 and triclosan (Kuo et al., 2003), the GSK inhibitors did not interact with 
Tyr158 directly. Consequently, the GSK compounds are representatives of a new class 
of inhibitors, which do not need this conserved network of interaction with Tyr158 for 
their potency.  
Recently, it was proposed that high affinity slow binding inhibition of InhA is 
related to the ordering of the substrate binding loop through the increased residence time 





:GSK625A structures, the substrate binding loop 
(residues 197-226) was ordered and well resolved in the crystal structure, as previously 
seen with the high-affinity slow onset FabI inhibitor structures. This implies that the 
compounds may also be slow, tight binding inhibitors, which generally enhances in vivo 




The thiadiazoles are bactericidal  
In order to test whether the thiadiazoles share the fast killing mode of action of 
INH, we determined the in vitro killing rates of GSK625A at 20X MIC in growth 
medium inoculated with approximately 10
6
 bacteria, during seven days (Figure 4-3A). 
After the first two days of incubation, GSK625A behaved similarly to INH, killing more 
than 99% of the initial inoculum. Due to the high spontaneous mutation frequency to 
INH resistance, the number of bacteria increased after 4 days of culture in the presence 
of this drug. In contrast, the number of colony forming units kept decreasing down to the 
detection limit for the cultures treated with GSK625A. A very similar effect was also 
observed against Mtb growing inside the THP1 differentiated macrophages (Figure 4-









Figure 4-3. In vitro activity of GSK625A. A) Time killing kinetics of GSK625A in 







GSK625A generates resistant mutants at lower frequency than INH and mutations 
map in the InhA operon as established by targeted PCR 
The in vitro rate of spontaneous resistance for GSK625A at 20X the MIC was 
3.7x10
-8
 mutants/cfu, very similar to the frequency obtained with rifampicin and two 
orders of magnitude lower than that for isoniazid (Bergval et al., 2009). This rate is 
consistent with the presence of a single defined target. GSK625A resistant mutants 
exhibited a shift in MIC values by at least an order of magnitude and displayed no cross-
resistance with other antitubercular compounds such as INH or RIF (Table 4-3). Since 
the GSK compounds bound to the enzyme competitively with the DDCoA, it could be 
expected that mutations in the substrate binding site could affect the interaction of the 
thiadiazoles with the protein, while leaving the INH and ETH activity unaffected. The 
inhA alleles from single colonies of the seventeen mutants were amplified and 
sequenced. Four different point mutations were found in the protein coding regions from 
all mutants, producing a single amino acid change at either of two positions: Gly96 or 
Met103. These two amino acids map to the active site of the enzyme (Figure 4-2) and 







Table 4-3. GSK625A resistant strains carry mutations in the inhA gene. 
Spontaneous resistant mutant colonies were isolated and sequenced resulting in a 
number of key InhA mutations being identified. All mutations gave rise to significant 
MIC shifts against GSK625A.  
















GSK625A 1 >16 >16 >16 >16 
INH 0.4 1 1 1 1 
Rifampicin 0.002 1 1 1 1 
 
 
In order to link the point mutations in inhA to the resistant phenotype, the drug 
sensitivity of the encoded enzyme and the bacteria expressing the mutant genes were 
analyzed. Wild-type InhA and the four different point mutants were over-expressed as 
untagged proteins in E. coli and purified. All mutant enzymes displayed in vitro Vmax 
and Km values similar to the wild type enzyme. A good correlation was observed 
between the IC50 and the MIC values (Table 4-4). For the whole-cell analysis, the 
complete inhA operon (fabG1-inhA-hemZ) from the wild type H37Rv strain and from the 
resistant mutants were cloned in a multicopy plasmid and transformed into fast growing 
M. smegmatis mc
2
155 and into slow growing M. bovis BCG and M. tuberculosis H37Rv. 
In all cases, the genetic transformation of the mutant operons conferred resistance to the 
thiadiazoles well above that obtained by expressing the wild type version from the 





Table 4-4. Activity of GSK625 against InhA purified mutant proteins and Mtb 





Activity of the thiadiazoles against sensitive and M(X)DR Mtb clinical isolates 
Other InhA inhibitors, such as INH and ETH have been in use for decades and 
resistant Mtb strains have emerged without identifiable mutations in inhA or in any other 
studied gene (Vilcheze and Jacobs, 2007). It was therefore relevant to test a variety of 
clinical drug-resistant isolates for the possibility of pre-existing cross-resistance to the 
thiadiazole class. Two thiadiazole compounds were tested in a first instance against a 
group of INH-resistant clinical isolates with characterized mutations, either in KatG (the 
most frequent resistant class) or in nucleotide position 15 upstream of the transcription 
start site for InhA (promoter-up mutations). The compounds retained full activity against 
the first group of mutants, while a moderate shift (4-8 times) in MIC was observed 
against the group of strains over-expressing InhA, as described above for the laboratory 




InhA allele InhA IC50 (uM) IC50 Ratio MIC (uM) MIC Ratio
Wild Type 0.0028 1 1 1
M103I 0.396 144 >125 >125
M103V 1.011 368 >125 >125
M103T 0.829 302 >125 >125




Table 4-5. Activity of thiadiazole derivatives against INH resistant clinical isolates. 




GSK625A has been tested against recent clinical isolates of Mtb at two different 
TB reference centers (National Institute of Health Carlos III, Madrid and Hospital Vall 
d’Hebron, Barcelona) and two observations were noteworthy. The first one was that the 
MIC90 obtained with 100 recently isolated Mtb stains (Table 4-6) ranged from 0.3 to 3 
μM, showing that the thiadiazole sensitivity of our laboratory H37Rv strain was 
representative for the majority of the Mtb strains circulating in Spain, which were 
therefore sensitive to the compound. The second was that GSK625A was active against 
the most resistant isolates present in the sample (13 XDR and 12 MDR), with MIC 
values similar to that of the laboratory strain H37Rv independently of the resistance 




Compound/Strain H37Rv CI1 CI2 CI3 CI4 CI5 CI6 CI7
MIC (ug/ml) 2 >8 >8 >8 2 2 2 1
Ratio 1 >4 >4 >4 1 1 1 0.5
MIC (ug/ml) 1 8 8 NT 1 0.5 0.5 NT
Ratio 1 8 8 1 0.5 0.5
MIC (ug/ml) 0.25 2 2 2 64 32 32 32

































Strain MIC(uM) Strain MIC(uM) Strain MIC(uM) Strain MIC(uM)
175 1 10 3 2177 0.3 2557 1
186 0.3 105 3 2194 1 2637 HSRZ 3
191 3 122 3 2195 1 2638 HSRZ 3
200 0.3 135 3 2199 HS 1 2644 H 9
205 0.3 143 HSERZ 1 2200 0.3 2645 HER 1
207 0.3 153 3 2206 HR 3 2901 1
209 0.3 163 3 2207 HR 3 2935 1
215 3 1901 H 1 2221 M 0.1 2936 1
224 0.3 1943 1 2225 0.3 2944 1
228 0.3 1946 1 2227 1 2945 3
236 9 1947 1 2229 1 2948 3
238 0.3 1969 1 2231 1 2980 1
241 1 1973 0.3 2234 1 2982 3
243 3 2014 0.3 2247 H 1 2983 0.3
248 1 2018 0.3 2271 HRSZ 0.3 3020 1
250 3 2019 3 2285 HERZ 3 3023 3
252 9 2020 1 2316 H 1 3035 3
256 1 2038 1 2471 1 3043 1
258 3 2047 0.3 2482 1 34 3
263 0.3 2049 0.3 2496 1 42 HSERZ 3
268 9 2140 0.3 2497 1 52 0.3
271 1 2152 1 2521 0.3 62 9
275 3 2157 0.3 2527 1 70 9
301 3 2166 0.3 2545 1 86 3






















Table 4-7. Activity of GSK625A against Mtb strains resistant to different 





Lead optimization and identification of GSK2505693A 
Despite the interesting in vitro anti-tubercular profile stated in Table 4-1, the 
initial thiadiazole hits were affected by a number of compound development liabilities 
(drug metabolism and pharmacokinetics (DMPK) properties) that precluded their 
progression to the available in vivo acute murine TB efficacy model. Further medicinal 
chemistry efforts were hence dedicated to the identification of optimized compounds that 
were able to retain or even improve the anti-tubercular profile and simultaneously meet 
the good pharmacokinetic exposure values. These efforts led to the identification of 
GSK2505693A (GSK693A) as a new lead representative structure (Table 4-8).  
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Table 4-8. Structure of the optimized lead GSK693A. The lead was assessed for 
activity against M. tuberculosis H37Rv both intra- and extracellularly and against a 
broad-spectrum bacterial panel, cytotoxicity in HepG2 cells, clearance (in vitro and in 




InhA IC50  7 nM 
MIC H37Rv  0.2 μM 
MIC intracellular 0.2 μM 
Antibacterial panel ≥64 μg/mL 
HepG2 cytotox > 100 μM 
In vitro Cli mouse 2.1 mL/min.g 
In vitro Cli human 0.2 mL/min.g 
In vivo Cli mice 157mL/min/Kg 
% F (at 100 mg/Kg) 92 % 
 
 
GSK693A improved the previous leads’ in vitro potency values against H37Rv 
and was able to reach acceptable exposure levels after a single oral administration at 50 
mg/kg. The cross resistance experiments with the previously isolated mutants showed 
that the observed TB activity for the new lead compound was target related (data not 
shown). GSK693A fulfilled the minimum requirements in terms of in vitro potency and 
the PK properties to be progressed to in vivo proof of concept efficacy studies in both 





Acute and chronic in vivo efficacy of GSK693A 
The in vivo acute efficacy of GSK693A was evaluated using a previously 
reported model (Rullas et al., 2010) at doses of 30, 100 and 300 mg/Kg, using 
Moxifloxacin as a positive control at 30 mg/Kg. GSK2505693A at 100 mg/Kg was 
shown to match the efficacy of moxifloxacin at 30 mg/Kg (Figure 4-4A). The higher 
dose employed (300 mg/kg) produced a log cfu reduction in the lungs of infected mice 
equivalent to INH (data not shown). GSK693A was also progressed for evaluation in an 
established model of TB infection. In this model GSK693A (300 mg/Kg) was able to 







Figure 4-4. Dose-response studies of GSK693A. A) In an acute murine model of TB 













Bacterial strains and culture 
Mycobacterium smegmatis mc
2
155 (Snapper et al., 1990) and M. bovis BCG 
Pasteur (Institut Pasteur) were grown at 37ºC in Middlebrook 7H9 broth (Difco) 
supplemented with 0.0025% Tween 80 and 10% albumin-dextrose-catalase (ADC) or on 
Middlebrook 7H10 plates supplemented with 10% oleic acid-albumin-dextrose-catalase 
(OADC). Cell-free extracts were done in 7H9 supplemented with 100 ml of 10X AS 
solution (5% albumin solution in salt: 10 mg albumin, 1.7 mg NaCl in 200ml water), 2.5 
ml of 10% Tween 80 solution and 0.1% carbon substrate (acetamide, succinate, or 
glucose). Escherichia coli DH5α was grown in LB broth (LB). 
 
Cloning and purification of InhA  
The inhA gene was amplified from Mtb genomic DNA by PCR and cloned into 
the pET15b vector (Novagen) using NcoI and BamHI restriction sites. The plasmid was 
transformed into BL21(DE3) E.coli cells for protein overexpression. Cells carrying InhA 
over-expression plasmid were cultured in terrific broth media together with 100 μg/ml 
carbenicillin as the antibiotic resistance selection marker at 37ºC with continuous 
shaking till the OD600 reached 0.6-0.8. Cells were cooled down to 18ºC and induced with 
0.5 mM IPTG for 16-18 hours, which gave ~20 mg of soluble protein per liter culture. 
The cells were harvested and resuspended for lysis in 50 mM PIPES buffer pH 6.8 




were centrifuged at 15K rpm for 45 minutes. The supernatant was loaded on a blue-
sepharose column which was pre-equilibrated with buffer A. The fractions containing 
the InhA protein were eluted from the column by using a gradient of buffer B (50 mM 
PIPES pH 6.8 and 2 M NaCl). These fractions were pooled and then loaded onto an 
hydrophobic octyl-sepharose column pre-equilibrated with buffer B. After consecutive 
wash steps with buffer A, the majority of the impurities were removed and the InhA 
protein was eluted from the column with water. The fractions containing InhA were 
pooled and supplied with 50 mM PIPES pH 6.8 buffer immediately. As the final 
purification step, the protein was concentrated and run through a Superdex S200 gel 
filtration column. The purity of the protein was checked by SDS-PAGE and activity was 
verified by enzymatic assay. The protein was concentrated to 10 mg/ml, stored in -80ºC 
and used for further biochemical and crystallographic studies. 
 
InhA biochemical assays 
InhA catalyzes the last step in the elongation cycle of the FAS-II pathway and 
reduces the 2,3 double bond of trans-2-enoyl-ACP in a NADH dependent manner 
(Quemard et al., 1995). High Throughput Screening (HTS) and Led Optimization (LO) 
biochemical assays were based in the oxidation of the cofactor in the presence of 
dodecenoyl-CoA (DDCoA). 
InhA inhibition by file compounds in a high throughput format was assessed 
using a substrate-induced quenching (SIQ) assay as described previously (Vazquez et al., 






, 30µM NADH, 10 nM resorufin, 0.2% w/v pluronic acid F-127, 0.01% 
BSA, 1% DMSO and 1.25nM InhA in 30mM PIPES buffer at pH 6.8 were incubated in 
glass-bottom 1536-well plates for 1 hour at 20°C and 95% relative humidity. Plates were 
then read in a confocal microscope (4-Channel Reader, Evotec Technologies) using 1D-
FIDA settings with beamscanner, 532nm excitation with a laser power of 150µW for 
200ms/well. Confocal FLINT data from each screening plate were normalized against 
control wells containing reaction mixtures in the absence of test compounds (high 
controls) and in the absence of enzyme (low controls). Assay quality was monitored for 
each plate using the Z’ factor (Zhang et al., 1999b) and the inhibition observed in 
additional control wells containing a known inhibitor at its IC50. In order to identify and 
discard signal quenchers, each plate was pre-read before addition of the enzyme.  
Enzymatic activity to support LO phase was measured fluorimetrically by 
following the NADH oxidation at exc=340 nm and em= 480 nm, using 50 μM NADH 
and 50 μM DDCoA as substrates. Dose-response experiments to determine IC50 were 
performed using 5 nM InhA, percentage of remaining enzymatic activity (%AR) at 
different compound concentrations were calculated with the next formula [%AR = 
100*((sample – control 2)/(control 1- control 2))] where sample is the enzymatic activity 
for each compound concentration, control 1 is the enzyme activity in absence of any 
compound and control 2 is NADH oxidation in absence of the enzyme. IC50 were 
calculated fitting %AR to a 2 parameter equation [%AR = 100% /(1+ (compound conc/ 
IC50)^s)], where s is a slope factor, using GraFit 5.0.12 software (Eritacus Software Ltd). 





Crystallization of the native protein and the protein-inhibitor complexes was 
done by using both hanging drop and sitting drop methods. For all of the crystallization 
trials, NAD
+
 was used as the cofactor at 10 fold molar excess compared to the protein 
concentration. Protein-inhibitor complex crystals were obtained by co-crystallization, 
except for the compounds GSK133 and GSK915.  The complex structures with GSK133 
and GSK915 were obtained by soaking of the native protein crystals crystallized in 20% 
(v/v) Peg400, 5% (v/v) ethylene glycol, 0.2 M HEPES pH 7.4 in the presence of NAD
+
. 
The crystals were soaked with 2-4 mM of inhibitor compound for 30 min-4 h. All of the 
inhibitor compounds were dissolved in 100% DMSO and 10-100 mM stock solutions 
were used in the experiments. For co-crystallization trials, briefly, 0.2 mM InhA, 2 mM 
NAD
+
 and 1-2 mM inhibitor compound was incubated at room temperature for ~20 min 
and screened against the sparse matrix crystallization conditions. The crystallization 
conditions for the different InhA:GSK inhibitor co-crystals were as follows: GSK876 
and GSK735 in 10-20% (v/v) 2-Methyl-2,4-pentanediol, 0.1 M HEPES pH 7.5, 4% (v/v) 
DMSO and 50 mM NaCitrate pH 6.5; GSK218 in 0.2 M NaAcetate trihydrate, 0.1 M 
Tris HCl pH 8.5, 30% (w/v) Peg4000; GSK713 in 0.1 M N-(2-acetamido) 
iminodiaceticacid pH 6.8, 6% (v/v) DMSO, 14-24% (w/v) Peg3350, 0.18 M NH4(OAc); 
GSK490 in 1.6 M tri-sodium citrate dehydrate pH 6.5; GSK625 in 1.1 M Sodium 






Data collection and processing  
The diffraction data were collected at 120 K under cryoproction by a Rigaku 
Raxis detector coupled to an X-ray generator with a rotating copper anode (λ= 1.541 Å)  
and at the beamlines 23ID and 19ID of Advanced Photon Source, Argonne National 
laboratory. Data was processed by HKL2000 (Otwinowski and Minor, 1997).  InhA-
GSK inhibitor complex crystal structures were solved by molecular replacement (MR) 
using the PDB entry 3OEW as a search model. The models were built by XtalView and 
Coot and were further refined by using Refmac in CCP4 package (Murshudov et al., 
1997; Winn et al., 2011). Data processing statistics are given in Table 4-2. 
  
Cloning and overexpression of InhA in mycobacteria 
Double digestion with BglII and BamHI liberates M. smegmatis and Mtb inhA 
genes from plasmids pATB15 and pATB14, respectively. The 918bp and 917bp 
fragments were cloned into pATB45 that was previously linearized by BamHI digestion. 
Ligations were performed into E. coli DH5α cells. The inhA gene in the final plasmids 
was verified by sequencing. Electroporation of M. smegmatis mc
2
155 and M. bovis BCG 
were carried out according to the method of Snapper et al. (Snapper et al., 1990) and the 
transformants were selected on Middlebrook 7H10 plates supplemented with 10% 
OADC and 50 µg/ml hygromycin. Verification of the transformants was made by colony 
PCR using the PuRe Taq Ready-To-Go PCR Beads kit (GE Healthcare) with the primers 





Protein expression levels were followed by SDS-PAGE. M. smegmatis mc
2
155 
and M. bovis BCG cultures were grown in Middlebrook 7H9 broth with 0.0025% Tween 
80 and 10% ADC to OD600nm=0.6. The cells were harvested by centrifugation (5000 rpm 
for 5 min) and resuspended in 5 ml sterile distilled water. 0.5 ml of M. smegmatis 
mc
2
155 or M. bovis BCG cells were used to inoculate 250 ml conical flasks containing 
100 ml minimal medium with 1% acetamide, 0.1% succinate, or 0.1% succinate plus 1% 
acetamide (for M.Smegmatis) or with 0.1% acetate, 0.1% acetate plus 1% acetamide, 
10% ADC or 10 % ADC plus 1% acetamide (for M.bovis). Cultures were incubated at 
37ºC and harvested after 24 hours (M. smegmatis) or 7 days (M. bovis). 
Cell-free extracts were prepared from both cultures using the Mini-BeadBeater 
(Biospec Products). 50 ml of bacterial cells were resuspended in 1 ml buffer of 50 mM 
HEPES/KOH pH 7.5, 10 mM MgCl2, 60 mM NH4Cl, 10% (v/v) glycerol, 5 mM 2-
mercaptoethanol and mixed with 0.5 ml of 0.1mm sterile glass beads and shaken for 1 
min three times, while incubating the samples on ice for 1 min between pulses. The 
supernatant was recovered after centrifugation. Cell-free extracts were analysed by SDS-
PAGE and protein concentration was determined using the BCA protein assay (Pierce). 
 
Isolation and characterization of Mtb H37Rv GSK625A resistant mutants 
GSK625A-resistant M. tuberculosis H37Rv mutants were isolated by plating 10
8
 
CFU on Middlebrook 7H10 plates supplemented with 10% OADC containing the 
compound at 20µM (20X MIC). After 4 weeks of incubation at 37ºC, colonies were 




Single colonies were used to amplify and sequence the inhA alleles. DNAs of the 
17 resistant mutants were extracted from liquid cultures grown in Middlebrook 7H9 
broth supplemented with 0.0025% Tween 80 and 10% ADC. 1 ml of culture was 
centrifuged; the pellet was resuspended in 500 µl of distilled water and incubated at 
90ºC for 1 h, and then filtrated by using 0.22µm filters. 5 µl of the supernatant was used 
as a source of genomic DNA for amplification of the inhA gene. PCRs of the entire gene 
were performed for each mutant by using the PuRe Taq Ready-To-Go PCR Beads kit. A 
988 bp region was amplified with the primers Forward (5'-CAGCTTCCTGGCTTCC 
GAG-3') and Reverse (5'-TAACGTTCTCCAGGAACGG-3'). PCR products were 
purified and sequenced using the dRhodamine Terminator Cycle Sequencing Ready 
Reaction kit in an ABI Prism 310 automated DNA sequencer (Applied Biosystems).  
 
Complementation experiments 
The whole fabG1-inhA-hemH operon from wild type H37Rv and mutants 
carrying the four mutant alleles (M103V, G96V, M103I, M103T) were cloned in the 
shuttle vector pSUM36 (Ainsa et al., 1996). M. tuberculosis H37Rv was transformed 
with the five plasmids and transformants were selected using kanamycin, and verified by 
colony PCR using the PuRe Taq Ready-To-Go PCR Beads kit. The sequences of the 
primers were as follows: pSUM36_2, 5'-GTTGTGTGGAATTGTGAGCGG-3'; 
Inharev1, 5'-GAAACGCGATCGACGAGTCGG-3'. Positive transformants were used 





MIC determination against mycobacteria and clinical strains 
The measurement of the MIC against Mycobacterium strains for each tested 
compound was performed in 96-well flat-bottom, polystyrene microtiter plates in a final 
volume of 200 μl. Ten two-fold drug dilutions in DMSO starting from 50 mM were 
performed. Drug solutions were added to Middlebrook 7H9 medium and Isoniazid 
(INH) (Sigma Aldrich) was used as a positive control with two-fold dilutions of INH 
starting at 160 μg/ml. The inoculum was standardized to approximately 1x10
7
 cfu/ml 
and diluted 100 fold in Middlebrook 7H9 broth. This inoculum (100 μl) was added to the 
entire plate except the G-12 and H-12 wells that were used as blank controls. All plates 
were placed in a sealed box to prevent drying of the peripheral wells and incubated at 
37ºC without shaking for six days. Resazurin solution was prepared by dissolving one 
tablet of resazurin (VWR) in 30 ml of sterile phosphate buffered saline. Of this solution, 
25 μl were added to each well. Fluorescence was measured (Spectramax M5 Molecular 
Devices, Exc. 530nm, Emis. 590 nm) after 48 hours to determine the MIC value.  
The BACTEC MGIT 960 System (Becton Dickinson) was used for MIC 
determination in clinical isolates (Institute Carlos III and Hospital Val d’Hebron) 
following the manufacturer instructions. 
 
Intracellular activity determination  
Bacteria were grown in Middlebrook 7H9 broth supplemented with 10% ADC, 
0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then 




FCS (fetal calf serum) and resuspended in the same buffer. The suspension was 
dispersed by sonication, using a probe sonicator (Ultrawave), at power level moderate 
and pulse level 40 KHz; 2 rounds of  8 pulses (1
st
 round 1min/pulse, 2
nd
 round 30 
secs/pulse). Between the pulses samples were placed in ice for 5 secs to avoid heat 
damage. Two centrifugation cycles at 1500 rpm 5 min recovering the supernatant were 
performed to collect the final bacterial suspension. Bacteria were quantified by 
measuring the absorbance at 600nm, where 0.1 OD corresponded to 3x10
8
 bacteria. 
PMA-differentiated THP-1 cells (PMA 20 ng/mL for 48h) were infected with 
Mtb H37Rv at a multiplicity of infection of one. Infection was performed in antibiotic 
free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were 
incubated for 4 hours at 37°C with 5% CO2. Non-engulfed bacteria were removed by 
washing 5 times with warm RPMI.  
Master plates of compounds were prepared and added to each well (final DMSO 
concentration lower than 0.5%). After 5 days of incubation the cells were lysed in 100 μl 
of 0.06% SDS for 10 min at room temperature and dilutions were prepared. Lysate 
dilutions of 1:10 and 1:100 were each plated separately in duplicate sets on 7H10 agar 
plates supplemented with OADC. The plates were then allowed to dry and subsequently 
incubated in a humidified incubator at 37°C. Colonies were first counted on 18
th
 day, 
and then again on the 21
st







General antimicrobial activity assay 
Whole cell antimicrobial activity was determined by broth microdilution using 
the Clinical and Laboratory Standards Institute recommended procedure, Document M7-
A7, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically". 
Compounds have been evaluated against a panel of Gram-positive and Gram-negative 
organisms, including Enterococcus faecium, Enterococcus faecalis, Haemophilus 
influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Escherichia coli and 
Streptococcus pyogenes. The MIC was determined as the lowest concentration of 
compound producing a >80 % reduction in fluorescence observed. 
 
HepG2 cytotoxicity assay 
HepG2 cells (HB-8065) were fed fresh medium (Essential Minimum Eagle 
Medium, EMEM, supplemented with 5% FCS and 2 mM L-glutamine) on the day before 
subculturing. On the day of plate seeding, 100 μL of 100,000 cells/mL was added to 
every well of a collagen coated, black clear bottom, 96-well microplate (Becton 
Dickinson) except in column 11, where 100μL of culture medium was dispensed. The 
plates were incubated for 24 h before the addition of 10 doses of 1:2 dilutions of test 
substances to achieve a final concentration of 0.5% DMSO. Plates were incubated for 48 
hours at 37ºC under 5% CO2 and 95% relative humidity. Then the culture medium was 
removed and 200μL of fresh culture medium with 50 μL of Resazurin solution were 
added. After 90 minutes, plates were removed from the incubator and were left at room 




Resazurine (BDH) was used to read out the viability of the cells. The fluorescence was 
measured at an excitation wavelength of 515 nm and an emission wavelength of 590 nm 
in a Microplate reader1420 Multilabel HTS counter Victor 2 (Wallac). 
The fluorescence value of each well was corrected by subtracting the background 
value (average of column 11) from the absolute value. The percent of inhibition was 
calculated relatively to the DMSO control wells (average of column 12). For each 
compound, the average value of the duplicate samples was calculated and the curve was 
fitted to Sigmoidal dose-response (variable slope) nonlinear regression curve adjustment 
(GraphPadPrism 5 (GraphPad Software, Inc).) in order to calculate the IC50 (Tox50). 
 
Microsomal fraction stability assay 
Pooled mouse, rat, dog and human liver microsomes were purchased from 
Xenotech. The microsomes (final protein concentration 0.5 mg/ml, 5 mM MgCl2) and 
the test compound (final substrate concentration 0.5 µM; final DMSO concentration 0.5 
%) in 0.1 M phosphate buffer pH 7.4 were pre-incubated at 37°C prior to the addition of 
NADPH (final concentration 1 mM) to initiate the reaction. The final incubation volume 
was 600 µl. Control samples were included for each tested compound, where 0.1 M 
phosphate buffer pH 7.4 was added instead of NADPH (minus NADPH). Midazolan was 
included as a control in every experiment. Each compound was incubated for 30 minutes 
and samples (90 µl) were aliquoted at 0, 5, 10, 20 and 30 minutes. The minus NADPH 
control was sampled at 0 and 30 minutes only. The reactions were stopped by the 




followed by the centrifugation at 3700 rpm for 15 minutes at 4°C to precipitate the 
protein. Quantitative analysis was performed using specific LC-MS/MS conditions. The 
ln peak area ratio (compound peak area/internal standard peak area) was plotted against 
time and the gradient of the line was determined. Subsequently, half-life and intrinsic 
clearance were calculated using the equations below: 
Elimination rate constant (k) = (-gradient) 
Half life (t1/2) (min) = 0.693/k 
Intrinsic Clearance (CLint) (ml/min/g protein) = (V x 0.693) / t1/2 where V is the 
incubation volume ml/g microsomal protein. 
 
Killing kinetics and in vivo assays 
Bacteria were grown at 37ºC in 7H9 broth ADC Tyloxapol to mid-exponenetial 
phase and then diluted in 10ml fresh Middlebrook 7H9 to an 5x10
5
 cfus/ml. Incubation 
was continued after the addition of compounds at 20X the MIC. At specified time points, 
aliquots of cultures were withdrawn, serially diluted in 7H9 broth Tyloxapol and plated 
on solid culture medium. Plates were then incubated at 37ºC and CFU were counted 
after 3 to 4 weeks. 
Specific Pathogen-free 6-8-week-old female C57BL/6j mice (18 – 20 g) were 
obtained from Harlan (Harlan Interfauna Iberica, Spain). The experiments were 
performed at AAALAC-accredited GlaxoSmithKline Laboratory Animal Science animal 
facilities in Tres Cantos (Madrid, Spain). The mice were kept in air-conditioned facilities 




ºC and 40- 70%, respectively. The mice were accommodated in groups of up to five 
individuals in Tecniplast® type IV cages with autoclaved dust free corncob bedding 
(Panlab, Barcelona, Spain). The mice were maintained under a twelve hours light/dark 
period. Autoclaved tap water and γ-irradiated pelleted diet were provided ad libitum.  
All the experiments were approved by the DDW Ethical Committee. The animal 
research complied with Spanish and European Union legislation on Animal Research 
and GlaxoSmithKline policy on the Care and Use of Animals. 
 
Pharmacokinetic studies  
Experimental compounds were administered by oral gavage at 50 mg/kg single 
dose at a volume of 20 ml/kg to n=5 mice. All mice received treatment in the fed state. 
25 μl of peripheral total blood was taken from the lateral tail vein of each mouse at 15, 
30 and 45 minutes, 1, 2, 4, 8 and 24 hours for the establishment of compound 
concentrations. LC-MS was used as the analytical method of choice to determine the 
concentration of the compound in blood. The non-compartmental data analysis (NCA) 
was performed with WinNonlin Phoenix 6.3 (Pharsight, Certara L.P) and supplementary 
analysis was performed with GraphPad Prism 5. 
 
In vivo acute efficacy assessment 
The mice were intratracheally infected with 100,000 CFU/mouse (Mtb H37Rv). 
The products were administered for eight consecutive days starting one day after 




assay, mice were infected with 100,000 CFU/mouse and the products administered daily 
seven days a week for eight consecutive weeks starting six weeks after the infection. All 
lung lobes were aseptically removed 24 hours after the last administration, homogenized 
and frozen. Homogenates were plated in 10% OADC-7H11 medium for 14 days at 37ºC. 
The homogenates from compound treated mice were incubated for 18 days at 37ºC in 
plates supplemented with 0.4% (w,v) activated charcoal (Sigma Aldrich) to prevent the 




HTS screening and lead selection 
Several screening campaigns were run by GSK against InhA, which covered a 
total of 1.9 million compounds. The initial average hit rate of 3.7% was reduced to 
0.63% of true hits after the removal of false positives. Dose-response studies were 
performed on the true hits using compound concentrations ranging from 1.7 nM to 100 
µM, and several chemotypes showing IC50 less than 10 μM were found (Table 4-9). All 
of the identified inhibitors were progressed to the enzymatic mode of action studies 
where non-specific enzyme inhibitors were removed. The new filtered InhA inhibitors 
were selective against InhA. Steady state competition experiments showed that most of 
the compounds competed with the fatty acid substrate for binding to the enzyme, but 
they were uncompetive with NADH, which is consistent with inhibitors binding to a pre-




The antitubercular activity of the newly identified InhA inhibitors was tested 
against M. tuberculosis H37Rv in liquid medium (Table 4-9). A robust correlation was 
observed between the enzymatic and whole cell activities for compounds from the same 
series. Thiadiazoles or arylbenzamides were found to be nanomolar inhibitors of InhA 
with MICs against H37Rv in the micromolar range, while for the other series, like the 
triazines, IC50 and MIC values were very similar. This contrast between the chemical 
series may reflect differences in cell penetration, intracellular accumulation or enzymatic 
mode of action, but it could also stem from off-target activities. When the physico-
chemical profiles of the selected InhA inhibitors were evaluated and compared, the 
thiadiazole series emerged as the family with the best balanced scaffold (Table 4-9). A 
complete profile of GSK826613 and GSK826625 thiadiazoles was built to ascertain their 
value as antitubercular leads. As described in the results and discussion section of this 
chapter, further development of these series yielded the identification of GSK2505693A 



















Table 4-9. InhA inhibitor hits identified from the HTS screen. Hits belonged to 








Crystal structures of the InhA:GSK compound complexes 
The co-crystal structures of the InhA:GSK compounds were determined by X-ray 
crystallography. The tested compounds belonged to different chemical series to 
understand the differences in the binding mode of these inhibitors. Compounds received 
from GSK were directly used for crystallographic studies without further chemical 
modifications.  
In total, 13 compounds were received and eight of these compounds, which had 
various degrees of inhibitory activities (IC50: 2 nM to 28 μM), were successfully co-
crystallized with InhA. The co-crystal structures were obtained for two compounds from 
the thiadiazole series (compounds 490 and 625; Figure 4-2), four compounds from the 
aryl benzamide series (compounds 218, 876, SB713 and 915; Figure 4-5), one 
compound from the benzazepin sulfonamide series (compound 735; Figure 4-6 (co-
crystal structure with compound 246 was determined by GSK)), and one compound from 









Figure 4-5. The aryl benzamide series of GSK inihibitors. The scaffold of this series and the 
corresponding substituents for each compound is shown. The compounds which were 








Figure 4-6. The benzazepin sulfonamide (735 and 246) and the benzothiazole (133) series of 
GSK compounds. The compounds which were successfully co-crystallized with InhA are 
marked with an asterix (*).   
 
 
The co-crystal structures of InhA:GSK compounds revealed that all of the 
investigated compounds bound to the hydrophobic substrate binding pocket of InhA, 
which was surrounded by residues Met199, Leu207, Ile215, Leu218, Met103, Met155, 
Met161, Phe149, Tyr158, Ala198 and Ile202 (Figure 4-7). As was observed for the 
thiadiazole series, compounds belonging to the aryl benzamide, the benzazepin 
sulfonamide or the benzothiazole series also formed the enzyme:inhibitor complex only 
in the presence of the cofactor NAD
+
, verifying the uncompetitive character of the 






Figure 4-7. Binding mode of the GSK inhibitors to the InhA active site. Eight InhA:GSK co-
crystal structures (light blue) are superimposed with NAD
+
 (blue) and the C16-fatty acyl 
substrate analog (orange). A cross-section through the surface of the active site of InhA is 
shown. As seen from the figure, GSK compounds occupied the substrate binding pocket. 
 
 
As a common scaffold, all of the investigated GSK inhibitors, including the 
thiadiazole series, had aromatic pyrazole/thiazole/pyrimidine/imidazole or pyridine 
rings, which interacted with the nicotinamide ring of NAD
+
 via π-π stacking interactions 
(3.6 - 4 Å). In addition, the nitrogen of these aromatic rings made H-bonds to the 2’ 
hydroxyl of the ribose moiety of NAD
+
 (2.6-3 Å), except for the compound GSK218. 
For compound GSK218 this interaction was provided by the H-bonding of the linker 
methoxy oxygen atom between the 2-methylpyridyl and the phenyl rings to the 2’ 
hydroxyl of the NAD
+
 ribose (Figure 4-8). This direct H-bonding interaction with 
NAD
+




can be clearly seen by comparing the co-crystal structures of compounds GSK490 and 
GSK876. Both compounds interacted with NAD
+
 through direct H-bonding with the 
nitrogen atom in their pyrazole and pyrimidine rings, but they displayed IC50 values of 





Figure 4-8. Binding mode of the aryl benzamide series to the InhA active site. A) Four 
InhA:GSK co-crystal structures are superimposed. The GSK compounds are shown in ball-and-
stick in green (218), magenta (SB713), purple (876) and orange (915) colors. NAD
+
 is shown in 
cyan sticks. B) Key interactions between the aryl benzamide compounds and the InhA active 
site. As a representative, interaction of the compound 218 (green) with the substrate binding 
pocket residues is shown. GSK218 interacts with NAD
+
 (cyan) and M98 via H-bonds; with 
M199, M161, P99, Q100, F149, Y158 and F97 through hydrophobic and van der Waals 
interactions. For both panels atom coloring is: oxygen red; nitrogen blue; sulfur yellow; chlorine 





Based on the InhA:GSK inhibitor co-crystal structures, one of the key 
interactions identified between the inhibitor compounds and InhA was the direct H-
bonding between the inhibitor compound and the carbonyl oxygen and/or the amide NH 
of the main chain Met98. The range of this interaction varied between 2.7 to 3.3 Å 
(Figures 4-8 and 4-9). For compounds belonging to the thiadiazole series, these 
interactions were present between (i) the nitrogen of the thiadiazole ring and the amide 
NH of Met98, and (ii) the nitrogen linking the pyrazole and the thiadiazole rings and the 
carbonyl oxygen of Met98 (Figure 4-2). In comparison, for compounds belonging to the 
aryl benzamide series, this interaction was provided by the amide nitrogen of the 
inhibitor and the carbonyl oxygen of Met98 (2.7-3.4 Å) (Figure 4-8). For compounds 
735 and 133 belonging to the benzazepin sulfonamide and the benzothiazole series, H-
bonding was present between the sulfonamide nitrogen and the carbonyl oxygen of 
Met98 (3.0 Å), and the sulfur atom of the benzothiazole ring and the amide nitrogen of 








Figure 4-9. Binding mode of the benzothiazole and the benzazepin sulfonamide series to the 
InhA active site. Details of the InhA:GSK133 (A) and the InhA:GSK735 (B) interactions. Both 
GSK133 (purple) and GSK735 (gold) H-bond to NAD
+
 (cyan), Met98 and Gln100, and make 
hydrophobic and van der Waals interactions with the surrounding residues. Compounds also 
interact with the nicotinamide ring of NAD
+
 via π-π stacking. 
 
 
Hydrophobic and van der Waals interactions between the inhibitors and the side 
chains of the active site residues Met161, Phe97, Leu207, Met199, Met103, Ala198, 
Thr196, Gly96, Pro99, Gln100, Phe149, Tyr158 and Ile202 dominated the ligand-protein 
interactions for all classes of the inhibitors (Figures 4-8 and 4-9). This was expected as 
the inhibitors occupied the hydrophobic substrate binding pocket of the enzyme. 
Moreover, compounds 133 and 735 were unique in their direct, strong H-bonding 
interaction with the amide NH of Gln100 through their carboxylate and sulfonyl groups, 




substituted aryl group toward the end of the substrate binding pocket (compounds 218, 
625, 876, 713, 915, and 735) formed additional hydrophobic and van der Waals 
interactions with the main chain residues (Gln100, Met98, Gly104, Leu207 and Ile202)  
compared with the compounds 490 and 133. It was observed that the compounds 
involved in multiple interactions with the protein residues were more potent against the 
enzyme.  This difference can be clearly seen when the compounds 490 and 625 were 
compared.  
As was observed with the thiadiazole series, inhibitors belonging to the other 
series also did not cause a significant conformational change in the main chain backbone 
of InhA. In all of the co-crystal structures, the substrate binding loop (residues 197-226) 
was ordered and present in the crystal structure. Similar to GSK826625, GSK218 and 
GSK713 also caused the movement of the substrate binding loop by 3.3 Å and 1.6 Å 
away from the active site compared with the InhA:NAD(H) structure. This movement 
was caused by the interaction of the substrate binding loop with the halide substituted 
benzene moiety of the inhibitor compounds. The shift of the substrate binding loop 
indicates the flexible nature of the substrate binding crevice, which is necessary to 
accommodate the varying chain length fatty acyl substrates. Excluding the substrate 
binding loop, the RMSD of the main chain Cαs between the InhA:NAD(H) and 
InhA:NAD
+
:GSK compound structures was less than 0.5 Å. The catalytic residue 
Tyr158 did not make any H-bonds with the inhibitors; it participated in ligand binding 
only through van der Waals interactions (4.2-5.4 Å). In addition, the side chain of 




NADH adduct, none of the GSK compounds caused the flipping of the Phe149 side 
chain, and so they did not interact with the isonicotinic acid binding pocket.  
 
Summary  
Drug discovery is a long and tedious process. It takes at least 10-15 years for a 
single drug to come to the market. There are many factors considered before a 
compound can be administered as a drug, such as in vivo activity, low frequency of drug 
resistance, low toxicity, oral availability, and affordability. For target-based approaches, 
the drug discovery process starts with the target selection, hit/lead identification, 
verification and optimization. However, a highly potent compound active in vitro against 
an enzyme does not guarantee that a similarly good activity will also be obtained in vivo 
against the organism. Even after compounds are optimized for in vivo activity, they may 
not exhibit good pharmacokinetic (PK) properties (bioavailability, solubility, 
Absorption, Distribution, Metabolization and Excretion (ADME)), which will block 
further progress into drug development. Therefore, it is very important to run and invest 
resources in drug discovery projects, especially for diseases such as tuberculosis, which 
is particularly difficult to eradicate due to the unique biology of its causative agent Mtb.  
In this study, the collaboration with GSK and TB alliance resulted in the 
identification of compounds that exhibited potent antitubercular activity. These 
compounds were activation-free inhibitors of the InhA enzyme. The co-crystal structures 
of the InhA:GSK compounds revealed the details of the protein-inhibitor interactions 




were considered in designing new analogs of the hits.  The GSK inhibitors bound to the 
hydrophobic substrate channel of InhA, and achieved their specificity and potency 
against the enzyme by three types of interactions: (1) π-π stacking interaction with 
NAD
+
, (2) direct H-bonding interaction with NAD
+
 and the main chain backbone 
carbonyl oxygen and the amide NH (especially for Met98), (3) hydrophobic and van der 
Waals interactions with the side chain residues surrounding the substrate binding pocket, 
by the presence of hydrophobic moieties. It was observed that interaction of the 
compounds with the cofactor NAD(H) and the substrate binding loop was necessary for 
high potency.  
As a result of this collaboration, we reached the objective of developing novel 
activation-free InhA inhibitors that are active against the INH resistant Mtb strains 
carrying mutations in the katG gene. The lead thiadiazole compounds represent a 
previously unexplored class of InhA inhibitors. However, the initial compounds of this 
series did not have optimum PK values and additional chemical optimization was 
needed. Further chemistry yielded the final compound GSK693 as a new lead 
representative structure. GSK693 exhibited good antitubercular activity in vivo as well 




CHAPTER V  






Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl 
carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which 
leads to the lysis of Mycobacterium tuberculosis. Using a structure-based drug design 
approach, a series of 5-substituted triclosan derivatives was developed. Two groups of 
derivatives with alkyl and aryl substituents, respectively, were identified with 
dramatically enhanced potency against purified InhA. The most efficacious inhibitor 
displayed an IC50 value of 21 nM, which was 50-fold more potent than triclosan. X-ray 
crystal structures of InhA in complex with four triclosan derivatives revealed the 
structural basis for the inhibitory activity. Six selected triclosan derivatives were tested 
against isoniazid-sensitive and resistant strains of M. tuberculosis. Among those, the best 
inhibitor had an MIC value of 4.7 μgmL
-1 
(13 μM), which represents a tenfold 
improvement over the bacteriocidal activity of triclosan. A subset of these triclosan 
analogues was more potent than isoniazid against two isoniazid-resistant M. tuberculosis 
                                                 

 Reprinted with permission from “Triclosan derivatives: towards potent inhibitors of drug-sensitive and 
drug-resistant Mycobacterium tuberculosis” by Freundlich J.S., Wang F., Vilcheze C., Gulten G., Langley 
R., Schiehser G.A., Jacobus D.P., Jacobs W.R, Sacchettini  J.C., 2009. ChemMedChem, 4, 241-248, 






strains, demonstrating the significant potential for structure-based design in the 
development of next generation antitubercular drugs. 
 
Introduction 
For nearly fifty years, isoniazid (INH) has been utilized as a frontline drug to 
treat tuberculosis (TB) (Vilcheze and Jacobs, 2007). INH is a key component of short 
course chemotherapy for TB treatment, which entails six months of daily administration, 
and is also the sole component for TB prophylaxis, which includes nine months of daily 
administration. The emergence of INH-resistant strains has compromised TB control 
programs worldwide (CDC, 2006; Crofton et al., 1997). 
INH and ethionamide (ETH) are known to target the Mycobacterium tuberculosis 
enoyl acyl carrier protein (ACP) reductase (InhA) (Banerjee et al., 1994; Rozwarski et 
al., 1998; Vilcheze et al., 2006; Wang et al., 2007), validating it as an excellent 
antitubercular drug target. INH and ETH are prodrugs, and their activities are dependent 
on activation in M. tuberculosis by KatG, a catalase/peroxidase enzyme, and EthA, a 
flavin monooxygenase, respectively (DeBarber et al., 2000; Morlock et al., 2003). Upon 
activation, INH or ETH forms a covalent adduct with NAD cofactor, which inhibits 
InhA. As prodrugs, INH and ETH are highly specific and effective. However, mutations 
in activators katG and ethA have been linked to most of the clinical resistance in the 
diagnosed cases of drug-resistant TB (Hazbon et al., 2006; Morlock et al., 2003). 
Compounds that do not require activation and directly target InhA represent a promising 




molecule InhA inhibitors came from our laboratories in 2003, featuring triclosan and 
two members of the Genzyme compound library (Kuo et al., 2003). Triclosan, for 
example, inhibits InhA without the need for prior activation, although its use as an 
antitubercular may be limited by its less than optimal bioavailability (Wang et al., 2004). 
These small molecules, however, represent reasonable starting points for structure-based 
drug discovery efforts to afford effective InhA inhibitors. Aiding such an effort are 
several crystal structures, such as those of InhA:NADH (Dessen et al., 1995), 
InhA:NAD
+
:triclosan (Kuo et al., 2003), InhA: NAD
+
:Genz-10850 (Kuo et al., 2003), 
InhA:NAD
+
:C16-substrate (Rozwarski et al., 1999), and InhA: INH-NAD (Rozwarski et 
al., 1998) that were accessible at the outset of these investigations. During the course of 
this work, Sullivan et al. reported the X-ray structures of two triclosan analogues with 5-
alkyl (n-pentyl and n-octyl) moieties, lacking the two B-ring chlorines (Vilcheze et al., 
2006). This collection of structures provided a precisely defined active site of InhA and 
a thorough understanding of the ligand–enzyme interactions that render potent enzyme 
inhibition. 
One promising route for the design of potent InhA inhibitors involves triclosan, a 
commercially available compound that has been reported to inhibit the enoyl acyl ACP 
reductases (ENR) from several species, including Plasmodium falciparum (Surolia and 
Surolia, 2001), Escherichia coli (Heath et al., 1998), Bacillus subtilis (Heath et al., 
2000), Brassica napus, (Roujeinikova et al., 1999) and Pseudomonas aeruginosa 
(Hoang and Schweizer, 1999). The structures of ENR from E. coli (FabI) (Levy et al., 




2002), and M. tuberculosis (InhA) (Kuo et al., 2003) bound with triclosan have been 
characterized. In our laboratories, a series of 5-substituted triclosan derivatives was 
designed and synthesized in order to optimize the potency of triclosan in parallel against 
both purified PfENR (Freundlich et al., 2007) and InhA. This report discusses these 
efforts focused specifically on the SAR developed versus purified InhA and INH-
sensitive and resistant M. tuberculosis. 
 
Results and discussion 
Our efforts began with a survey of the complex structures of InhA bound with 
INH–NAD (Rozwarski et al., 1998) and triclosan (Kuo et al., 2003), respectively. Two 
hydrophobic cavities capable of being filled were identified: the substrate-binding site 
and the pocket into which the isonicotinoyl group of INH–NAD protrudes. To date, all 
reported inhibitors of InhA occupied the hydrophobic cavity of the substrate-binding 
site, except the INH–NAD and ETH–NAD adducts. The isonicotinoyl moiety of the 
INH–NAD and ETH–NAD adducts were found in a hydrophobic pocket formed by 
movement of the side chain of Phe 149. The pocket was underneath the fatty acyl 
substrate-binding site (Figure 5-1) and, lined predominantly by hydrophobic groups 
from the side chains of Tyr 158, Phe 149, Met 199, Trp 222, Leu 218, Met 155, Met161, 
Gly 192, and Pro 193. This pocket may also serve as a portal to the external solvent to 
the left side of the active site (Figure 5-1). The active forms of both INH and ETH 
occupied the same pocket and were extremely potent against InhA (Ki =5 nM and 7 nM, 




suitable site to target with new inhibitors. Superimposition of the structures of 
InhA:INH–NAD and InhA:NAD
+
:triclosan indicated that the chlorine atom at the 5-
position of the triclosan A-ring was about 2 Å away from the binding pocket of 
isonicotinoyl moiety of the INH-NAD adduct and was in contact with Pro 193, Met 199, 
and Phe 149 through van der Waals interactions. Based on this structural information, 
we hypothesized that it may be possible to replace the 5-chloro with various moieties to 
occupy this isonicotinoyl binding pocket and, thus, increase the in vitro activity against 
InhA.  
It should be noted that this strategy contrasts with that of Sullivan et al. to extend 
relatively long n-alkyl chains off what is essentially the triclosan 5-position (in 
molecules where the two B-ring chlorines have been excised) to mimic substrate 
analogue trans-2-hexadece-noyl-(N-acetylcysteamine)thioester, whose structure with 







Figure 5-1. Cross-section through the surface of the InhA active site of super-
imposed structures of InhA in complex with the INH–NAD adduct and triclosan. 
The carbon atoms of the INH–NAD adduct and triclosan are colored in gold and white, 
respectively. Other atoms are colored according to the atom type: oxygen, red; nitrogen, 
blue; chlorine, cyan; phosphorus, purple. This figure was produced using Spock (version 




A series of triclosan derivatives with modifications at the 5-position of triclosan 
was evaluated for their inhibition of purified InhA. These small molecules were 
prepared during the course of a concurrent program to investigate 5-substituted triclosan 
analogues as PfENR inhibitors (Freundlich et al., 2007). Inhibitors with hydrophobic 
substituents, such as alkyl groups (compounds 2 and 7) were much more potent than 
those with hydrophilic substituents (compounds 3, 4 and 5) (Table 5-1). This result is 
consistent with our proposal that the 5-substituent of triclosan projects into a 
hydrophobic cavity of InhA. It is interesting to note the lack of activity of phenyl 





Following the initial modest activity of compounds 2 and 7, a series of 5-alkyl 
triclosan derivatives was examined for their inhibitory activity against InhA. Their 
potency against InhA appeared to increase with the chain length of the 5-alkyl groups 
(Table 5-2). Highest inhibitory potencies were observed for compounds 10 and 12 with 
four-carbon chains. Sullivan observed the same trend with 5-alkyl substituted, des-











Compound R InhA IC50 [nM] 
    
triclosan Cl 1100± 180 
2 Me 800 ±99 
3 2H-tetrazol-5-yl >10 000 
4 COOH >10 000 
5 C(O)NH2 >10 000 
6 Ph >10 000 
7 CH2(C6H11) 110 ±31 



















 InhA IC50 [nM]  
8 CH2CH3 Cl 120 ±19  
9 (CH2)2CH3 Cl 91 ±15  
10 (CH2)3CH3 Cl 55 ±20  
11 CH2CH(CH3)2 Cl 96 ±46  
12 (CH2)2CH(CH3)2 Cl 63 ±9  
13 CH2CH(CH3)CH2C
H3 
Cl 130 ±56  
14 2-pyridyl CN >10 000   
15 3-pyridyl Cl >10 000   
16 4-pyridyl CN >10 000   
17 CH2(2-pyridyl) Cl 29 ±11  
18 CH2(3-pyridyl) Cl 42 ±10  
19 CH2(4-pyridyl) CN 75 ±16  
20 o-CH3-Ph Cl 1300 ±77  
21 o-CH3-Ph CN >10 000 ±110  
22 m-CH3-Ph Cl 870  
23 p-F-Ph Cl >10 000   
24 CH2Ph Cl 51 ±6  
25 (CH2)2Ph Cl 21 ±8  
26 (CH2)3Ph Cl 50 ±14  







It was found that the in vitro activity of those inhibitors was optimal at a carbon 
chain length of eight. Triclosan inhibitors show better in vitro activity than their des-
chloro counterparts, with 5-substituents of the same carbon chain length, from the report 
by Sullivan et al. (ethyl, IC50 =120 ± 19 nM vs. 2000 ± 700 nM; n-butyl, IC50 =55 ± 20 
nM vs. 80 ± 15 nM), suggesting that the two chlorine atoms on the B-ring contribute to 
the binding of the inhibitor to the enzyme. Molecular modeling suggests that this may be 
due to favorable van der Waals interactions of the 4’-Cl with Phe 97 and Met 103. These 
results imply that the hypothesis of Sullivan et al. (Sullivan et al., 2006) that the B-ring 
chlorines do not contribute to efficacy may not be correct. 
The alkyl substituents investigated in previous studies were all linear in nature. In 
the present report, compounds 11, 12, and 13, with β- or γ-branched methyl substituents, 
failed to improve upon the potency of their straight-chain counterparts of the same chain 
length (compounds 9 and 10). Similarly, cyclohexylmethyl analogue 7 exhibited an IC50 
value of 110 nM. The 2.8 Å crystal structure of InhA in complex with compound 7 
(Figure 5-2) was solved to provide a structural basis for the activity difference amongst 
the alkyl substituents. The crystal belonged to I4122, a space group for InhA that has not 
been reported previously. It is worth noting that the substrate binding loop (residues 
195–205) was ordered in the structure of InhA bound with compound 7, while it has 
been disordered in the structures of InhA bound with triclosan, and all other triclosan 
derivatives solved to date. The structure was readily superimposed on that of InhA in 
complex with 5-pentyl-2-phenoxy-phenol (Sullivan et al., 2006),  which  intriguingly  




substrate analogue (Rozwarski et al., 1999) (overlapping the position of C4 to C7 of the 
U-shaped acyl chain). The 5-cyclohexylmethyl group formed predominantly 
hydrophobic interactions with the side chains of Phe 149, Ile 215, Leu 218, Met 155, Tyr 
158, and Met 199. Based on this structure, we hypothesized that 5-substituents with a 
longer alkyl chain would create more extensive hydrophobic interactions in this pocket. 
Therefore, it was not surprising that the potency of the 5-alkyl triclosan analogues 
increased with the chain length. However, it is not so obvious from a structural point of 
view why our limited subset of methyl-branched inhibitors do not exhibit greater 
potency than the nonbranched inhibitors of the same chain length. A possible 
explanation could be steric clashes with one or more of the side chains of Phe 149, Tyr 
158, and Met 199 with the branched methyl groups. Compared to the structure of InhA 
bound with the 5-pentylphenol derivative designed by Sullivan et al., the side chain of 
Met 199 on the substrate-binding loop flipped ~ 100° to form a hydrophobic interaction 
with the cyclohexyl group at a distance of 3.6 Å. In addition, the B-ring of compound 7 
also rotated ~ 30° from its position in 5-pentyl-2-phenoxyphenol to allow the 4’-chloride 
to form a weak hydrogen-bonding interaction with the amide NH of Met 98 at a distance 








Figure 5-2. The superposition of crystal structures of InhA (ribbons and tubes, key 
residues in stick format) in complex with 5-pentyl-2-phenoxyphenol (Sullivan et al., 
2006) (purple) and compound 7 (carbon atoms in gray) in the presence of NAD
+
 
(cyan). The B-ring of the 5-pentyl triclosan analogue was in a different orientation from 
7, because of the lack of two chlorides. The cyclohexylmethyl group of compound 7 
was in a similar position to the pentyl group of 5-pentyl triclosan analogue. This figure, 
in addition to Figure 3 and 4, was made using SwissPDB viewer (version 3.7) (Guex 




Analogues of phenyl 6 were examined to improve upon the surprisingly poor 
enzyme inhibition observed (Table 5-2). Pyridyl derivatives 14–16 and simple phenyl 
analogues 20–23 were also poor InhA inhibitors. Although the crystal structures for 
InhA bound with 5-phenyl or 5-pyridyl triclosan analogues have not been obtained to 




structure of InhA:triclosan. A directly attached aryl group at the 5-position appeared to 
be too close to the side chain of Phe 149 (shortest distance was ~ 1.4 Å between the aryl 
substituent and the phenyl group of Phe 149), leading to steric clashes. The hydrophobic 
pocket of interest was separated from the 5-position by a distance of 2.5 Å. 
Therefore, to reorient and better position the hydrophobic aryl group into the 
target pocket, a linker varying from 1–3 carbons was incorporated between the aryl 
substituent and the 5-position carbon on the A-ring (Table 5-2). Consistent with the 
molecular modeling results, an evaluation of 5-position substituents of the type 
(CH2)nAr demonstrated that carbon linkers significantly increased the inhibitory potency 
versus purified enzyme. Among them, compound 25 had the highest potency (IC50 =21 
nM), representing a 50-fold increase compared to triclosan. It is the most potent 
triclosan derivative against purified InhA we have studied to date. Compounds 24 and 
26, with similar activities against InhA (24, IC50 =51 nM; 26, 50 nM), were also active 
inhibitors. The crystal structures of InhA bound with 24 and 25 showed that the 
(CH2)nAr group extended into the pocket and formed hydrophobic interactions with 
residues Leu218, Ile 215, Phe149, Met199, and Pro 193 (Figure 5-3). The triclosan 
backbone atoms of compounds 24 and 25 were in nearly identical positions, but their 5-
substituents were clearly different. The phenyl group of derivative 24 was positioned in 
the center of the binding pocket, while the phenyl group of derivative 25 protruded ~2 Å 
deeper into, and was closer to the end of, the binding pocket due to the longer carbon 
linker. Thus, compound 25 additionally engaged Trp222 in a hydrophobic interaction. 




accommodate the phenyl ring of compound 25, which also flipped ~70° from the 
position of the phenyl group of compound 24. All of these conformational changes 
suggest that there were more hydrophobic interactions between the active site residues 
and the 5-substituent of compound 25 than that of compound 24, which may explain 
why compound 25 was twice as potent than compound 24 against InhA. 
To further increase the potency of the 5-(CH2)nAr series through potential 
mimicry of the INH–NAD isonicotinoyl moiety, derivatives with 5-CH2(n-pyridyl) (n 
=2, 3, and 4) substituents (compounds 17–19) were examined for in vitro activity. In the 
crystal structure of InhA:INH–NAD (Rozwarski et al., 1998), the pyridyl group of the 
INH–NAD adduct formed a hydrogen-bonding interaction with a buried water molecule. 
Without a carbon linker, the 5-pyridyl triclosan derivatives 14–16 showed very low 
activity against InhA (IC50 >10 μM), presumably due to a steric clash with Phe 149. In 
contrast, with a one-carbon linker, pyridyl analogues 17–19 were all potent inhibitors 
(IC50 < 80 nM), and their IC50 values were in the order 17 <18 <19. Compared to benzyl 
derivative 24, the activity of 17 increased approximately twofold while the activity of 
compound 18 increased only slightly, and compound 19 was slightly less potent. The 
structure of InhA:NAD
+
:17 demonstrated that the pyridyl ring of derivative 17 extended 
into the substrate-binding site to form hydrophobic interactions with the side chains of 
Tyr 158 and Phe 149 (Figure 5-4). These interactions are similar to those of the phenyl 
group in InhA:NAD
+
:24. However, the nitrogen atom on the 2-position of the pyridyl 
ring also formed a hydrogen-bonding interaction with the side chain carboxylate of Glu 





Figure 5-3. The superposition of crystal structures of InhA (ribbons and tubes, key 
residues in stick format) in complex with triclosan (carbon atoms in gray), 
compound 24 (purple), and compound 25 (gold) in the presence of NAD
+
 (cyan). 
The 5-phenyl groups of compounds 24 and 25 are shown making van der Waals 
contacts with the side chains of Tyr 158, Pro 193, Leu 218, Ile 215, and Phe 149. The 
movements of Ile 215 and Leu 218 in response to the triclosan 5-substituent are 
depicted by showing this residue in stick format with the coloring of the respective 




also exist for 18, but were not likely for 19, based on the distance between the pyridyl 
nitrogen atom and the side chain oxygen of Glu 219. The nitrogen atom of 19 potentially 
pointed to the hydrophobic side chains of residues Met 155 and Leu 218, which may not 








:triclosan (Kuo et al., 2003), demonstrated movement of both Glu 219 and 
Leu 218 to accommodate the 5-pyridylmethyl moiety. 
A comparison of the X-ray crystal structures of bound compounds 7, 17, 24, and 
25 with that of INH–NAD (PDB code 1ZID) is instructive. At the outset, our goal was to 
reach from the 5-position of triclosan into the isonicotinoyl-binding pocket. The Phe 149 
side chains from the four triclosan analogue structures overlapped well with each other, 
but not that of 1ZID. In 1ZID, the isonicotinoyl group of INH was stabilized by the 
rotation of Phe 149. The various triclosan 5-substituents, however, did not occupy the 
same volume as the isonicotinoyl group, orienting similarly to the C16 chain of the 
structurally characterized substrate analogue (Rozwarski et al., 1999) and the appended 
alkyl substituent in the structures reported by Sullivan et al. (Sullivan et al., 2006), and 
thus did not perturb Phe 149. In the 1ZID structure, the movement of Phe 149 evidently 
displaced Tyr 158. While this motion was tolerated in 1ZID, in the triclosan structures, 
the phenol moiety is positioned through an interaction with the hydroxyl of Tyr 158. 
Loss of the triclosan phenol–Tyr 158 interaction would most likely result in complete 
loss of inhibitor binding, supported by the observed weak inhibitory activity of des-
phenol triclosan analogues against InhA. Thus, while the triclosan analogues can attempt 
to place substituents proximal to the INH binding pocket, they cannot occupy the exact 
volume of the isonicotinoyl moiety, as this would ultimately require the movement of 





Figure  5-4. The superposition of crystal structures of InhA (ribbons and tubes, key 
residues in stick format) in complex with triclosan (purple) and compound 17 
(carbon atoms in gray) in the presence of NAD
+
 (cyan). The nitrogen atom on the 
pyridyl ring formed a hydrogen-bonding interaction with the side chain of Glu 219 
through a water molecule. The side chain of Glu 219 rotated 90° from its original 
position (purple) to form this hydrogen-bonding interaction. It should be noted that Phe 




The activities of three 5-alkyl (7, 10, and 11) and three 5-aryl triclosan 
derivatives (24, 25, and 26) against six different M. tuberculosis strains were assayed 
(Table 5-3). Among these strains, H37Rv is the M. tuberculosis wild-type, sensitive to 
isoniazid. The InhA(S94A) strain, carrying the inhA(S94A) allele, has been demonstrated 
to confer resistance to isoniazid through the weakening of co-factor binding (Vilcheze et 




inhA expression region mutation (C-15T) (Vilcheze et al., 2006). It has been shown that 
the C-15T inhA promoter mutation mediates enhanced transcription of inhA, resulting in 
INH and ETH resistance. The ∆katG mutant features the complete deletion of the katG 
gene and, thus, INH activation cannot take place. Most significantly, strains 12081 and 
5071 are multidrug resistant clinical isolates from Mexico that are INH resistant without 
known mutations in katG, inhA, ndh, and ahpC. The 12081 (SCG V) strain was, in our 
hands, resistant to INH, streptomycin, and rifampicin, while 5071 (SCG 3b) was 
resistant to only INH and streptomycin. 
The selected six compounds with high potency against InhA in vitro (IC50 ≤ 110 
nM) all demonstrated good antitubercular activity against the wild-type H37Rv strain, 
exhibiting improvements over the whole-cell efficacy of triclosan. Clearly, the 5-chloro 
group of triclosan is not optimal and the use of larger and more hydrophobic moieties is 
advantageous both in terms of InhA inhibition and whole-cell potency. The most active 
compound, 26 (MIC =13 μM), was superior to that of ETH (MIC =18 μM) (Vilcheze et 
al., 2006), while being greater than tenfold more potent than triclosan. The activities of 
these compounds against purified InhA and cultured tuberculosis strains generally 
correlated well. For example, compound 10, which had two-fold higher activity against 
InhA than compound 11, also exhibited twofold better antitubercular activity. This 
supports a hypothesis that the straight chain 5-alkyl substituent has an advantage over 
the analogous branched derivative. In addition, compound 26, which displayed the 
highest antitubercular activity in the series, also had the second highest potency against 




Table 5-3. Minimum Inhibitory Concentration (MIC) values of triclosan 













































7 9.4 (27) 37 (110) 37 (110) 19 (55) 37 (110) 4.7 (13) 
10 9.4 (30) 37 (120) 37 (120) 19 (60) 37 (120) 4.7 (15) 
11 19 (60) 37 (120) 37 (120) 37 (120) 75 (240) 19 (60) 
24 9.4 (27) 75 (220) 37 (110) 19 (55) 75 (220) 9.4 (27) 
25 19 (52) 75 (210) 75 (210) 37 (110) 75 (210) 19 (52) 
26 4.7 (13) 19 (50) 19 (50) 9.4 (26) 37 (100) 4.7 (13) 
INH 0.060 
(0.44) 
0.50 (3.6) 0.80 (5.8) >200 
(>1400) 
1.0 (7.3) 8.0 (56) 




potency among the (CH2)nAr series and yet the worst antitubercular activity. As may be 
expected, a number of factors other than in vitro efficacy against purified InhA, 
including pharmacokinetic parameters, contribute to the whole-cell inhibition of 
mycobacterial growth. 
It is interesting to compare the H37Rv data for 5-n-butyltri-closan (10) and the  
corresponding des-chloro analogue of Sullivan and co-workers. While compound 10 




=80 nM) (Sullivan et al., 2006), the des-chloro compound (MIC =10.8 μM) was more 
efficacious against H37Rv compared with compound 10 (MIC =30 μM). It should be 
noted that the most potent triclosan analogue reported to date is the n-octyl analogue 
reported by Sullivan et al. (InhA, IC50 =5.0 nM; H37Rv, MIC =6.5 μM) (Sullivan et al., 
2006). 
Triclosan has previously been reported to display promising activity against both 
INH sensitive and resistant M. tuberculosis strains (Kuo et al., 2003; Sullivan et al., 
2006). We next examined five strains against which the triclosan family of compounds 
had not been tested. Compared to their efficacy against the wild-type strain, five of the 
six analogues examined showed 4–8-fold lower activity against the InhA(S94A) and 
InhA(C-15T) strains. This was slightly lower, yet still comparable in magnitude, to the 
8- and 13-fold losses in potency for INH against these two strains, respectively. The 
InhA(C-15T) strain has a higher expression of InhA, which leads to resistance to 
compounds that target the protein. The resistance to triclosan by InhA(S94A) strains of 
either M. tuberculosis or other bacteria has not been previously reported to the best of 
our knowledge. Mutation of the G93V in FabI, a residue conserved in InhA, has 
previously been found to confer E. coli resistance to triclosan (McMurry et al., 1998). 
The inhA(S94A) mutation has been demonstrated to decrease the efficacy of INH by 
weakening the binding of INH–NAD (Vilcheze et al., 2006). Comparatively, the binding 
of triclosan and its analogues to InhA depends greatly on the interaction between the 
diaryl ether scaffold and NAD
+
. Quemard and co-workers reported that the S94A 




proposed that the same mutation may decrease the stability of the InhA: NAD
+
:triclosan 
derivative complex and, thereby, diminish inhibition. The resistance of the InhA(S94A) 
and InhA(C-15T) strains to triclosan derivatives is supportive of our proposal that the 
target of these triclosan relatives is indeed InhA. 
The activity of the triclosan analogue subset against the ∆katG mutant further 
substantiates the potential advantage of these InhA inhibitors over INH. While INH was 
more than 3000-times less active against the ∆katG mutant, the triclosan analogues were 
only twofold less active, as measured by their MIC values. This is consistent with our 
genetic, enzymatic, and X-ray crystallographic data that demonstrate InhA inhibition by 
the triclosan family without the need for activation. It, therefore, follows that one would 
expect a lack of cross-resistance with many INH-resistant M. tuberculosis strains, where 
the katG mutations represent the dominant allele conferring resistance. Sullivan and 
colleagues have also demonstrated their phenol diaryl ethers to not suffer significant 
losses in potency against clinical isolates with varying degrees of INH resistance 
(Sullivan et al., 2006). 
The two clinical strains shown in Table 5-3 were much more sensitive to the 
triclosan analogues compared with INH. Strain 12081 afforded 17-fold resistance to 
INH, which was reduced to a 4–8 factor resistance against the triclosan subset. Against 
clinical isolate 5071, the triclosan subset maintained or improved (in two cases by 
twofold) their respective wild-type potencies. These results should be contrasted to the 
greater than two orders of magnitude resistance conferred against INH. Thus, triclosan 







The efficacy of these 5-substituted triclosan analogues has been shown to be 
tunable through a structure-based optimization of the 5-position. Novel analogues 
afforded a 50-fold increase in InhA inhibition and tenfold in bacteriocidal activity. Most 
significantly, these triclosan derivatives demonstrated efficacy against INH-resistant 
laboratory and clinical strains of M. tuberculosis. Further studies of triclosan and other 
small-molecule inhibitors of InhA hold significant promise for the delivery of novel 
antitubercular agents that are effective against drug-resistant M. tuberculosis. Current 
efforts are underway to examine the physiochemical properties of our most promising 
analogues. Substitution of the phenol will be investigated to avoid potential liabilities 
due to rapid Phase II metabolism (Wang et al., 2004), preceding clearance. In addition, 
other modifications to the A-and/or B-rings of the diaryl ether scaffold can be envisioned 
that would potentially increase the stability of these derivatives to oxidative metabolism, 




Triclosan analogue synthesis 
The small molecules tested against InhA and the mycobacterial strains were 





Cloning, expression, and purification for Mycobacterium tuberculosis inhA 
M. tuberculosis inhA was cloned into E. coli BL21 (DE3) as described previously 
(Dessen et al., 1995). The transformed E. coli were cultured in Terrific Broth media with 
50 μg mL
-1
  carbenicillin at 37 °C until an OD600 of 0.8 was observed. inhA expression 
was induced for 20 h at 16 °C through addition of 1 mM isopropyl β-D-
thiogalactopyranoside. The resulting cells harvested through centrifugation were re-
suspended in 50 mM PIPES (pH 6.8) and 1 mM phenylmethylsulfonyl fluoride and 
lysed via French press. Exposure to DNAse I was followed by removal of insoluble 
material through centrifugation. The supernatant was subjected to a HiTrap Blue 
Sepharose column (AP Biotech), pre-equilibrated with the same buffer, using a fast 
protein liquid chromatography system and eluted through a NaCl gradient (0–2 M). 
Elution with 0.9 M NaCl solution afforded fractions containing InhA that were 
subsequently subjected to an octyl-sepharose column (AP Biotech), pre-equilibrated 
with 1 M NaCl, and eluted through a NaCl gradient (1–0 M). Pooling of InhA fractions 
and gel filtration through a Superdex 200 column were carried out to separate 
monomeric protein from aggregated material. SDS-PAGE and Coomassie Blue staining 
were consistent with homogeneous InhA, yielding 40 mg L
-1
 from E. coli culture. 
 
InhA enzyme assay 
Experiments were carried out utilizing a Cary100 Bio spectrophotometer at 25 
°C, through monitoring the oxidation of NADH to NAD
+




initiated via addition of dodecenoyl-CoA (50 μM) substrate to mixtures containing InhA 
(5 nM), NADH (100 μM), and inhibitor (1–10000 nM). The IC50 values were determined 




The relevant M. tuberculosis strains were obtained from laboratory stocks and 
grown in Middlebrook 7H9 medium (Difco), supplemented with 10 % (v/v) OADC 
enrichment (Difco), 0.2% (v/v) glycerol, and 0.05 % (v/v) tyloxapol to an OD600 of ~ 
1.0. The cultures were diluted 4 logs and 0.1 mL of the resulting dilutions were 
inoculated into 2 mL of Middlebrook 7H9 media with varying concentrations of 
inhibitor. The cultures were incubated with shaking at 37 °C for four weeks. The MIC 
was defined as the concentration of inhibitor that prevented visible mycobacterial 
growth. 
 
Crystallization of InhA with selected inhibitors 
The hanging drop vapor diffusion method was utilized. Typically, InhA was 
incubated with an inhibitor and NAD
+
 in the molar ratio of 1:2:100 for 2 h. Co-
crystallization was then attempted in hanging droplets consisting of 2 μL of 10 mg mL
-1
 
protein solution and 2 μL of buffer (20% PEG 3350, 6% DMSO, 0.1 M N-(2-
acetamido)iminodiacetic acid pH 6.8, 0.08 M NH4OAc) at 16°C in Linbro plates against 




Data collection and processing 
Data were collected at 121 K utilizing cryo-protection solution with reservoir 
solution and an added 30% ethylene glycol. A crystal of InhA:17 diffracted X-rays to 
1.98 Å at beam line 23ID at the Advanced Photo Source (APS), Argonne National 
Laboratory.  Crystals of InhA:24, InhA:25 and InhA:7 diffracted X-rays to 2.30 Å, 2.80 
Å and 1.98 Å, respectively, using a Rigaku Raxis detector coupled to an X-ray generator 
with a copper rotating anode (CuKα, λ=1.54 Å). Diffraction data was obtained from a 
single crystal with 0.5° degree oscillation widths for a range of 180°. The data were 
integrated and reduced using HKL2000 (Table 5-4)  (Otwinowski and Minor, 1997).  
 
Structure determination and model refinement 
Initial phases of the InhA:inhibitor complexes were obtained through molecular 
replacement utilizing the apo-InhA structure (PDB code: 1ENY) and refined with CCP4 
(Collaborative Computational Project, 1994) (Table 5-4). Electron density maps were 
calculated and additional density was found, consistent with the respective inhibitor. The 
inhibitor was fit into the additional density and the whole model was rebuilt utilizing 
XtalView (McRee, 1999). In the final refinement cycles, water molecules were added 
into peaks above 3-σ of the Fo–Fc electron density maps, such that the water molecules 
were within hydrogen-bonding distance from the appropriate protein atoms. Final 








Table 5-4. Data collection and refinement statistics for reported X-ray structures.
[a] 
 
 InhA: 7 InhA: 17 InhA: 24 InhA: 25 
Maximum resolution [Å] 1.97 1.98 2.30 2.80 
Space group I4(1)22 C2 C2 I4(1)22 
a [Å] 90.0 125.6 125.6 90.0 
b [Å] 90.0 92.3 92.4 90.0 
c [Å] 183.9 103.0 102.4 183.1 
α [°] 90.0 90.0 90.0 90.0 
β [°] 90.0 106.4 106.5 90.0 
γ [°] 90.0 90.0 90.0 90.0 
Unique reflections
[b]








Rsym [%] 6.0 (74.3) 9.9 (70.5) 10.3 (88.3) 12.8 (82.3) 
Completeness [%] 99.8 (100) 87.3 (65.5) 99.1 (98.5) 99.8 (100) 
Redundancy 10.2 (10.0) 3.7 (2.1) 5.3 (4.9) 8.5 (8.6) 
I/σ 42.5 (4.3) 15.7 (1.3) 28.6 (3.3) 22.3 (3.7) 
Resolution range [Å] 19.92- 1.97 19.96–1.98 19.85–2.30 19.85–2.8 
# reflections 25 755 68885 46 976 9157 
# atoms per subunit     
Protein 1994 7826 7739 1994 
Cofactor (NAD) 52 176 176 52 
Ligand 22 88 88 23 
Solvent 168 703 253 11 
Rcryst [%] 20.7 20.0 20 22.1 
Rfree [%] 25.2 25.3 26 26.8 
Average B-factors [Å2] 35.0 1.98 40.2 54.8 
[a] PDB accession code are 3FNG (7), 3FNE (17), 3FNF (24), and 3FNH (25). [b] The value of 






Additional unpublished results 
 
Activity of JPC2278 against InhA 
The 5-p-methylphenyl substituted triclosan derivative, named as JPC2278 
(Figure 5-5A), which was not tested initially together with the other analogs, was also 
tested for in vitro inhibition against InhA. The compound showed surprisingly good 
activity against InhA with an IC50 of 77.6 ± 2.8 nM (Figure 5-5B). This result was 
unexpected, because the other close derivatives of JPC2278 with a 5-phenyl (Table 5-1, 
compound 6), a 5-o-methylphenyl (Table 5-2, compound 20), a 5-m-methylphenyl 
(Table 5-2, compound 22), and a 5-p-fluorophenyl (Table 5-2, compound 23) group did 
not display any inhibitory activity (IC50 > 10 μM) for InhA (Figure 5-5C).    
In order to understand the structural basis of the activity difference between these 
analogs, JPC2278 was manually modeled into the InhA active site. The A-rings of the 
JPC2278 and compound 25 (the 5-ethylbenzene derivative, Table 5-2) from the InhA:25 
complex structure were superimposed to position JPC2278 into the binding site (Figure 
5-6). While the initial docking experiments with compounds 6 and 15 suggested that 
directly attached aryl group at the 5 position will lead to steric clashes with Phe149 (see 
Results and Discussion for details), it was seen from the JPC2278:InhA model that the 
methylphenyl group lay in close proximity (<3.0 Å) to the side chains of Phe149 and 
Pro193 to make favorable hydrophobic and van der Waals interactions. In addition, a π-






Figure 5-5. Chemical structure and inhibition activity of JPC2278 for InhA. A) 
Chemical structure of JPC2278. B) Inhibition activity of JPC2278 against InhA. C) 




It is likely that the potent activity of JPC2278 compared with its structural 
analogs, was due to the p-methyl substituent. Based on the model, in the absence of the 
p-methyl substituent, the hydrophobic and van der Waals interactions between the -CH3 
group and Phe149 and Pro193 would be lost. This can explain why the 5-p-
methylphenyl had better potency than the 5-phenyl derivative. A methyl substituent at 
the -meta or -ortho positions may position too close to Phe149 and cause steric clashes. 




   
 
Figure 5-6. Docking of JPC2278 to the InhA active site. JPC2278 (salmon color) is 
superposed manually with the A-ring of compound 25 (blue color) from the crystal 
structure of InhA: 25. Based on this model, the methylbenzene substituent lies in close 
proximity to the side chains of F149 and P193 (< 3.0 Å) and makes favorable 




vity. This could be due to the high negative charge density and low polarizability 
character of the fluorine atom. The affinity loss might result from the close 
electrostatically repulsive contacts between the organic fluorine, with its high negative 
charge density, and the negatively polarized π-clouds of the Phe149 side chain. A similar 
phenomenon was also observed with neprylisin, a mammalian Zn
II
-dependent 




pocket caused a decrease in affinity. This was explained by the electrostatically 
unfavorable close contacts of organic fluorine with the negatively polarized π-surfaces of 
the surrounding aromatic amino acid side chains (Morgenthalera et al., 2008). In 
contrast, fluorination of the benzimidazole moiety of the neprylisin inhibitor, which was 
surrounded by three Arg side chains, led to an increase in the binding affinity. Thus, the 
authors partitioned the active site of neprylisin to fluorophilic and fluorophobic regions  
(Morgenthalera et al., 2008). Similarly, the two chlorine substituents on the B ring of 
triclosan can make favorable interactions with the surrounding residues, whereas the –F 
of JPC2278 cannot. Organic fluorine prefers dipolar interactions and orientating into the 
electropositive protein environments (Bissantz et al., 2010; Morgenthalera et al., 2008). 
This might explain why a hydrophobic –CH3 group was more potent than the –F 
substituent for the JPC2278 analogs.   
 
Challenges in obtaining the InhA-ligand complex crystals 
Two methods are usually followed to obtain protein-ligand crystals: co-
crystallization and soaking. Soaking of the native crystals with the ligand compound 
solution is usually preferred over co-crystallization, because it’s rapid, easy to optimize, 
and there is no need to search for new crystallization conditions. In contrast, co-
crystallization requires the incubation of the ligand with protein prior to crystallization 
and often results that the crystallization conditions for the native protein do not yield 
protein-ligand complex crystals. This brings the requirement of searching for new 




 For InhA, the native crystals can be obtained fairly easily in a week using the 
published crystallization condition of 12% methylpentanediol (MPD), 4% 
dimethylsulfoxide (DMSO), 100 mM Hepes at pH 7.5, and 50 mM sodium citrate at pH 
6.5 (Rozwarski et al., 1998). However, these crystals are very sensitive to soaking with 
compounds dissolved in DMSO, acetonitrile, ethanol or methanol. The crystals cannot 
tolerate >2% of any organic solvent that is required to keep the compounds in solution. 
Even short periods (<30 minutes) of soaking irreversibly damages the crystals causing 
cracks or dissolving of the crystal, which often results in the loss of diffraction. 
Furthermore, dissolving the compounds in an aqueous crystallization solution or adding 
the compound powder to the crystal drop is also not feasible as most of the compounds 
are hydrophobic and have very poor solubility in aqueous solutions. Even though native 
InhA crystals can be obtained in some other unpublished crystallization conditions, none 
of those produce high diffraction quality crystals that can be further used for soaking. 
Out of the all InhA: inhibitor complex crystal structures described in this dissertation (12 
structures in total), only two complex crystals were obtained through soaking. The 
majority of the complex crystals were obtained by co-crystallization.  
For co-crystallization experiments multiple approaches were followed. Since 
both GSK inhibitors and triclosan derivatives were uncompetitive inhibitors, all of the 
co-crystallization experiments were performed in the presence of NAD
+
. It was observed 
that at least 10 fold molar excess of NAD
+
 was needed for successful crystallization. All 
of the inhibitor compounds were dissolved in 100% DMSO and 10-100 mM stock solutions 




two to five fold; however, a key factor to consider was the final concentration of DMSO, 
because InhA protein cannot tolerate more than 4% of DMSO in solution. It was also 
observed that in some cases, instead of mixing the concentrated protein solution (10 
mg/ml) with the inhibitor compound, mixing a more diluted (1 mg/ml) protein solution 
with the compound and then co-concentration helped successful protein-inhibitor 
complex formation. It also prevented protein precipitation by lowering the local DMSO 
concentration. Once the protein was incubated with NAD
+
 and the inhibitor compound 
for approximately 20 minutes at room temperature, crystallization plates were set with: i) 
the published native crystallization condition, ii) the sparse-matrix crystallization screens 
(~900 crystallization conditions). Among the ten co-crystal structures mentioned in this 
dissertation, only two of them were obtained in the native crystallization conditions and 
the other eight required for screening of new crystallization conditions. All of the 
triclosan derivatives were also co-crystallized in a previously unpublished crystallization 
condition.    
To sum up, obtaining InhA-ligand crystals was not feasible by soaking. Co-
crystallization and searching of new crystallization conditions were necessary. Finding 
the right crystal, which diffracted to high resolution and contained the ligand, required a 
lot of screening and collection of many data sets.  
 
Summary  
Triclosan is composed of two phenyl rings (ring A and B) linked with an oxygen 




ring are important for the potency of the compound. In the InhA:NAD
+
: triclosan crystal 
structure, the 5-chlorine of the A ring was positioned at the entrance of the  INH-NAD 
adduct binding pocket (2 Å distance) (Kuo et al., 2003). In this study, the 5-Cl position 
of the A ring was modified with different substituents of hydrophobic and hydrophilic 
character in order to occupy the INH-NAD adduct binding pocket (Figure 5-2). The 
derivatives were first investigated by enzymatic assays and the compounds showing 
good enzyme inhibition were used for the crystallographic studies.  
It was found by enzymatic assays that compounds with hydrophobic substituents 
at the 5-position such as alkyl groups showed better inhibition than the compounds with 
hydrophilic substituents like carboxylate groups (Tables 5-1 and 5-2). The potency of 
the hydrophobic group substituted compounds increased with the chain length of the 
alkyl substituents up to four carbon chains. A similar trend was also observed by 
Sullivan et. al. with an optimum chain length of eight carbons for the des-chloro 
triclosan derivatives. The most potent derivatives were the compounds 17 and 25 with 2-
pyridyl-methyl and benzylmethyl substituents (Table 5-2). 
The comparison of the InhA:triclosan derivative structures with the InhA:INH-
NAD(H) adduct and the InhA:C16 fatty acyl substrate analog structures revealed that the 
hydrophobic moieties attached to the 5-position of the A ring did not perturb the side 
chain of Phe149, and thus, they did not occupy the same pocket as the INH-NAD(H) 
adduct (Figure 5-7). Instead, these substituents were positioned similar to the substrate 
analog. In the InhA:INH-NAD structure, flipping of the Phe149 side chain was 




(Figure 5-7B). However, in the InhA:triclosan derivative structures, Tyr158 was a key 
residue for inhibitor binding due to the direct H-bonding interaction with the hydroxyl of 
the A ring. Importantly, loss of this interaction resulted in loss of potency. The 5-
substituted triclosan analogs were positioned proximal to the isonicotinoyl binding 
pocket but they were not able to access to this site as this would require the movement of 
Phe149 and Tyr158 simultaneously, which in turn would cause the loss of the direct H-
bonding interaction between the compound and Tyr158. Even though the 5-substituted 
derivatives could not reach INH-NAD binding pocket, these derivatizations clearly 
increased the inhibitor potency by 10 to 50 fold compared with the parent compound 
triclosan. Notably, the 5-substituted derivatives were activation free inhibitors and found 
to be effective against the isoniazid resistant strains. For instance, derivative #7 
displayed an MIC of 19 μg ml
-1
 against the Mtb H37Rv ΔkatG strain compared to INH 
having an MIC of >200 μg ml
-1










Figure 5-7. Comparison of the InhA:triclosan derivative structures with the InhA: 
INH-NAD(H) adduct and the InhA:C16 fatty acyl substrate analog structures. A) A 
cross-section through the surface of the active site of InhA. Four InhA:triclosan analog 
structures (light blue) were superposed with the InhA:C16 fatty acyl substrate analog 
structure. NAD
+
 and the C16-fatty acyl substrate analog are shown in blue and orange 
sticks, respectively. As seen from the figure, triclosan analogs occupied the substrate 
binding pocket. B) Comparison of the conformation of Tyr158 and Phe149 in the InhA: 
triclosan analogs structures (light blue) with the InhA:INH-NAD structure (orange) 
(PDB ID:1ZID). The INH-NAD adduct causes rotation of the Phe149 side chain ~90°, 
which in turn moves Tyr158 away from NAD(H). In contrast, none of the triclosan 
analogs perturbed the side chain of Phe149, and the A ring hydroxyl H-bonded with the 
side chain of Tyr158 (2.3 Å). For both panels atom coloring is: oxygen red; nitrogen 

























CarD from Mycobacterium tuberculosis (Mtb) is an essential protein shown to be 
involved in stringent response through downregulation of rRNA and ribosomal protein 
genes. CarD interacts with the β-subunit of RNAP and this interaction is vital for Mtb’s 
survival during the persistent infection state. We have determined the crystal structure of 
CarD in complex with the RNAP β-subunit β1 and β2 domains at 2.1 Å resolution. The 
structure reveals the molecular basis of CarD/RNAP interaction, providing a basis to 
further our understanding of RNAP regulation by CarD. The structural fold of the CarD 
N-terminal domain is conserved in RNAP interacting proteins such as TRCF-RID and 
CdnL, and displays similar interactions to the predicted homology model based on the 
TRCF/RNAP β1 structure. Interestingly, the structure of the C-terminal domain, which 
is required for complete CarD function in vivo, represents a distinct DNA-binding fold. 
                                                 

Reprinted with permission from “Structure of the Mtb CarD/RNAP β-Lobes complex reveals the 
molecular basis of interaction and presents a distinct DNA-Binding domain for Mtb CarD” by Gulten G. 







Tuberculosis (TB) is a global health threat responsible for approximately two 
million deaths annually (WHO, 2013). The treatment for the primary causative agent of 
TB, Mycobacterium tuberculosis (Mtb), is challenging due to the emergence of 
multidrug (MDR-TB) and extensively drug-resistant (XDR-TB) strains. Because most of 
the antibiotics currently used for Mtb therapy are potent only against replicating bacteria, 
mycobacteria are able to survive in the host in a nonreplicating, persistent, or chronic 
state. Identifying new drugs that can target Mtb during the persistent stages of infection 
is very important (Gupta et al., 2009; Raman et al., 2008; Sacchettini et al., 2008). 
In Mtb, the gene product of Rv3583c, annotated CarD, is required for persistence, 
and has been identified as an essential protein in vitro and in vivo during normal growth 
conditions as well as under genotoxic stress and nutrient deprivation (Stallings et al., 
2009). Microarray studies have shown that not only is Rv3583c upregulated in response 
to oxidative stress, DNA damage, and starvation, but also that depletion of Mtb CarD 
results in loss of transcriptional regulation of rRNA and ribosomal components, 
indicating its involvement in stringent response (Stallings et al., 2009). Mtb CarD can be 
used to complement Escherichia coli DksA protein, which regulates stringent response 
alongside the main stringent response element hyperphosphorylated guanine nucleotide 
((p)ppGpp), suggesting that the two proteins are functional homologs. DksA directly 
interacts with the RNA polymerase (RNAP) through the RNAP secondary channel and 
potentiates the effect of (p)ppGpp (Paul et al., 2004b; Srivatsan and Wang, 2008). Mtb 




The first and best studied CarD protein is from Myxococcus xanthus and is a 
transcription regulator involved in carotenogenesis. M. xanthus CarD interacts with 
RNAP, CarG, and the carQRS promoter DNA through its N- and C-terminal domains 
(Nicolas et al., 1996; Penalver-Mellado et al., 2006). Mtb CarD shares only a 30% 
sequence homology with the N terminus of M. xanthus CarD, and the C-terminal domain 
is not similar, suggesting that Mtb CarD does not contain the HMG1-like DNA-binding 
domain (AT hook DNA-binding motif sequence) found in M. xanthus CarD (Figure B-
1). Bacterial two hybrid assays and immunoprecipitation experiments have shown that 
Mtb CarD associates with the RNAP β-subunit (Stallings et al., 2009; Weiss et al., 
2012). All CarD and CarD N-terminal like (CdnL) proteins belong to the transcription-
repair coupling factor (TRCF) family of proteins, and share sequence and structural 
homology with the TRCF RNAP interacting domain (RID). Also, they are thought to 
interact with RNAP in a homologous manner as TRCF. The previously determined 
crystal structure of the Tth TRCF-RID/Taq RNAP β1 complex (Westblade et al., 2010) 
and the homology models generated for CarD-RNAP interaction based on this structure 
(Weiss et al., 2012) predicted a similar set of interactions of CarD with RNAP. 
However, the mechanism CarD uses to regulate RNAP function and transcription, and 
the role of the Mtb CarD C-terminal domain are unknown. The CarD/RNAP interaction 
is crucial for Mtb’s stringent response, viability, and resistance to oxidative stress and 
loss of the CarD/RNAP interaction sensitizes Mtb to the anti-TB drug rifampicin, 
emphasizing the importance of understanding this protein-protein interaction. 




β-subunit lobe domains at 2.1 Å resolution. The CarD/RNAP β structure reveals that the 
RNAP CarD binding site is located on the β-subunit arm of the RNAP claws, 
specifically on the solvent exposed surface of the β1 domain, and is far from the 
catalytic center of the RNAP. The structure not only provides insight into the molecular 
basis of RNAP interaction with Mtb CarD, but also with other CarD family proteins and 
CarD homologs. The structural basis for the RNAP regulation through CarD interaction, 
which is distinct from the DksA regulation mechanism, is presented by comparing the 
uncomplexed Mtb RNAP-β and CarD/RNAP-β complex structures. While the structural 
fold of the CarD N-terminal domain is conserved among other CarD, CdnL, and TRCF-
RID domains, the C-terminal domain structure is not been identified in any other 
structure in the Protein Data Bank (PDB). We show that Mtb CarD is a DNA-binding 
protein with a distinct DNA-binding domain and that it exhibits a nonsequence-specific 
DNA-binding mode. 
 
Results and discussion 
 
Structure determination of Mtb Rpobtr and the CarD/RNAP complex 
E. coli expression plasmids for the full-length Mtb RNAP β-subunit (RpoB) and 
several truncations (based on the secondary structure predictions) were made to test for 
recombinant protein expression. One truncation containing the β-lobes (consisting of 
residues 47–433) of RpoB (referred as RpoBtr) yielded soluble protein and when co-




subsequent crystallographic studies. The β1 (residues 47–172 and 375–428, 
corresponding to the Taq-β residues 1–130 and 334–395 of the TRCF/β1 structure) and 
β2 (residues 177–370) domains contained within this truncation are important for RNAP 
regulation. They form the β-arm of the RNAP claws that cover the DNA/RNA hybrid 
and dsDNA in the transcription complex. Regulation through these domains often occurs 
through interaction with various regulatory proteins such as TRCF and sigma70 
(Vassylyev et al., 2002; Westblade et al., 2010). RpoB does not have any dispensable 
regions, and the archaebacterial split site, which maps around residue 570 of RpoB, is 
not contained within the β-subunit truncation used in this work. Crystals of RpoBtr were 
determined to be in the P212121 space group with two molecules in the ASU. The 
RpoBtr structure was solved by single-wavelength anomalous diffraction using Se-Met 
derived crystals to a resolution of 2.9 Å. Subsequently, the resolution was improved to 
2.5 Å for native (non Se-Met) RpoBtr crystals. The structure was refined to Rwork = 21% 








Table 6-1. Data collection and refinement statistics. 
 Se-Met RpoBtr Native RpoBtr CarD/RpoBtr 
complex 
Data collection    
Space group P212121 P212121 C2221 
Cell dimensions 
a, b, c (Å) 




52.8, 124.1, 135.5 
90,90,90 
 
53.1, 123.9, 135.6 
90,90,90 
 
49.1, 128.9, 225.5 
90,90,90 
Wavelength 0.979 0.979 0.979 
Resolution (Å) 2.8 (2.79) 2.5 (2.45) 2.1 (2.11) 
Completeness (%) 98.5 (90.3) 99.5 (97) 98.1 (92) 
Redundancy 3.1 (3.1) 7.0 (6.3) 4.8 (4.6) 
I/Iσ 13.9 (2.4) 15.1 (1.9) 10.1 (2.0) 
Rsym (%) 5.28 (53.4) 5.45 (65.7) 7.8 (73.14) 
Refinement    
Resolution 48.6-2.79 49-2.45 37.6-2.11 
No. reflections 22552 33551 40747 







































Highest resolution shell values are given in parenthesis. 
 
 
Full-length CarD bound to RpoBtr was crystallized after co-expression and 
purification of the complex. The crystals belonged to the C2221 space group with a 




(hereafter referred to as the CarD/RNAP complex) was determined by molecular 
replacement, using the uncomplexed RpoBtr β1 and β2 domain structures as two 
individual search molecules. After locating RpoBtr using molecular replacement and 
initial refinement, there was clear electron density |Fo|- |Fc| that was unaccounted for 
(Figure B-2A). This extra electron density belonged to the protein, and the entire atomic 
model of CarD was manually built into the difference electron density map. The crystal 
structure of the complex was refined to Rwork = 20% and Rfree = 23% using diffraction 
data to 2.1 Å resolution. 
 
Overall structure of Mtb CarD 
Mtb CarD belongs to the α + β protein class (SCOP) (Murzin et al., 1995). The 
structure is composed of two distinct domains: an all β-stranded N-terminal domain 
(residues 1–49) and an all α-helical C-terminal domain (residues 63–160; Figures 6-1A 
and  6-2A). The N- and C-terminal domains are connected by a six-residue twisted α 
helix (α1) and an eight residue loop. The N-terminal domain has a Tudor-like fold 
(Selenko et al., 2001) consisting of four antiparallel β strands. Residues Thr26, Ile27, 
Lys28, and Gly29, which lie on the β-turn connecting the β2 and β3 strands, were the 






Figure 6-1. Ribbon representation of the Mtb CarD/RNAP β1-β2 domain complex 
structure. RpoBtr is represented by orange ribbons; CarD is represented by blue 
ribbons. A) Overall structure of the complex. β1 and β2 domains of RNAP β-subunit, β4 
strands of each protein, and N and C termini of each chain are labeled. The interdomain 
bridging β sheet of RpoBtr (β7 and β15) is also indicated. B) Zoom of the CarD-RNAP 
interface. Direct and water-mediated H-bonding interactions between side chains and 
backbone-backbone interactions are shown. Hydrogen bonds and nonbonded contacts 
between RpoBtr and CarD are formed by the residues located on the β4 strands of both 
proteins, on the loop connecting α12 and α13 of the RNAP β1 domain, and on the turn 
between the β1 and β2 strands of CarD. H-bonds are represented by dashed lines and 
water molecules are shown in red spheres. For the distances, refer to Table 6-2. See also 
Figure B-2.  
 
 
The structure of the CarD N-terminal domain is conserved among RNAP 
interacting proteins such as TRCF-RID and Thermus thermophilus (Tth) CdnL (CarD N-
terminal like protein involved in cell division). Superposition of the Mtb CarD N-




(Gallego-Garcia et al., 2012) and Tth TRCF-RID structures (PDB ID: 3MLQ) 
(Westblade et al., 2010) gives a root-mean-square deviation (rmsd) of 1.1 Å over the Cα 




Figure 6-2. Ribbon representation of Mtb CarD. A) Superposition of Mtb CarD N-terminal 
domain structure (blue) with the Tth CdnL-NMR structure (yellow) and the Tth TRCF-RID 
structure (cyan). The RNAP-interacting β4 strand is labeled. The rmsd over the Cα backbone is 
1.1 Å. B) Ribbon representation of the CarD C-terminal domain. The helices contain mostly 
hydrophobic amino acids at their helix-helix interfaces, generating a hydrophobic core. The 
remainder of the structure is omitted for clarity.  C) The leucine zipper present between α4 and 
α5 in the C-terminal domain of CarD is formed by residues Leu120, Leu111, Leu128, and 
Leu135, and surrounded by hydrophobic residues Val104, Val108, and Ala131. The rest of the 
structure is omitted for clarity. The leucine zipper lies inside the hydrophobic core of CarD and 
is not involved in dimerization or DNA interaction. In both panels, hydrophobic residues are 











The CarD C-terminal domain is comprised of an α-helical bundle of five α 
helices that contains an unexpected internal leucine zipper between helices α4 and α5 
(Figures 6-2B and 6-2C). Helices α4 and α5 interact only through hydrophobic and van 
der Waals interactions, afforded by the leucine zipper. Helices α2 and α3 are positioned 
parallel to each other, whereas α4, α5, and α6 pack orthogonally to each other. Helices 
α3 and α4 are connected by a γ-turn, while α4-α5 and α5-α6 are connected by β-turns 
(Figure 6-2B). The loop connecting α2 and α3, spanning residues His78 to Asn83, is 
completely disordered in the structure. The helices contain mostly hydrophobic amino 
acids at their helix-helix interfaces, generating a hydrophobic core. There are just two 
polar interactions inside this compact bundle, the hydrogen bonds between Lys95 (α3)-
Glu106 (α4; 2.7 Å) and Arg132 (α5)-Asp155 (α6; 2.9 Å). 
The three-helix bundle of α3, α4, and α5 is involved in DNA binding (see DNA-
binding studies on Mtb CarD section for details). The structure of this three-helix bundle 
is unlike other DNA-binding proteins in the PDB, including all of the other HTH motifs 
and leucine zipper domains. DNA-binding proteins with classical HTH motifs usually 
insert their second (recognition) α helix in the major groove for base-specific DNA 
interaction. Leucine zippers containing DNA-binding proteins usually dimerize through 
the hydrophobic leucine zipper region, while also interacting with the major groove of 
the DNA; however, this is not the case for CarD. The DNA-interacting region of Mtb 
CarD is mapped to the N termini of α3 and α5, the C terminus of α4, and the β-turn 
connecting α4 and α5. The leucine zipper motif of CarD appears to stabilize the 




dimerization or DNA interaction (Figure 6-2C). 
Neither the AT-hook DNA-binding motif of M. xanthus CarD nor any other 
recognizable DNA-binding motif is present in the Mtb CarD protein sequence. Structural 
similarity searches of the CarD C-terminal domain structure, using the PDBeFold, 
VAST, and DALI servers against the PDB and Structural Classification of Proteins 
database, did not identify any significant structural homologs. The structural alignment 
scores were well below the threshold of significance (VAST score < 5.5, VAST -log(p) 
value < 4.0, and Q-score < 0.49) for each alignment program (Gibrat et al., 1996; Holm 
and Rosenstrom, 2010; Krissinel and Henrick, 2004). It has been observed that the 
VAST hits do not share any common functional or structural features with Mtb CarD, 
besides being α-helical proteins. 
 
Overall structure of Mtb RNAP β1-β2 domains 
The RpoBtr structure reported here consists of the β1 and β2 domains of the Mtb 
RNAP β-subunit (corresponding to the protrusion and lobe domains, respectively, of 
eukaryotic RNAP II) that form the RNAP claws, together, with the β’ subunit. RNAP 
interacts with the transcription bubble nontemplate strand, especially with the G+2 base, 
through the β2 domain residues, and these interactions are critical for sequence-specific 
promoter recognition of RNAP along with the transcription bubble formation and 
stability (Zhang et al., 2012a). 
The RpoBtr β1 domain aligns well with the β1 domain from the TRCF/β1 




coli, Tth, and Taq RNAP β-lobe structures gives an rmsd of approximately 10 Å over the 
Cα atoms of the β2 domain (Figures B-3A and B-3B). β-lobes are known to have 
conformational flexibility (Tagami et al., 2010), and the relative conformation adopted 
by the β1 and β2 domains of RpoBtr has not been observed in any other bacterial core or 
holo RNAP structure. The two molecules in the ASU of the uncomplexed RpoBtr 
structure, RpoBtr_A and RpoBtr_B, are also in different conformations. When the β1 
domains of RpoBtr_A and RpoBtr_B are aligned, the rmsd of the Cαs of the β2 domains 
is 5.2 Å (over 191 atom pairs). The conformational difference observed in the β1-β2 
domain-domain orientation can be explained by rotation around the hinge axis centered 
on the two stranded antiparallel β sheet connecting the two domains (Figure B-3C). 
The RNAP β-subunits are structurally highly conserved among different 
kingdoms, even though sequence conservation is low (Lane and Darst, 2010; Severinov 
et al., 1996). As expected, the secondary and the tertiary structure of the Mtb RNAP β1-
β2 domains are almost identical to the E. coli and Tth RNAP β1-β2 domains (Figures B-
3A and B-3B). The β1 domain (residues 47–172 and 375–428) consists of four 
antiparallel β strands flanked by five α helices on one side and one α-helix and a β-
hairpin from the other side (Figure 6-3A). The β2 domain (residues 177–370) is 
composed of four antiparallel β strands flanked by seven α helices. The two domains are 
connected by a two-stranded antiparallel β sheet (the β7 strand and β15 strand), 
positioned like a bridge (Figure 6-3A). In contrast to other bacterial RNAPs, RpoBtr has 






Figure 6-3. Conformational differences in RpoBtr in the uncomplexed and 
complexed forms. A) Ribbon representation of an uncomplexed RpoBtr molecule. The 
secondary structure assignments were done with PDBsum server (Laskowski, 2009). B) 
The conformational differences observed in the β1-β2 domain-domain orientation 
between uncomplexed RpoBtr (green) and RpoBtr complexed with CarD (orange). 
Superposition of the β1 domains yields an rmsd of 2.8 Å over the Cαs of the β2 domains. 
The hinge axis centered on the two-stranded antiparallel β sheet (β7 and β15) bridging 
the two domains is also shown. C) Local conformational changes of the RNAP β1 
domain residues at the CarD/RNAP interface. β1-E404, S143, and E140 change 
conformation to interact with CarD-H13, R47, T45, and Y11. D) Local conformational 
changes of the RNAP β1 domain residues at the β1-β2 domain interface. E396 and R392 
of the β1 domain make additional water-mediated interactions with the β2 domain 
residues P277 and G278 in the CarD/RNAP complex. The CarD residues are shown in 
blue. Coloring of RpoBtr is the same as in (B). Molecular visualization and analysis, 
including rmsd calculations, were performed with the UCSF Chimera package (Pettersen 






Overall structure of the CarD/RNAP-β1-β2 complex 
The CarD binding site of RNAP is located at the solvent exposed surface of the 
β1 domain, which is approximately 70 Å away from the RNAP active site Mg
+2
 (based 
on the Tth EC; PDB ID: 2O5I) (Figure 6-4A). Despite the long distance between the 
binding site and the active site, this domain serves as an interaction module for various 
regulatory proteins, including sigma factors at different stages of transcription, and is 
important for RNAP DNA binding and open complex stability (Trinh et al., 2006; 
Vassylyev et al., 2002). 
At the CarD-RNAP interface, the primary four-stranded β sheet of the CarD N-
terminal domain forms an extended eight-stranded β sheet with the β1 domain of the 
RNAP β-subunit (see Figure B-2 for a stereo image). Specifically, the β4 strand of CarD 
comprising residues Leu44 to Pro49 forms an antiparallel β sheet with the β4 strand 
residues Thr138 to Gln144 of RpoBtr (1:1 heterodimer; Figures 6-1A and  B-2B). This 
results in a mixed β sheet in the 1↑ 2↓ 3↑ 4↓ 4’↑ 3’↓ 2’↑ 1’↓ topology. Surprisingly, 
association of RNAP with CarD results in only a 500 Å
2
 (otherwise solvent exposed) 
buried surface area, which is below average (1,500–2,000 Å
2
) for heteromeric protein-
protein complexes (Kleanthous, 2000). While the buried surface is relatively small, it is 
rich in intermolecular hydrogen bonds. There are eight hydrogen bonds and 69 
nonbonded contacts between RpoBtr and CarD formed by the residues located on the β4 
strands of both proteins, on the loop connecting α12 and α13 of the RNAP β1 domain, 
and on the turn between the β1 and β2 strands of CarD.  Specifically, β1-Ile141 interacts 




four backbone-backbone hydrogen bonds (Figure 6-1B).  Interestingly, the side chain-
specific hydrogen bonding interactions are present only between β1-Lys142:CarD-His14 
(2.9 Å), β1-Glu140:CarD-Tyr11 (2.4 Å), β1-Thr138:CarD-Asn52 (2.8 Å), and β1-





Figure 6-4. Superposition of the Mtb CarD/RNAP complex structure with the 
bacterial elongation and initiation complex structures. The Mtb CarD/RNAP 
complex is colored as previously (RpoBtr is orange and CarD is blue). A) Superposition 
of the Mtb CarD/RNAP complex structure with the Tth RNAP EC structure (PDB ID: 
2O5I). Tth RNAP is gray, the DNA duplex and DNA-RNA hybrid are dark blue, and the 
active site Mg
+2
 is shown as a magenta sphere. The molecular surface of the α and β’ 
subunits is shown in gray, where the β1-β2 domains of the Tth RNAP are represented as 
ribbons under a transparent yellow surface. CarD binds to the solvent exposed surface of 
the β1 domain, ~70 Å away from the catalytic center. B) Superposition of the Mtb 
CarD/RNAP complex structure with the Taq RNAP IC structure (PDB ID: 1L9Z). The 
molecular surface of the Taq RNAP is gray except for the β1-β2 domains, which are 
represented as a transparent yellow surface. The DNA duplex is colored dark blue. The 
flexible α1 and eight-residue loop of CarD are cyan. CarD’s DNA interacting patches as 
determined by EMSA are green. The direction of transcription is also indicated. The 
CarD C-terminal DNA interaction domain lies in proximity to the downstream end of the 




The intermolecular interface is also stabilized by electrostatic, hydrophobic, and 
van der Waals interactions (Figure B-2). In fact, electrostatic forces contribute 
significantly to the CarD/RNAP interaction because altering the local charge distribution 
at the interface was reported to abolish CarD/RNAP interaction completely (Weiss et al., 
2012). A more detailed analysis of the intermolecular contacts is provided in Table 6-2. 
In contrast to the structural model generated by homology modeling (based on 
Tth TRCF-RID/β1 structure), mutagenesis and two-hybrid assays (Weiss et al., 2012), 
which suggested that β1-Glu132 interacts with both Arg25 and Arg47 directly through 
hydrogen bonding and that these residues are critical for intermolecular interaction, we 
observed from the Mtb CarD/RNAP structure that β1-Glu132 is not in direct contact 
with CarD-Arg25 and CarD-Arg47 (5.0 Å and 6.1 Å, respectively). Arg25 interacts with 
β1-Ile141 only through van der Waals interactions and does not appear crucial for 
CarD/RNAP interaction. Similarly, Glu132 and Arg47 interact only through a water 
molecule in the CarD/RNAP crystal structure, and Arg47 is engaged in other hydrogen 
bonding and van der Waals interactions with β1-Ile141, β1-Glu140, and β1-Gly139 
(Table 6-2). Therefore, loss of the CarD/RNAP interaction, as suggested by two-hybrid 
assays, upon E132R, R25E, and R47E mutations, should be due to these factors rather 






Table 6-2. Details of the intermolecular interactions between Mtb β1 domain 
residues and Mtb CarD. See also Figure B-4.    
 
RNAP β1 CarD Distance 
(Å) 
Interaction type 





van der Waals 
van der Waals 
    
Gly139 Pro49 3.5 van der Waals 
 Arg47 3.5 van der Waals 
    
Glu140 Arg47 3.4 van der Waals 
 Val48 3.8 van der Waals 
 Tyr11 2.4 H-bond and van der Waals 
 Val56 3.6 van der Waals 
    
Ile141 Arg47 2.8 H-bond and van der Waals 
 Thr45 3.4 van der Waals 
 Val46 3.2 van der Waals, hydrophobic 
 Arg25 3.9 van der Waals 
    
Lys142 Thr45 3.3 van der Waals 
 His14 2.9 H-bond and van der Waals 
    
Ser143 Thr45 2.8 H-bond and van der Waals 
 Leu44 3.6 van der Waals 
    
Gln144 Leu44 3.8 van der Waals 
 Asp43 3.8 van der Waals 
 Gly42 3.0 H-bond and  van der Waals 
    
Glu404 His14 3.8 van der Waals 
 His13 3.4 van der Waals 
    
Ala405 His13 3.7 van der Waals 
 His14 3.7 van der Waals 
    






Comparison of Mtb CarD/RNAP and Tth TRCF-RID/β1 complex structures 
reveals that CarD and TRCF-RID display a similar set of interactions with RNAP, even 









) strands that interact with the RNAP β1 domain (except for 
the last proline residues;  Figure B-4A). CarD residues Tyr11, His13, and His14, located 
on the turn between β1 and β2 strands, also interact with the RNAP-β1 domain, which 
was not observed in the TRCF-RID/β1 structure. We have tested the contribution of Y11 
and H14 to the CarD/RNAP interaction by generating CarD-Y11A-H14A mutant, and 
comparing the thermal stability of CarD-Y11A-H14A/RpoBtr and CarD-wt/RpoBtr 
complexes by ThermoFluor (DSF) experiments. The thermal denaturation profiles 
suggested that the CarD-Y11A-H14A/RpoBtr complex is less stable than the CarD-
wt/RpoBtr complex (TmC11A–14A = 37.9 ± 0.1 °C versus TmCwt = 39.2 ± 0.1
 
°C; Figure 
B-4B), which was also supported by the size exclusion chromatography (data not shown) 
consistent with our structure that these residues are involved in CarD/RNAP interaction. 
On the other hand, the salt bridge interaction observed in the TRCF-RID/β1 structure 
between residues RNAP Glu110 and TRCF Tyr362 and Arg341 (Westblade et al., 2010) 
is not present in CarD/RNAP structure. 
 
DNA binding studies on Mtb CarD 
Mtb CarD is classified as a CdnL protein due to the lack of a DNA-binding motif 
in its protein sequence. It has been proposed that CdnL proteins do not interact with 




interact with DNA by electrophoretic mobility shift assay (EMSA). 
Because CarD is required for stringent response in mycobacteria, we tested CarD 
binding to ribosomal protein and rRNA operons. The 200–300 base pairs (bp) upstream 
of the rpsH, 16S, 23S, and 5S rRNA genes were amplified for gel shift assays. Our 
results showed a clear shift of electrophoretic mobility between the free DNA and the 
CarD-bound DNA for these probes (Figure 6-5A). The gel shift assays done with 
various random DNA probes, as well as DNase footprinting experiments (data not 
shown), suggested that Mtb CarD does not show a sequence preference for DNA 
binding, indicating a nonspecific DNA-binding mode. 
To elucidate the Mtb CarD-DNA interaction further, four different N- and C-
terminally truncated CarD variants (CarD61–162, CarD83–162, CarD1–53, CarD1–74) were 
cloned and expressed to test each domain’s DNA-binding activity. CarD61–162 and 
CarD83–162 contain the α-helical C-terminal domain and exhibited a gel shift, although 
with different mobilities, which could be due to the charge, size, and shape differences 
of the two constructs. EMSA results verified that the C-terminal domain is the DNA 
interaction domain (Figure 6-5B). The N-terminal domain is not involved in DNA 








Figure 6-5.  DNA binding activity of Mtb CarD determined by EMSA. A) CarD 
interaction with upstream DNA of 16S rRNA gene (313 bp). Lane 1: MW (molecular 
weight) marker. Lane 2: DNA probe, no protein. Lanes 3–7: 4.4–13.8 μM CarD. B) 
Interaction of CarD domains and a well-known non-DNA-binding protein with 16S 
rRNA upstream DNA probe. Lane 1: InhA (10 μM). Lane 2: CarD1–53 (10 μM). Lane 3: 
CarD1–74 (10 μM). Lanes 4 and 5: CarD61–162 (5 and 10 μM). Lanes 6 and 7: CarD83–162 
(5 and 10 μM). Lane 8: CarD full length (10 μM). Lane 9: 16S rRNA upstream DNA 
probe, no protein. Lane 10: MW marker. C) EMSA experiments with CarD mutant 
proteins. Mutation of Arg and Lys residues to Ala significantly reduced the DNA-
binding activity of Mtb CarD. R87A-R88A-K90A showed the greatest effect. Lanes 1, 8, 
15: 16S rRNA upstream DNA probe, no protein. Lanes 2–7, 9–14, and 16–21: 0–44 μM 
mutant CarD protein (as labeled on the gel). Lanes 22 and 23: 11 and 22 μM native 
CarD. (D and E) Mutations are mapped on the ribbon representation and electrostatic 
potential surface of CarD. R87-R88-K90 are red, K125-R126-K130 are dark orange, and 
R114-R118 are light orange. Gel imaging was done using the Bio-Rad Chemidoc XRS+ 
molecular imager, by excitation at 255 nm and emission at 520 nm. Electrostatic 
potential surface calculations were done with PyMol (The PyMOL Molecular Graphics 
System, Version 0.99rc6, Schrödinger) using APBS as the macromolecular electrostatics 






Figure 6-5 Continued. 
 
 
Electrostatic potential surface calculations on the Mtb CarD structure revealed a 
single positively charged patch in the C-terminal domain formed by helices α3, α4, and 
α5 (Figures 6-5D and 6-5E). The basic residues contributing to this positively charged 
surface, i.e., Arg87-Arg88-Lys90 on α3, Arg114-Arg118 on α4, and Lys125-Arg126-
Lys130 on α5, were mutated to alanine and subjected to EMSA. As anticipated, mutation 




binding activity of CarD, with the R87A-R88A-K90A mutation located on the solvent 
exposed surface of α3, showing the greatest effect (Figure 6-5C), suggesting that the 
CarD-DNA interaction is mainly electrostatically driven, as expected. 
Sequence independent DNA-binding modes are commonly seen in bacterial 
nucleoid associated proteins, which are involved in chromosome compaction and 
structuring, DNA replication, repair, and transcription (Basu et al., 2009). The M. 
xanthus CarD protein, which has affinity for AT-rich DNA sequences, and the M. 
xanthus CdnL protein, which does not have a DNA-binding sequence motif, were both 
localized to the nucleoid, but this localization was proposed to occur through protein-
protein interactions with RNAP (Elias-Arnanz et al., 2010; Garcia-Moreno et al., 2010). 
It is plausible that Mtb CarD also localizes to the nucleoid in the same manner as the M. 
xanthus CdnL and M. xanthus CarD proteins, but considering the sequence-independent 
DNA-binding activity, we suggest that this localization might be provided by the DNA-
binding ability of CarD rather than by associating and tailing with RNAP. The C-
terminal domain, and thereby the DNA-binding activity of Mtb CarD, is crucial for 
mycobacterial viability because CarD depletion cannot be complemented with the RID 
domain alone (Weiss et al., 2012). 
 
Conformational changes in RNAP upon CarD binding 
The conformation of the β1 and β2 domains observed in the CarD/RNAP 
complex differs from the conformations observed in the uncomplexed RpoBtr structure. 




CarD/RpoBtr β1 domain structure gives an rmsd of 6.8 Å and 2.8 Å, respectively, over 
the Cαs of the β2 domains (Figure 6-3B). In this context, the conformation of RpoBtr in 
complex with CarD is closer to the conformation of the uncomplexed RpoBtr_B 
molecule. It was reported in the TRCF/β1 structure that the RNAP β4 strand undergoes a 
‘‘register shift’’ with respect to the β3 strand in the complex structure (Westblade et al., 
2010). In contrast, CarD does not cause a register shift or conformational rearrangement 
in the β4 strand upon RNAP binding. 
The CarD/RNAP β1 domain interaction causes local conformational changes 
primarily in the nearby RNAP side chains that are propagated through the water-
mediated network of interactions and transferred to the β1-β2 domain interface and β2 
domain residues. In particular, in the CarD/RNAP complex, β1-Glu404, Ser143, and 
Glu140 change conformation to interact with CarD-His13, Arg47, Thr45, and Tyr11, 
respectively (Figure 6-3C). The side chain of β1-Lys142 also moves 1.4 Å and loses 
direct H-bonding interaction with β1-Ile406, instead forming hydrogen bonds with 
CarD-His14 and β1-Glu140. Consecutively, the β1 domain residues Glu396 and Arg392, 
located at the β1-β2 domain interface of RpoBtr, adopt different conformations in 
CarD/RNAP complex and make additional water mediated interactions with the β2 
domain residues Pro277 and Gly278 (Figure 6-3D). This can explain the particular 
conformation adopted by the two domains in the complex structure. 
 
RNAP regulation by CarD 




regulate RNAP through different mechanisms. DksA is proposed to bind to the RNAP 
secondary channel, very close to the active site, to coordinate to a (p)ppGpp-bound 
active site Mg
2+
 ion through its coiled-coil Asp residues, and stabilize the (p)ppGpp-
RNAP complex (Perederina et al., 2004). In contrast, CarD interacts with the β1 domain 
of the β-subunit, approximately 70 Å away from the active site, through its Tudor-fold 
N-terminal domain. It is interesting that even though CarD and DksA do not share 
sequence and structural homology, CarD can complement DksA function in a ∆dksA E. 
coli strain (Stallings et al., 2009). Furthermore, DksA is not a DNA-binding protein, 
whereas we have shown that CarD can interact with DNA. Whether CarD functions 
synergistically with (p)ppGpp the same way as DksA needs to be determined 
experimentally. 
It is not known whether CarD regulates RNAP function during transcription 
initiation or elongation, or has any effect on the rate of transcription. Based on our 
structural data, we propose that CarD might be involved in RNAP regulation in three 
different ways. The first is by inducing conformational changes in the β-lobes and 
affecting the open complex stability and the downstream non-specific DNA-binding 
activity of RNAP. This can explain how Mtb CarD can complement DksA, which 
destabilizes the open complex together with (p)ppGpp during stringent response in E. 
coli (Paul et al., 2004a; Stallings et al., 2009). Bacterial RNAP β1 and β2 domains 
(equivalently eukaryotic RNAP II protrusion and lobe domains) are involved in various 
processes during transcription such as downstream DNA binding and selection of the 




the proper transcription bubble via downstream DNA gripping, keeping the template and 
nontemplate strand-separated DNA in place during transcription initiation, and covering 
the DNA/RNA hybrid inside the RNAP active-site channel (Figures 6-4A and 6-4B) 
(Lane and Darst, 2010; Murakami et al., 2002a; Nechaev et al., 2000; Trautinger and 
Lloyd, 2002; Trinh et al., 2006). Therefore, conformational changes in this region may 
likely alter critical interactions of RNAP with DNA and DNA/RNA hybrid. To test if 
CarD interaction with the β1 domain would affect RNAP’s DNA-binding affinity, we 
compared the nonspecific DNA-binding activity of RpoBtr in both the uncomplexed 
form and in complex with CarD by EMSA. Our results suggest that the CarD/RpoBtr 
complex has a higher affinity than the uncomplexed RpoBtr for the same DNA probe 
(Figure 6-6). We propose that CarD might affect the DNA-binding affinity of the β-
lobes, and the affinity change of RpoBtr for DNA may result primarily from the 
conformational changes of the β-lobes induced by CarD interaction. 
Overlay of the Taq RNAP initiation complex and CarD/RNAP complex 
structures show that the CarD C-terminal DNA interaction domain lies in proximity 
(<40 Å) to the downstream end of dsDNA in the initiation complex (Figure 6-4B), 
suggesting that CarD may interact with the promoter DNA together with RNAP during 
initiation. The CarD C-terminal domain is connected to the CarD N-terminal domain by 
a twisted α1 helix and a short loop and may adopt a different relative conformation in 
solution than the one observed in the crystal structure. Therefore, a second possibility is 
that this domain can either function as an anchor on DNA to hold CarD in place and 




transcription regulation such as promoter selection and binding. The role of the C-




Figure 6-6. Comparison of the DNA binding activity of RpoBtr by EMSA. A) 
Uncomplexed form. Lane 1: dsDNA probe, no protein. Lanes 2–10: 0.5–32 μM RpoBtr. 
B) In complex with CarD. The CarD/RpoBtr complex has higher affinity than the 
uncomplexed RpoBtr for the same DNA probe. Lanes 1–9: 0.5–32 μM RpoBtr/CarD 




Another possible mechanism is allosteric regulation by inducing conformational 
changes around the RNAP active site despite the distance of the CarD binding site from 
the RNAP catalytic center. In fact, mutations at the interface that weaken the 
CarD/RNAP interaction were reported to make Mtb more susceptible to rifampicin (Rif), 
which binds to the RNAP active site and inhibits transcription elongation. This suggests 




β1-β2 domains but also in the Rif binding pocket, causing Rif to bind more weakly to 
RNAP. The clinically isolated Rif-resistant Mtb strains carrying mutations on distant β 
residues, such as Val170, which do not interact directly with Rif, affect the conformation 
of the Rif binding pocket, and alter the affinity of RNAP for the drug (Campbell et al., 
2001). Similarly, CarD interaction with the β-lobes may result in a reduced affinity of 
RNAP for Rif. A more complete understanding of the effect of CarD on RNAP both 
structurally and functionally must await the solution of the full-length RNAP/CarD 
structure. 
The CarD/RNAP structure presented here reveals the molecular basis of this 
protein-protein interaction and provides insights into RNAP regulation by CarD. EMSA 
experiments revealed an unexpected DNA-binding activity for Mtb CarD, which is 
required for complete in vivo function and mycobacterial viability, and is provided by a 
distinct domain not associated with RNAP interaction. Determination of the CarD/DNA 
complex and RNAP/CarD/DNA ternary complex crystal structures is needed to further 




Generation of expression constructs and cloning 
Rv3583c, encoding the Mtb CarD protein, and DNA encoding the Mtb RNAP β-
subunit (Rv0667) residues 47–433 (labeled RpoBtr), were amplified from Mtb H37Rv 




expression vectors using the NdeI-BamHI and NdeI-HindIII restriction sites. The 
pET15b construct contained an N-terminal 6X-His tag and labeled RpoBtr-NHis, while 
the pET30b construct had a stop codon at the end of the gene sequence, generating an 
untagged protein (CarD-notag). DNA encoding the full length and truncated CarD 
proteins (CarD1-74, CarD1-53, CarD61-162 and CarD83-162) were amplified from Mtb H37Rv 
genomic DNA by PCR with the NdeI-HindIII restriction sites and inserted into the 
pET28b vector (Novagen). CarD_R87A-R88A-K90A, CarD_R114A-R118A, and 
CarD_K125A-R126A-K130A plasmids were generated using a site directed mutagenesis 
kit (Stratagene). The sequence of each construct was verified by DNA sequencing. The 
primers used in this study are provided in Table B-1. 
 
Expression and purification 
Expression plasmids for the uncomplexed RpoBtr, native, and mutant CarD 
proteins were transformed to E. coli BL21(DE3) cells, and recombinant protein 
expression was induced with 1 mM IPTG. For co-expression of Mtb RNAP β1-β2 
domains and Mtb CarD, the plasmids RpoBtr-NHis and CarD-notag were cotransformed 
into E. coli Rosetta2(DE3)pLysS cells, and expression was induced with 0.75 mM IPTG. 
Proteins were extracted with French press and purified by metal affinity and size 
exclusion chromatography. The RpoBtr-NHis:CarD complex eluted as a single peak 
from the size exclusion column. Co-elution of RpoBtr and CarD from the IMAC and 




concentrated to 10 mg/ml and stored at -80°C for further use. Details of the expression 
and purification process are provided in Appendix B. 
 
Crystallization 
RpoBtr-NHis-SeMet and native protein crystals were obtained using hanging-
drop vapor diffusion method by incubating 2 μl of purified protein solution with 2 μl of 
crystallization solution (0.1 M MgCl2, 0.1 M HEPES [pH 7.5], 10% [w/v] PEG4000, and 
0.2 M potassium citrate tribasic monohydrate, and 20% [w/v] PEG3350, respectively) at 
16°C. The RpoBtr-NHis:CarD complex was crystallized by mixing 2 μl of protein 
solution with 2 μl of mother liquor (2% [v/v] tacsimate [pH 5.0], 0.1 M sodium citrate 
tribasic dihydrate [pH 5.6], and 14% [w/v] PEG3350) by hanging-drop vapor diffusion. 
Crystals were cryo-protected with 20% (v/v) ethylene glycol and flash-frozen prior to 
data collection. Data were collected at the Advanced Light Source (ALS; Lawrence 
Berkeley National Laboratory) and at the Advanced Photon Source (APS beamlines 
23ID and 19ID; Argonne National Laboratory) at 0.979 Å.  
 
Data collection and structure determination 
The structure of the Mtb RNAP β-subunit β1-β2 domains was solved by single-
wavelength anomalous diffraction (SAD) using RpoBtr-NHis-SeMet crystals. Crystals 
belonged to the P212121 space group and diffracted to 2.9 Å. Subsequently, resolution 
was improved to 2.5 Å by diffraction data obtained from native (non-SeMet) RpoBtr-




Phenix (Adams et al., 2010) and COOT (Emsley et al., 2010), and the final model had 
Rwork and Rfree values of 0.21 and 0.26, respectively. 
The RpoBtr-NHis:CarD complex crystals belonged to the C2221 space group and 
the diffraction data to 2.1 Å resolution was processed with Denzo/Scalepack. The 
structure was solved by MR using the RpoBtr β1 and β2 domains as two different search 
ensembles (Phaser, CCP4) (McCoy et al., 2007; Winn et al., 2011). After locating one 
copy of RpoBtr in the ASU, CarD was built into the additional |Fo|-|Fc| density manually. 
The final model included one RpoBtr:CarD complex in the ASU, and the structure was 
refined with Phenix Refine to a Rwork = 0.20 and an Rfree = 0.23. Data collection and 
processing statistics are provided in Table 6-1. Details of the data collection and 
structure determination are provided in Appendix B.  
 
EMSAs 
For EMSA, DNA 200–300 bp upstream of the rpsH, 16S, 23S, and 5S rRNA 
promoters were amplified from H37Rv genomic DNA with PCR (for primers, see Table 
S1) and purified by gel-extraction. At room temperature, 40 ng of double-stranded DNA 
was incubated with different amounts of protein (0–8 μg) for 30 min in 25 mM Tris (pH 
7.5) and 50 mM NaCl. As a negative control, a known non-DNA-binding protein, enoyl-
ACP reductase InhA from Mtb, was used to confirm that binding of Mtb CarD to DNA is 
protein-specific. The mixture was loaded on a precast 10% nondenaturing polyacryl-
amide gel and the gel was run at a constant voltage (120 V) with prechilled 0.5X TBE 
(89 mM Tris base, 89 mM boric acid, 1 mM EDTA [pH 8.0]) buffer at 4
°




was completed, the gel was stained with 1X Syber green (Invitrogen) DNA stain 
solution for 30 min in the dark and imaged (Jing et al., 2003). 
 
ThermoFluor measurements 
Differential scanning fluorimetry experiments were carried out with 1 μM of 
CarD/RpoBtr or CarD-Y11A-H14A/RpoBtr complex in 200 mM Tris (pH 7.5) 100 mM 
NaCl buffer, in the presence of 5X Sypro orange dye (Molecular Probes), in a 20 μl 
reaction volume. The temperature of the samples was changed from 25°C to 95°C at a 
heating rate of 0.5°C/min, and the fluorescence was monitored with an Mx3005P qPCR 
instrument (Agilent). The melting point (Tm) was calculated as the lowest point of the 
first derivative plot (DeSantis et al., 2012).  
 
Additional unpublished results 
 
Degradation of CarD protein in solution 
It was observed that CarD protein (with N-terminal His-tag or without any tag) 
underwent proteolytic cleavage over time in solution (Figure 6-7). Addition of EDTA, 
protease inhibitor cocktail or PMSF did not help in preventing the truncation of the 
protein. To eliminate any possible protease contamination coming along the purification, 
the protein was passed through high-salt washes and several columns including gel 
filtration and benzamidine FF columns. Even though 99% pure protein was obtained, the 





Figure 6-7. Degradation of the CarD protein in solution over time. Purified CarD (full 
length- 18 kDa) was incubated in 25 mM Tris 7.5, 150 mM NaCl buffer at 18 °C for four weeks. 
At the end of each week, a sample was aliquoted for SDS-PAGE. Consistent with the mass-
spectrometry analysis, the truncation products at around 8 and 14 kDa were observed. As judged 
from the SDS-PAGE, CarD is >98% pure and further purifications did not resolve the truncation 
issue. Addition of protease inhibitors or EDTA also did not prevent the degradation.    
 
 
The degradation of the protein was analyzed by mass spectrometry. The ESI-FT 
mass analysis resulted in seven major peaks indicating that CarD was truncated at three 
different aminoacid positions; i.e., Leu37, Phe71, and Leu74 (Figure 6-8), which 
suggested a chymotrypsin like cleavage. The single, double and triple alanine mutants of 
the protein at these residues (L37A, F71A-L74A, L37A-F71A-L74A) were generated to 
increase the protein stability; however, none of the mutant proteins prevented the 
truncation of the protein (data not shown). In parallel with these observations, a similar 
truncation behavior for the Mtb CarD protein was reported in a recent publication. In 
those experiments, only a C-terminally His-tagged CarD construct was observed to be 
stable in solution and yielded full length protein crystals. The crystal structure revealed 









Figure 6-8. ESI-FT mass spectrometry analysis of the CarD protein. As concluded from the 
spectrum, seven major peptides were produced as a result of truncation. Below, the peptide 
masses were mapped to the protein sequence, showing the corresponding region for each peak 




Structure determination of uncomplexed CarD 
Despite several attempts, the crystals for the full length protein could not be 
obtained due to the proteolytic cleavage of CarD over time in solution. None of the 
single, double or triple mutant proteins (L37A, F71A-L74A, and L37A-F71A-L74A) 
yielded full length protein crystals. Crystallization trials set with the full length protein 
resulted in formation of the truncated CarD crystals, which covered only the C-terminal 
of the protein (residues 82 -141). Mass spectrometry analysis (MSWIFT) also confirmed 
that these crystals were the truncation products with molecular weights of 10 and 14 kDa 
(Figure 6-9C). Interestingly, complex formation between the Mtb CarD and RNAP 
proteins prevented the proteolysis of CarD, and hence, the full length CarD bound to the 
β-subunit of RNAP was crystallized after co-expression and purification of the complex 
(as described in the results and discussion section of this chapter). Compared with the 
uncomplexed CarD protein, CarD complexed with RpoBtr was stable in solution, and 
could be stored without any degradation.  
The truncated CarD crystals were obtained in the presence of nucleating agents 
like seaweed, hydroxyapatite and bioglass. Wild-type and Se-met derivatized fine hair-
like crystals were obtained in 0.2 M trisodium citrate monohydrate and 20% (w/v) 
Peg3350 in 2 to 3 weeks (Figure 6-9B). The crystals belonged to the P61 space group 
with unit cell dimensions of 67.6, 67.6, 33.7 Å, containing one molecule in the 
asymmetric unit. Diffraction data was collected at Argonne National Laboratory 
Advanced Photon Source (APS) at 0.97 Å to a resolution of 2.0 Å. The structure was 




data obtained from the Se-Met crystals. Model building and structure refinement was 
done with Coot and Phenix Refine, respectively, yielding a final model with Rwork=22% 




Figure 6-9. Truncated CarD crystals. A) SDS-PAGE of the CarD protein before 
setting the crystal plate (lane 1) and the truncated CarD crystals obtained after two 
weeks (lanes 4-9). B)  Fine hair-like crystals of the truncated CarD protein. Crystals 
were obtained in the presence of seaweed, which can be seen next to the crystals as the 
brownish spots. C) MSWIFT analysis of the crystals verified that they were truncation 




Table 6-3. Data collection, phasing and refinement statistics for truncated CarD 
structure. 
 
 Se-Met CarD C-
term. Truncation 
Data collection  
Space group P61 
Cell dimensions 
a, b, c (Å) 




67.6, 67.6, 33.7 
90, 90, 120 
Wavelength  0.979 
Resolution (Å) 1.95 (1.95) 
Completeness (%) 99.6 (99.9) 
Redundancy 6.6 (6.6) 
I/Iσ 13.0 (2.6) 
Rsym 0.39 (0.04) 
Refinement  
Resolution 58.5-1.95 
No. reflections 6266 






B factors 36.7 
RMSD deviations 
















No significant conformational differences were observed between the protease 
truncated CarD C-terminal and the full-length CarD C-terminal domain structures. The 
structure of the truncated CarD C-terminal domain (residues 82-141) was comprised of 
three α-helices with two helix-turn-helix (HTH) motifs (Figure 6-10). This three-helix 
bundle covered α3, α4, and α5 (numbered according to the full length structure), and 
comprised the leucine zipper motif between the α4 and α5. Also, it represented the DNA 
interaction domain of the protein as described in the results and discussion section of this 
chapter. 
 
Characterization of the CarD-DNA interaction  
The CarD-DNA interaction was examined extensively by using several DNA 
probes with different sequence, length, shape and secondary structures. It was observed 
that CarD had similar binding affinity to the dsDNAs generated from the 200-300 bp 
upstream of the rpsH, 16S, 23S and 5S rRNA genes. Next, to narrow down the specific 
DNA region needed for the CarD interaction, the 16S, 23S and 5S rRNA upstream 
dsDNAs were digested at a single restriction site with the restriction enzymes, BsrI or 
NheI, generating pieces of DNA varying in length from 76 bp to 237 bp (Figure 6-11). 
These restrictedly digested fragments were used in EMSA experiments as the DNA 
probes. Mtb CarD interacted with each restricted fragment, showing a slightly higher 
affinity for the longest (237 bp) fragment. In fact, it was observed that longer the length 






Figure 6-10. Structure of the truncated CarD protein. A) The amino acid sequence of 
the Mtb CarD C-terminus that was crystallized is shown. Positively charged residues that 
were tested for DNA interaction are colored blue. The secondary structure elements are 
presented below the sequence. B) Cartoon representation of the structure of the three 
helix bundle of CarD C-terminal domain. Only two polar interactions were present 
between K95-E106 and N92-D110. On the right, the leucine zipper formed by the side 
chains of the residues Leu120, Leu111, L128, and L135 on the α4 and α5 is shown. α3 is 








Figure 6-11. EMSA experiments with the restrictedly digested 16S, 23S and 5S 
rRNA upstream DNA probes. The 16S, 23S and 5S rRNA upstream dsDNAs were digested 
at a single site with the restriction enzymes, BsrI or NheI, generating pieces of DNA varying in 
length from 76 bp to 237 bp. CarD binding to each fragment was tested. A) A diagram showing 
the restriction digestion map of the 16S, 23S and 5S rRNA upstream dsDNA sequences. B) 
EMSA with the BsrI digested 16S rRNA upstream DNA probe. Lanes 1-4: 76 bp fragment + 0-
33 μM CarD. Lanes 5-9: 237 bp fragment + 0-33 μM CarD.  C) EMSA with the NheI digested 
23S rRNA upstream DNA probe. Lanes 1-4: 98 bp fragment + 0-33 μM CarD. Lanes 5-9: 152 
bp fragment + 0-33 μM CarD. M: Molecular marker.  
 
 
Intriguingly, there was no conserved sequence motif in the DNA sequences 
tested for the EMSA experiments leading us to suspect the sequence specificity of the 
Mtb CarD-DNA interaction. The DNA binding specificity of Mtb CarD was further 




not related to the stringent response. EMSA experiments demonstrated that Mtb CarD 
was also able bind to these non-specific DNA sequences, supporting the idea of 
sequence independent DNA-binding (Figure 6-12A). CarD was even able to bind to the 
dsDNA sequences of the molecular markers (Figure 6-12A), confirming the non-
sequence specific binding mode. Moreover, the CarD-DNA interaction was strongly 
dependent on salt concentration, indicating mainly electrostatic interactions rather than 
the base specific interactions are present (Figure 6-12B). In addition, the CarD-DNA 
interaction was not affected by the reaction buffer pH (pH range 5.0-9.0) (data not 
shown), supporting the involvement of the arginine or lysine residues in DNA 
interaction. At the tested pHs, Arg and Lys residues would be positively charged due to 
their high pKa values and can contribute to electrostatic interactions with the negatively 
charged DNA backbone. 
Next, it was investigated if the DNA binding activity of CarD was dependent on 
the secondary and tertiary structure of the DNA probe. Cruciform DNA and bulged 
DNA probes were used in EMSA experiments to test if CarD could interact with DNA in 
different conformations. Mtb CarD did not show any binding to these probes. 
Furthermore, CarD did not show any binding to the single stranded DNAs (data not 
shown). Consequently, based on the EMSA results it was concluded that the DNA 
binding mode of Mtb CarD was not sequence dependent and the protein was able to bind 







Figure 6-12. Non-specific DNA binding, and salt and buffer effect on the DNA 
binding. A) EMSA experiments performed with the DNA probes in different sizes that are not 
related to the stringent response. Lanes 1-2: Mtb MurI gene sequence (816 bp) + 0-11 μM CarD.  
Lanes 3-4: Mtb WhiB6 gene sequence (351 bp) + 0-11 μM CarD. Lanes 5-6: Mtb Rv1993 gene 
sequence (273 bp) + 0-11 μM CarD. Lanes 7-8: 16S rRNA upstream dsDNA probe (313 bp) + 0-
11 μM CarD. Lane 9: molecular marker + 11 μM CarD. Lane 10: molecular marker. B) pH and 
salt dependence of the CarD-DNA interaction. Lane 1: 23S upstream DNA probe. Lanes 2-6: 
23S upstream DNA probe + 11 μM CarD in acetate pH 5.0, Tris pH 6.8, Tris pH 7.5, Tris pH 8.5 
and Tris pH 9.0, respectively. Lanes 7-9: 23S upstream DNA probe + 11 μM CarD in 0, 100 and 
500 mM NaCl, respectively, in the reaction buffer.  
 
 
Complex formation between CarD and RNAP 
Before we started the complex formation trials of Mtb CarD and RNAP, there 
was a single report in the literature suggesting that CarD interacts with the N-terminus of 
the RNAP β-subunit (Stallings et al., 2009). A subsequent report on the Tth TRCF-
RID/RNAP β1 structure had predicted that the Mtb CarD/RNAP interaction region 
would also be located on the β1 domain of the β-subunit, between the conserved residues 
123 to 153 of RNAP (Westblade et al., 2010). Even though Mtb RNAP displays ~50% 
identity and ~70% similarity to the E.coli and Taq RNAPs, whose structures have been 




full length Mtb RNAP or its β subunit in the PDB till date. It is well accepted that it is 
difficult to crystallize large proteins or protein-protein complexes due to the presence of 
high number of flexible domains and loops in these macromolecules (Dale et al., 2003). 
Therefore, to facilitate crystallization and increase the probability of getting high 
resolution diffracting crystals of the complex, we focused on the RpoB domains that 
were needed for the complex formation with Mtb CarD. Different constructs were 
designed for the β-subunit covering the predicted interaction region based on the 
secondary structure predictions and homology models generated using the published Taq 
and Tth RNAP structures. The homology models suggested that the first 40 residues of 
Mtb RpoB would be disordered without any secondary structure, and this disordered 
region could significantly lower the chances of obtaining high-resolution diffracting 
crystals. Therefore, the residue 40 was selected as the N-terminal starting point for the β-
subunit constructs. Four different constructs of the β-subunit spanning the residues 40-
403, 47-174, 47-433, and 1-1172 (full length β-subunit) were cloned and tested for 
soluble recombinant protein expression.  
Mtb CarD and the β-subunit variants were co-expressed in E. coli to investigate 
the complex formation between the two proteins. In order to facilitate the purification of 
the complex, a co-expression system was selected that allowed us to put an N-terminal 
His6-tag on one of the protein constructs, while keeping the other protein tagless. The 
CarD-no-tag plasmid was co-transformed with the RpoB-N-His plasmids in E. coli 
Rosetta2(DE3)pLysS cells. Separately, RpoB-no-tag plasmids were co-transformed with 




between the proteins by analysis of the co-elution profiles from the IMAC purification 
on SDS-PAGE gels. Among these co-expression systems, CarD-no-tag co-expression 
with the RpoB-tr-N-His (47-433) construct showed that both proteins co-eluted from the 
IMAC with gradient elution. The band corresponding to CarD was verified by mass 
spectrometry and SDS-PAGE gel sequencing. To confirm that the co-elution of the two 
proteins represented a stable complex, size-exclusion chromatography was performed. 
Both proteins co-eluted from the gel-filtration column giving a single peak for the 
complex (Figure 6-13). Even though the full length RpoB was able to associate with 
CarD in vivo as judged by the IMAC results, this association was found to be weak since 
both of the proteins eluted under separate peaks from the gel-filtration column (data not 
shown). The RpoB-47-174 construct did not give any soluble protein expression, while 
the RpoB-40-403 construct dissociated from CarD on the gel-filtration column similar to 
the full length RpoB construct. As the primary objective of this study was to determine 
the crystal structure of the complex, the stable complex formed between the RpoB-tr-N-
His (47-433) and CarD-no-tag constructs (RpoBtr:CarD complex) was selected for 
crystallographic studies.  
Conversely, there was no complex formation upon co-expression of the CarD-
NHis and RpoBtr-notag constructs, which suggested that the N-terminal His6-tag on 






Figure 6-13. Co-purification of the CarD-RNAP complex. After co-elution from the 
IMAC, fractions were combined, concentrated and loaded to the gel-filtration column 
(lane 1). Both proteins co-eluted in a single peak (lanes 5-8). Uncomplexed RpoBtr 
eluted later than the CarD/RpoBtr complex as expected (lanes 11-15). The elution 














Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, and 
continues to be a global health threat. It is estimated that one-third of the world’s 
population is infected by latent Mtb. Emergence of the multi-drug resistant Mtb strains 
along with the ability of the bacterium to persist in host for years, despite the use of 
antibiotics, exacerbates the problem and threatens the efforts to keep TB under control. 
Current TB therapy continues for at least six months and requires administration of at 
least four drugs, which were discovered decades ago. Furthermore, co-infection with 
HIV raises the mortality rates to close to 100% in the case of extensively-drug resistant 
TB. Therefore, it is incredibly urgent to discover new anti-tubercular agents that are 
effective against drug-resistant and persistent bacteria.  
Chapter I of this dissertation introduced the facts about TB disease, provided a 
brief explanation of TB drugs, current TB therapy, drug-resistance, and persistence, as it 
aimed to further our understanding of these concepts. The important components of the 
mycolic acid biosynthesis pathway, which represent valuable drug targets, were 
described in detail. Also, the transcriptional response and regulation of Mtb during 
adaptation to persistent state was examined in order to understand the factors required 
for the establishment of this state. Lastly, an overview of transcription and regulation of 




Chapter II described the mechanism of drug action of isoniazid and ethionamide 
against Mtb and M. leprae. By developing a cell-based activation method, the active 
forms of ethionamide and prothionamide were isolated and characterized by mass-
spectrometry and X-ray crystallography. It was found that isoniazid and ethionamide 
targeted and inhibited InhA in a similar manner as both formed adducts with the cofactor 
NAD
+
. The crystal structures of InhA complexed with the adducts revealed the binding 
mode of these prodrugs. Using the same cell-based activation method, it was shown that 
InhA and not Dhfr was the primary cellular target of isoniazid. Absence of mutations in 
the dfrA gene in isoniazid resistant clinical isolates and the fact that overexpression of 
Dhfr did not cause any resistance to isoniazid confirmed that InhA was the clinically 
relevant target of isoniazid, bringing an end to the controversies about the target of this 
anti-TB drug.  
The biochemical and structural investigations on regulation of the InhA enzyme 
was addressed in Chapter III. Since InhA is an essential protein and is a well validated 
drug target, deciphering its post-translational regulation is quite important to understand 
the regulation of mycolic acid production in mycobacteria. It was found that InhA 
function was regulated negatively by phosphorylation. In vitro phosphorylation assays 
indicated that InhA was phosphorylated by multiple Mtb serine-threonine kinases at a 
single threonine residue (T266) close to the C-terminal of the protein. Enzymatic assays 
and fluorescence quenching experiments done with the phosphomimetic aspartate and 
glutamate mutants suggested that the decreased enzymatic activity was mainly due to the 




phosphomimetic InhA proteins revealed that the mutation of T266 to aspartate or 
glutamate caused local structural changes by perturbing the H-bonding network and 
introducing water molecules. It was noteworthy that even though T266 was 15 Å away 
from the active site and not involved in catalysis, mutation of this residue caused 
significant activity loss. In addition, transfer of the T266D or T266E InhA alleles to 
mycobacteria was lethal confirming the required InhA activity for cell viability. 
Chapters IV and V covered the drug discovery studies for InhA. A target based 
high-throughput screening (HTS) was performed in collaboration with GlaxoSmithKline 
(GSK), and a structure based drug design study on triclosan scaffold was performed in 
collaboration with the Jacobus Pharmaceutical Company that led to the discovery of 
highly potent InhA inhibitors. The HTS at GSK resulted in the identification of multiple 
hits belonging to different chemical series. Among these, the thiadiazole series were the 
most potent and featured the best pharmacokinetic properties; therefore, these series of 
compounds were further studied. The optimized GSK lead compound was a potent 
inhibitor of InhA with an IC50 of 7 nM and was effective against drug-sensitive and 
drug-resistant clinical strains. It also showed better pharmacokinetic properties than the 
mother compound. In addition, the broad spectrum antibacterial compound triclosan was 
used as a template for structure-based drug design. Triclosan derivatives modified at the 
5-position were tested in vitro and in vivo for anti-tubercular activity. It was seen that 
hydrophobic alkyl and aryl substituents increased the potency of the derivatives toward 
InhA, with the most potent compound having an IC50 of 21 nM. Triclosan derivatives 




inhibitors and triclosan analogs were determined by X-ray crystallography. It was seen 
that both sets of inhibitors bound to the hydrophobic substrate binding pocket of the 
enzyme interacting with NAD
+
 and the protein backbone. In regard to the GSK 
inhibitors, InhA residue Met98 was involved in direct H-bonding with the inhibitor 
compound, whereas for triclosan derivatives Tyr158 made an H-bond with the inhibitor 
compounds. It is noteworthy that both GSK inhibitors and triclosan derivatives are 
activation-free inhibitors unlike isoniazid, which Mtb develops a majority of the drug 
resistance against due to the mutations in the activator gene katG.  
Chapter VI discussed the structural and functional studies on CarD, which is an 
Mtb transcription regulator that is essential for bacterial viability and the establishment 
of persistence. CarD is involved in stringent response through downregulation of rRNA 
and ribosomal protein genes, and it interacts with the β-subunit of RNAP. The crystal 
structure of the CarD/RNAP complex revealed the molecular basis of this important 
protein-protein interaction and suggested possible mechanisms CarD can employ on 
RNAP for transcription regulation. Furthermore, it was found that CarD could bind to 
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Figure A-1. Mass spectrometric analysis of phosphorylated InhA. A) Mass 
spectrometric analysis of in vitro PknB-phosphorylated InhA. MS/MS spectrum of the 
triply charged ion [M +3H]
3+
 at m/z 1051.51of peptide [241-269] (monoisotopic mass: 
3151.52 Da). Unambiguous location of the phosphate group on Thr266 was shown by 
observation of the “y” C-terminal daughter ion series. Starting from the C-terminal 
residue, all “y” ions lose phosphoric acid (-98 Da) after the Thr266 phosphorylated 
residue. B) Mass spectrometric analysis of InhA purified in vivo. MS/MS spectrum of 
the triply charged ion [M+3H]
3+
 at m/z 1051.51 of peptide [241-269] (monoisotopic 
mass: 3151.52Da). The phosphate group on T266 was unambiguously located by 
observing the “y” C-terminal daughter ion series. Starting from the C-terminal residue, 

















































Figure A-2. Structures of binary complexes of InhA_WT:NADH, InhA_T266D: 
NADH and InhA_T266E:NADH. Crystals were obtained using the hanging drop vapor-
diffusion method by mixing 2 μl of 5-10 mg/ml protein solution containing NADH (1:2 ratio of 
enzyme to NADH) with an equal volume of reservoir solution (100 mM Hepes 7.2, 50 mM 
sodium citrate 6.5, 8-12% methylpentanediol and 4% DMSO). Crystals were cryoprotected by 
30% MPD mixed with reservoir solution prior to flash-cooling at 100K in a cold nitrogen stream. 
Data sets were collected at 0.97947 Å using synchrotron radiation on GM/CA-CAT 23ID 
beamline at Advanced Photon Source, Argonne National Laboratory. Data were processed and 
scaled by DENZO/Scalepack (Otwinowski and Minor (1997)  Methods in Enzymology, 307-326) 
and initial phases were obtained by molecular replacement using previously published wild-
type_InhA:NAD+ structure (PDB code: 2AQ8) as a starting model. Model building and 
refinement of the structures were done by Coot (Emsley and Cowtan (2004) Acta Crystallogr D 
Biol Crystallogr. 60, 2126-32) and Phenix (Adams et al. (2002) Acta Cryst. D. 58, 1948-1954), 
respectively. In the final refinement cycles, water molecules were added to the peaks above 3 σ 
of the Fo-Fc electron density map such that the water molecules were within H-bonding distance 
to the surrounding protein/water molecules. Data collection and processing statistics are 
provided in Table A-3. Comparative three-dimensional structures and H-bonding interaction of 
InhA-WT, InhA_T266D and InhA_T266 are represented in the up, middle and low down panels, 
respectively. A new water molecule (W9), not present in InhA_WT, is introduced between 
residues D266 and N267 residues. As observed in T266D structure, a new water molecule (W5) 
is found to be present introduced between D266 and N267 residues in the T266E structure. 
Atomic coordinates and structure factors of wild-type InhA:NADH, T266D:NADH and 















Figure A-3. Overexpression of the various InhA variants and effect on growth in M. 
bovis BCG. A) Electrocompetent M. bovis BCG were transformed with the empty 
pMK1 construct, the pMK1::inhA_WT, pMK1::inhA_T266A, pMK1::inhA_T266D or 
pMK1::inhA_T266E to allow constitutive expression of the various inhA alleles under 
the control of the strong hsp60 promoter. Transformed mycobacteria were plated and 
incubated at 37°C for 3 weeks. B) InhA expression levels in the InhA-overproducing M. 
bovis BCG strains. Western blot analysis of M. bovis BCG cells overexpressing the 
phosphoablative inhA_T266A and phosphomimetic inhA_T266D and inhA_T266E 
alleles were harvested, resuspended in PBS and disrupted. Equal amounts of crude 
lysates (20 μg) were then loaded onto a 4-12% acrylamide gel, subjected to 
electrophoresis and transferred onto a membrane for immunoblot analysis using rabbit 







Figure A-4. Superimposition of InhA_WT (green), InhA_T266D (orange) and 
InhA_ T266E (blue) tetrameric structures. The Rmsd is 0.3 Å. NADH is represented 






Figure A-5. The crystal structure of InhA_T266D mutant. The figure shows the 
proximity of the mutation site to the active site. NADH is represented with cyan sticks, 
C16 fatty acid substrate analog (PDB:1BVR) with yellow sticks. Substrate binding loop 





Table A-1. Bacterial strains and plasmids used in this study. 
Strains or Plasmids Genotype or Description Source or Reference  
E. coli  TOP10 F
-
 mcrA (mrr-hsdRMS-mcrBC) Invitrogen  
 φ80lacZ M15 lacX74 deoR recA1 araD139   
 (ara-leu)7697 galU galK rpsL endA1 nupG;   
 used for general cloning   
    
E. coli BL21(DE3)Star F2  ompT  hsdSB(rB2  mB2)  gal  dcm  (DE3); Stratagene  
 used to express recombinant proteins in E. coli   
     
M. bovis BCG 1173P2 Vaccine strain  WHO, Stockholm  
M. smegmatis mc
2
155 ept-1   (Snapper et al., 1990)  
    
M. smegmatis mc
2
2359 ept-1 attB::pYUB412::ndh inhA40 (Vilcheze et al., 2000)  
 INH-R, Ts mutant of mc
2
2354   
    
pETPhos pET15b  (Novagen)  derivative  including  the (Canova et al., 2008)  
 replacement  of  the  thrombin  site  coding   
 sequence  with  a  tobacco  etch  virus  (TEV)   
 protease site and Ser to Gly mutagenesis in the   
 Nterm His-tag    
pETPhos_inhA_WT pETPhos derivative used to express His-tagged This work  
 fusion of WT InhA in E.coli   
    
pETPhos_inhA_T266A pETPhos derivative used to express His-tagged This work  
 fusion of InhA_T266A in E.coli   
    
pETPhos_inhA_T266D pETPhos derivative used to express His-tagged This work  
 fusion of InhA_T266D in E.coli   
    
pETPhos_inhA_T266E pETPhos derivative used to express His-tagged This work  
 fusion of InhA_T266E in E.coli   
    
pMK1 E.  coli/mycobacterial  shuttle  vector,  allows (Veyron-Churlet et al.,  
 expression   of   N-term   His-tagged   proteins, 2010)  
 derived from pMV261 (Stover et al., 1991) and   
 containing the pET28a polylinker   
pMK1_inhA_WT pMK1  derivative  used  to  express  His-tagged This work  
 fusion of WT InhA in mycobacteria   
    
pMK1_inhA_T266A pMK1  derivative  used  to  express  His-tagged This work  
 fusion of InhA_T266A in mycobacteria   
    
pMK1_inhA_T266D pMK1  derivative  used  to  express  His-tagged This work  




Table A-1 Continued.  
Strains or Plasmids Genotype or Description Source or Reference  
pMK1_inhA_T266E pMK1  derivative  used  to  express  His-tagged This work  
 fusion of InhA_T266E in mycobacteria   
    
pSD26 Acetamide-inducible expression vector (Daugelat et al., 2003)  
pSD26_inhA_WT pSD26  derivative  used  to  induce  His-tagged This work  
 fusion of WT InhA in mycobacteria   
    
pSD26_inhA_T266A pSD26  derivative  used  to  induce  His-tagged This work  
 fusion of InhA_T266A in mycobacteria   
      
      
pSD26_inhA_T266D pSD26  derivative  used  to  induce  His-tagged This work 
 fusion of InhA_T266D in mycobacteria  
   
pSD26_inhA_T266E pSD26  derivative  used  to  induce  His-tagged This work 
 fusion of InhA_T266E in mycobacteria  
   
p004 pJSC347   (Sambandamurthy   et   al.,   2002) Hsu and Jacobs, 
 derivative containing lambda phage cos sites, a manuscript in 






Table A-2. Primers used in this study. 
Primers 5' to 3' Sequence
ab
 
pMK1 InhA dir tcatcatatgacaggactgctggacgg (NdeI) 
pMK1 InhA rev tacggaattctagagcaattgggtgtgcgc (EcoRI) 
pSD26 InhA dir tataggatccatgacaggactgctggacggc (BamHI) 
pSD26 InhA WT rev gagcaattgggtgtgcgcgc 
pSD26 InhA T266A rev gagcaattgggcgtgcgcgc 
pSD26 InhA T266D rev gagcaattggtcgtgcgcgc 
pSD26 InhA T266E rev gagcaattgctcgtgcgcgc 
InhA T266A dir cgccgacggcggcgcgcacgcccaattgctctagaattcg 
InhA T266A rev cgaattctagagcaattgggcgtgcgcgccgccgtcggcg 
InhA T266D dir cgccgacggcggcgcgcacgaccaattgctctagaattcg 
InhA T266D rev cgaattctagagcaattggtcgtgcgcgccgccgtcggcg 
InhA T266E dir cgccgacggcggcgcgcacgagcaattgctctagaattcg 
InhA T266E rev cgaattctagagcaattgctcgtgcgcgccgccgtcggcg 
inhA_forward agagaagcatatgatgacaggactgctggacgg caaacg ttctggttagcg (ndei) 
inhA_T266A reverse cccaagcttttactagagcaattgggcgtgcgcgccgcc gtcggcgtagatg (hindiii) 
inhA_T266D reverse cccaagcttttactagagcaattggtcgtgcgcgccgcc gtcggcgtagatg (hindiii) 
inhA_T266E reverse cccaagcttttactagagcaattgctcgtgcgcgccgcc gtcggcgtagatg (hindiii) 
a
Restriction sites are underlined and specified into brackets. 
  
b





Table A-3. Data collection and processing statistics for InhA_WT:NADH, 
InhA_T266D:NADH and InhA_T266E:NADH crystal structures. 
 
 InhA_WT InhA_T266D InhA_T266E 
Unit cell dimensions a,c (Å) 98.551, 139.714 98.366, 139.887 98.154, 139.439 
Space group P6222 P6222 P6222 
Number of unique reflections 23240 39230 27393 
Data collection resolution range 40.88-2.1 40.9-1.75 40.78-2.0 
Refinement resolution range (Å) 40.88- 2.1 40.9-2.0 40.78-2.0 
Completeness 96.7 (98.3) 99.5 (97.4) 99.6 (99.9) 
I/σ 19.45(5.28) 14.3 (7.4) 36.97 (9.39) 
Rsym 3.5 (18.85) 4.36 (10.05) 1.79 (9.56) 
Rfactor/ Rfree 0.1667/ 0.2086 0.1756/ 0.2033 0.1819/0.2143 
Redundancy 11.1 (11.3) 9.3 (9.5) 17.5 (16.7) 
Total protein residues 268 268 268 
Heteroatoms 2 2 2 
 (MPD) (MPD) (MPD) 
 (NADH) (NADH) (NADH) 
Water molecules 186 207 191 
Average B-factors (A
2
)    
Protein 42.57 34.26 35.80 
NADH 47.32 35.88 37.22 
Water 51.52 43.51 42.94 








Table A-3 Continued.  
 InhA_WT InhA_T266D InhA_T266E 
Ramachandran analysis    
MolProbity (Davis et al., 2007)    
Favorable regions 96.99 96.24 96.24 
Allowed region 100 100 100 
Disallowed 0 0 0 
r.m.s.d    
Bond lengths (Å) 0.008 0.007 0.007 
Bond angles (
0
) 1.211 1.094 1.19 
Rsym =∑  h∑i|Ihi - ‹Ih›|/∑  h∑iIhi where Ihi is the intensity of observation I of reflection h. 
Rfactor ∑= h||Fo| - |Fc||∑|F/ o| where Fo and Fc are observed and calculated structure factors, 









SUPPLEMENTAL MATERIAL FOR CHAPTER IV  
 
Table B-1. Primers that are used in this work.  
Construct Forward 5’ 3’  Reverse 5’ 3’  



































































Figure B-1. Protein sequence alignment of Mtb CarD. Mtb CarD sequence is aligned with the closest homologs 
(determined by the BLAST search) and M. xanthus CarD and CdnL proteins. Identical residues are colored dark gray and 
boxed, similar residues are shaded with light gray. M. xanthus CarD has additional 135 residues at the C-terminus compared 
to Mtb CarD. The AT-hook DNA binding motif (four ‘RGRP’ motifs) of M. xanthus CarD are shaded in yellow boxes. The 
secondary structure of Mtb CarD is shown above its sequence. The missing residues in the final model are indicted by dashed 





Figure B-2. Stereo images of the CarD/RNAP complex and electrostatic potential 
surface representation of the CarD/RNAP interface. A) The |Fo|-|Fc| density (shown 
at 1.8 sigma in green) for CarD at the protein-protein interface was unambiguous after 
locating RpoBtr in the complex structure by MR. Cα backbone of the final model of the 
complex is included for clarity. B) The 2|Fo|-|Fc| map at 2.0 sigma of the CarD/RNAP 
interface after refinement. RpoBtr residues are shown in orange; CarD residues are 
shown in gray sticks. Images were prepared by Pymol. C) Wall-eyed stereo image of the 
CarD/RNAP complex in cartoon representation. D) CarD displays a positively charged 
surface (left), and RNAP has a negatively charged surface (right) at the interface. 
Electrostatic potential molecular surface calculations were done and images were 
prepared with PyMol using APBS as the macromolecular electrostatics calculation 
program. In all panels, RpoBtr is shown in orange, CarD is shown in blue ribbons. 






















Figure B-3. Comparison of the uncomplexed Mtb β1 and β2 domain structure 
(green) with the Tth (dark pink, PDB ID: 2O5I), Taq (yellow, PDB ID: 1I6V) and E. 
coli (light pink, PDB ID: 4IGC) RNAP β1 and β2 domain structures. Rest of the Tth, 
Taq and E. coli RNAP structures is omitted for clarity. Superposition of the β1 (A) and 
β2 (B) domains results ~10 Å RMSD over the Cα atoms of the other domain, which 
indicates that the relative conformation adopted by the two domains in RpoBtr is 
different than other bacterial core or holo RNAP structures. C) Superposition of the 
uncomplexed RpoBtr β1 domains of the two molecules in the ASU (RpoBtr_A 
(magenta) and RpoBtr_B (green)) gives an RMSD of 5.2 Å (over 191 atom pairs) on the 
Cαs of the β2 domains. The conformational difference observed in the β1-β2 domain-
domain orientation can be explained by a 13º rotation around the hinge axis centered on 
the two stranded anti-parallel β-sheet connecting the two domains. Figure B-3 is related 












Figure B-4. Comparison of CarD/RNAP interaction with TRCF-RID/RNAP 
interaction and the DSF experiments on CarD/RpoBtr and CarD-Y11A-
H14A/RpoBtr complexes. A) The CarD/RNAP interface (this study, left panel) and the 
TRCF-RID/RNAP interface (PDB ID: 3MLQ, right panel) are displayed. The sequence 
of the β4-strands is given below each chain with conserved residues in bold. Important 
residues for intermolecular interaction are labeled, and H-bonds are shown with gray 
lines. B) Differential scanning fluorimetry (DSF) experiments on CarD/RpoBtr (filled 
squares, solid line) and CarD-Y11A-H14A/RpoBtr (open circles, dashed line) 
complexes. Equal amount of each complex (1 μM) in 200 mM Tris pH 7.5, 100 mM 
NaCl buffer was mixed with 5X Sypro orange dye. The temperature of the samples was 
changed from 25 to 95 °C at a heating rate of 0.5 °C/min, and the fluorescence was 
monitored. The first derivative of fluorescence d(RFU)/dT is plotted against temperature 
and the melting point (Tm, indicated with red lines) was calculated as the lowest point of 
the first derivative plot. Experiments were repeated five times and standard errors are 










Supplemental experimental procedures 
 
Expression and purification 
For recombinant expression of uncomplexed RpoBtr, native and mutant CarD 
proteins, the corresponding plasmids were transformed into E. coli BL21(DE3) cells. 
The cells were grown at 37 ºC in the presence of antibiotic to an OD600 of 0.6, and 
protein expression was induced with 1 mM IPTG at 18 ºC overnight. The cells were 
harvested, resuspended in buffer A (25 mM Tris pH 7.5, 500 mM NaCl, 5 mM 




cocktail) and lysed by French press. After centrifuging the lysate, the supernatant was 
loaded onto a His Trap FF column pre-equilibrated with buffer A. After washing the 
column with at least 5 column volumes of buffer A, column bound proteins were eluted 
with a gradient of buffer B (15-100%) (25 mM Tris pH 7.5, 500 mM NaCl, 500 mM 
imidazole, 2 mM β-ME). Fractions containing RpoBtr-NHis or CarD were pooled, 
dialyzed against buffer C (25 mM Tris 7.5, 100 mM NaCl, 2 mM DTT), concentrated, 
and loaded onto a Superdex 200 gel filtration column pre-equilibrated with buffer C. 
Final pure protein was concentrated to 15 mg/ml and stored at -80 ºC.  
Selenomethionine (Se-Met) incorporated RpoBtr-NHis was expressed by using a 
methionine auxotrophic E. coli strain B834(DE3) in minimal media supplemented with 
Se-Met (Doublié, S. (1997). Methods Enzymol.276, 523–530). Purification of the Se-Met 
labeled protein was performed the same way as the native protein, except that the DTT 
concentration in buffer C was increased to 5 mM.  
For co-expression of Mtb RNAP β1-β2 domains and Mtb CarD, the plasmids 
RpoBtr-NHis and CarD-notag were cotransformed into E. coli Rosetta2(DE3)pLysS 
cells. The cells were grown at 37 ºC in the presence of kanamycin and carbenecillin to 
an OD600 of 0.6 and were induced with 0.75 mM IPTG at 18 ºC overnight. The cells 
were harvested by centrifugation at 3000 x g and resuspended in buffer D (25 mM Tris 
pH 7.5, 200 mM NaCl, 5% (v/v) glycerol, 5 mM imidazole, 2 mM β-ME, 2 mM MgCl2, 
40 μg/ml DNAse, and protease inhibitor cocktail), lysed by French press, centrifuged at 
16 K rpm for 45 min, and the supernatant was loaded onto a His Trap FF column pre-




buffer D and a stepwise gradient (5-25%) of buffer E (25 mM Tris pH 7.5, 200 mM 
NaCl, 300 mM imidazole, 2 mM β-ME). Column bound proteins were eluted with a 
gradient of buffer E (25-100%). Fractions containing the RpoBtr-NHis:CarD complex 
were pooled, concentrated, and loaded onto a Superdex 200 gel filtration column pre-
equilibrated with buffer C (25 mM Tris 7.5, 100 mM NaCl, 2 mM DTT). The RpoBtr-
NHis:CarD complex eluted as a single peak from the size exclusion column. Co-elution 
of RpoBtr and CarD from the IMAC and size-exclusion columns was verified by SDS-













 for RpoBtr/CarD 
complex at 280 nm using NanoDrop. Finally, the purified complex was concentrated to 
10 mg/ml and stored at -80 ºC for further use. 
 
Data collection and structure determination 
Molecular replacement (MR) trials to determine the structure of Mtb RpoBtr 
using homologous E. coli, Tth, and Taq RNAP structures did not yield a solution. The 
structure of the Mtb RNAP β-subunit β1-β2 domains was solved by single-wavelength 
anomalous diffraction (SAD) using RpoBtr-NHis-SeMet crystals. Crystals belonged to 
the P212121 space group and diffracted to 2.9 Å. Data was collected at the selenium peak 
wavelength (0.979 Å), processed with Denzo/Scalepack (Minor et al. (2006) Acta 
Crystallogr D Biol Crystallogr. 62, 859-66) and Phenix AutoSol, and Autobuilt modules 
were used to determine the initial phases and obtain the first atomic model (Adams et al. 




RpoBtr structure was improved to 2.5 Å by diffraction data obtained from native (non-
SeMet) RpoBtr-NHis crystals, which also belonged to the P212121 space group with two 
molecules in the ASU. The structure of native RpoBtr-NHis was obtained by MR using 
the RpoBtr-NHis-SeMet protein structure as the search model. The structure comprised 
residues 47-426 of the β-subunit and included six additional residues at the N-terminus 
between the His-tag and the first methionine residue. Refinement was performed with 
Phenix Refine. NCS restraints were applied to the atomic positions and individual B-
factors subsequent to simulated annealing and rigid-body refinements. Iterative manual 
model building was done with COOT (Emsley et al. (2010) Acta Crystallogr D Biol 
Crystallogr. 66, 486-501). Water molecules were added to |Fo-Fc| peaks >3σ and the 
model was further refined using Phenix Refine. The final model had Rwork and Rfree 
values of 0.21 and 0.26, respectively.  
The RpoBtr-NHis:CarD complex crystals belonged to the C2221 space group and 
the diffraction data to 2.1 Å resolution was processed with Denzo/Scalepack. The 
structure was solved by MR using the RpoBtr β1 and β2 domains as two different search 
ensembles (Phaser, CCP4) (McCoy et al. (2007) J Appl Crystallogr. 40, 658-674; Winn 
et al. (2011) Acta Crystallogr D Biol Crystallogr. 67, 235-42). After locating one copy 
of RpoBtr in the ASU, the additional |Fo-Fc| density for the CarD N-terminal domain β-
strands and the C-terminal domain helices were visible with enough clarity to allow us to 
build CarD manually. After a few cycles of rigid-body and simulated-annealing 
refinements, the |Fo-Fc| density for the side chains gradually improved. The model was 




>3σ. In the final stages of refinement, TLS refinement (four TLS groups: β1 domain, β2 
domain, CarD N-terminal domain, and CarD C-terminal domain) was included. Iterative 
cycles of model building and refinement resulted in a final model which included one 
RpoBtr:CarD complex in the ASU with an Rwork= 0.20 and an Rfree= 0.23. Data 








AUTHOR CONTRIBUTION FOR CHAPTERS II-VI 
 
For the publications reprinted in Chapter II, Gulten G. worked on cloning of 
constructs, InhA-EthA and Dhfr-KatG co-expressions, protein purification, InhA 
enzymatic assays, crystallization and data analysis.   
For the publication reprinted in Chapter III, the first two authors contributed 
equally to the work. Jacobs and Kremer labs performed genetics, kinase assays, and 
mass spectrometry analysis. Gulten G. did cloning, expression, purification, InhA 
enzymatic assays and crystallographic studies with the wild-type and T266D, T266E, 
and T266A InhA mutant proteins, and also contributed in manuscript preparation.  
Chapter IV was done in collaboration with GlaxoSmithKline (GSK). Gulten G. 
performed the crystallographic studies. GSK performed the high-throughput screening, 
hit identification and optimization, enzymatic assays, in vivo and pharmacokinetic 
studies. The compounds used for crystallographic studies were supplied by GSK. This 
manuscript is going to be submitted for publication. 
For the publication reprinted in Chapter V, JSF and GAS synthesized the 
triclosan analogs, Jacobs lab did genetic and in vivo studies,  RL did enzymatic assays, 
FW did data collection, processing, enzymatic assays and manuscript preparation, 
Gulten G. did protein purification, crystallization of the InhA-inhibitor complexes, data 




For the publication reprinted in Chapter VI, Gulten G. performed all the 
experiments, data collection and analysis, and wrote the manuscript.   
